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PART I
INTRODUCTION
 

CHAPTER 1
General introduction
Adapted from:
Nutritional support and the role of the stress response in critically ill children
Koen F.M. Joosten, Dorian Kerklaan, Sascha C.A.T. Verbruggen
Current Opinion in Clinical Nutrition and Metabolic Care 2016;19:226-233
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Nutritional challenges in the paediatric intensive care unit
Critical illness is characterised by anorexia and/or feeding intolerance. Critically ill children have 
limited macronutrient stores and higher energy requirements compared with adults. Without 
intervention, this results in substantial caloric and macronutrient deficits following paediatric 
intensive care unit (PICU) admittance, which have been associated with poor outcomes and 
impaired growth1,2. Therefore, current guidelines recommend to initiate nutritional support as 
soon as possible after admission3,4, as it is associated with improved recovery and outcome in 
critically ill children2,5. However, these international consensus-based guidelines mostly rely on 
expert opinion and studies in adults and noncritically ill children, as there is a scarcity of high-
level evidence on all aspects of nutritional support in critically ill children6.
These low-grade and inconclusive guidelines are likely to represent a barrier to implemen-
tation7,8, allowing wide variations in nutritional practices between PICUs9,10.
Several recent high-quality trials in critically ill adults have raised questions on the presumed 
benefits of full-replacement nutrition early during critical illness11,12. Also in critically ill children, 
the optimal route, amount, and timing of nutritional support are expected to be dependent on 
the phase of the stress response in critical illness.
The stress response of critical illness
The concept of stress was already introduced more than 300 years ago, to describe a regular 
occurring event that enables an organism to cope with daily changes in the environment13. 
However, excessive stress, as seen in critical illness, is a well-recognised precedent of harm13, 
and in order to survive it, a stress response is initiated. The teleological goal of this response is 
to provide effective supply of blood, energy and substrates to the injured site and vital tissues14.
The neuro-endocrine, immunologic and metabolic responses to trauma or severe illness 
evolve over time15,16. This concept of different phases of stress response probably also applies 
to critically ill children. The following three phases of illness in critically ill children admitted 
to the PICU are proposed: the acute phase, the stable phase and the recovery phase, all 
characterised by specific neuro-endocrine, metabolic, and immunologic alterations (Table 1). 
We hypothesise that these phase-specific changes necessitate different macronutrient intakes.
Table 1. Definitions of the three phases of the stress response in critically ill children
Defi nition
Acute phase First phase after event, characterised by requirement of (escalating) vital organ 
support
Stable phase Stabilisation or weaning of vital organ support, whereas the diff erent aspects of the 
stress response are not (completely) resolved
Recovery phase Clinical mobilisation with normalisation of neuro-endocrine, immunologic and 
metabolic alterations
Chapter 1
12
R1
R0
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Characteristics of the acute phase of critical illness
The acute phase of critical illness in children is characterised by the requirement of 
(escalating) vital organ support. The concomitant stress response, initiated by activation of an 
inflammatory cytokine cascade and the central nervous system, is aimed at surviving critical 
illness. A conceptual overview of the neuro-endocrine, metabolic and immunologic alterations 
is depicted in Figure 1. 
Figure 1. Conceptual overview of the different phases of critical illness with corresponding neuro-
endocrine, immunologic and metabolic changes
EGP, endogenous glucose production; PT, protein turnover; GH, growth hormone; rT3, reverse 
triiodothyronine; REE, resting energy expenditure; MPS, muscle protein synthesis; IGF-1, insulin-like 
growth factor; T3, triiodothyronine; counter-regulatory hormones are cortisol, catecholamines and 
glucagon
Neuro-endocrine response
Despite activation of the hypothalamic-pituitary axis to release the anterior pituitary 
hormones corticotrophin (ACTH), thyroid stimulating hormone (TSH) and growth hormone, 
concentrations of most peripheral effector hormones, such as triiodothyronine (T3, active 
thyroid hormone) and insulin-like growth factor (IGF-1) are low due to inactivation or target 
organ resistance17-19. In absence of adrenal insufficiency, levels of cortisol rise substantially, 
mainly due to reduced metabolism in liver and kidneys20,21. 
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Immunologic and metabolic response
The metabolic response is hypercatabolism. To guarantee substrate delivery to vital tissues, 
free amino acids and fatty acids (FFA) are mobilised by muscle protein breakdown and lipolysis, 
caused by elevated levels of cortisol and other counter-regulatory hormones (catecholamines 
and glucagon)19,22,23. This results in increased triglycerides levels and reduced high- and low-
density-lipoproteins, especially in children with sepsis24. Hyperglycaemia develops due to 
increased endogenous glucose production and peripheral insulin resistance25. Hypercata-
bolism in the acute phase is primarily induced by inflammation and is more pronounced in 
multiorgan failure26. After the initial cytokine release, other markers of immune cell activation 
become apparent, such as acute phase CD64+ expression on neutrophils and monocytes27. 
When comparing measured to predicted resting energy expenditure (REE), different metabolic 
patterns appear to interchange within the child during the clinical course of severe illness28-32. 
This might be explained by the varying and often opposing effects of the different components 
of the acute phase response on metabolic rate.
Duration of the stress response
This first phase can take hours to days after an event (such as trauma, sepsis or surgery) and, 
based on circumstantial evidence, might last shorter in surviving critically ill children than 
in critically ill adults. In the majority of children with meningococcal disease, blood glucose, 
cortisol and ACTH levels normalise within 48 hours suggesting an early resolution of the stress 
response concerning counter-regulatory hormones and glucose metabolism33,34. 
In critically ill and post-surgical neonates, the plasma levels of catecholamines, thyroid 
hormones and IGF-1 return to baseline even faster than in older children35,36, with the earliest 
return of anabolic protein metabolism found after acute injury in preterm neonates37.
Nutrient administration in the acute phase of critical illness
The acute stress response is affected by nutrition. However, in contrast to previous ideas, 
hypercatabolism and subsequent muscle atrophy are not reversed with increased provision of 
nutrients during this phase26,38. Recent high-quality trials in adults have extensively investigated 
the provision of artificial nutrition during this phase11,12, and showed no beneficial effects of 
early initiation of parenteral nutrition39-41. Nutrient restriction early in critical illness enhanced 
the central and peripheral neuro-endocrine response by further lowering T3, thyroxine (T4) 
and TSH levels as well as the T3 (active thyroid hormone)/reverseT3 (inactive thyroid hormone) 
ratio. The T3/rT3 ratio was also further reduced by the application of a tight glucose control 
protocol in critically ill children42. This decrease in T3/rT3 ratio was associated with a better 
outcome both in critically ill adults and children42,43, possibly indicating that changing the 
peripheral conversion of T4 from metabolically active T3 to inactive rT3 during the first days of 
critical illness is adaptive and beneficial for recovery42. 
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Autophagy
The benefits of withholding artificial nutritional support during the acute phase may also 
be explained by the stimulating effect on autophagy44,45. Autophagy is an essential survival 
mechanism by which cells break down their own (damaged) components to recycle intracellular 
nutrients and generate energy during starvation46-49. Besides its role as cellular housekeeper, 
autophagy is involved in protein quality control of tissue and organs. Additionally, it regulates 
both innate and adaptive immune responses, partly by efficient clearance of intracellular 
pathogens. Activation of autophagy by withholding parenteral nutrition during acute critical 
illness might result in a better, more balanced physiological response with greater protein 
synthesis, energy production and maintenance of cell structure41,44,45,49. On the other hand, 
when autophagy is suppressed by forced overfeeding early in critical illness, the risk of organ 
failure and cell death may increase, resulting in worse clinical outcome. Preservation of 
autophagy in skeletal muscle partially explained why parenteral nutrient restriction reduced 
ICU-acquired weakness and enhanced recovery38. Although nutrient restriction is regarded as 
a risk factor for muscle atrophy, increased energy intake is associated with worsened muscle 
function in critically ill adults and animal models38,44. Prolonged upregulation of autophagy 
may lead to increased degradation of organelles and a failure to maintain energy provision, 
resulting in increased apoptosis and cell death50. The beneficial effects of nutrient restriction 
are therefore likely to be limited to the acute phase of critical illness. 
Early enteral nutrition in critically ill children
Enteral nutrition is positioned as the preferred route over parenteral nutrition in critically 
ill children, and guidelines recommend initiation within 48 hours4. It prevents gut atrophy, 
preserves gut integrity and immunity, and hence decreases the risk for bacterial translocation 
and systemic infection51,52. In a retrospective study of 5105 critically ill children, early enteral 
nutrition, defined as the provision of 25% of target calories enterally over the first 48 hours of 
admission, was shown to be associated with a lower mortality rate in those with a PICU length 
of stay of at least 96 hours53. However, the observational design calls for caution in assuming 
that this association is causal, since patients who tolerate enteral nutrition early, are likely to 
have a better prognosis. In children with burns, early enteral nutrition (started within 3-6 hours) 
was clinically superior to late enteral nutrition (after 48 hours) with a lower mortality rate, 
shorter hospital stay and less weight loss54, but data from this distinct patient group cannot 
automatically be applied to the general PICU population. Despite the current tendency to 
provide early enteral nutrition during PICU stay, initiation is often delayed and administration 
is frequently interrupted due to clinical procedures, gastro-intestinal intolerance and a number 
of misconceptions (Table 2)55-59. 
This results in a discrepancy between the amount of prescribed and delivered calories, with 
overall 50-60% of the prescribed calories not being delivered when using the enteral route2,71,72. 
Introduction
15
1 R1
R0
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Table 2. Perceived barriers to (early) enteral nutrition in critically ill children 
Barriers Facts
Delayed 
initiation
(Non)-invasive positive 
pressure ventilation
Early enteral feedings are feasible, well tolerated, and cost-
eff ective in mechanically ventilated children60,61
Gastro-intestinal 
surgery
Early enteral nutrition after small and large operations in 
children, including intestinal resection, is safe and feasible. It 
promotes rapid elimination of intestinal paresis, early activation 
of motor function, mucosal regeneration and early activation of 
absorptive function, thereby reducing infection rate and length 
of hospital stay62,63
Use of vasoactive drugs Enteral nutrition in patients on vasoactive drugs improves 
gut blood fl ow and is associated with no diff erence in gastro-
intestinal outcomes and a tendency towards lower mortality61
Interruption 
of delivery
High GRV Available large RCTs in adults consistently showed no benefi cial 
eff ect of GRV monitoring64, with a higher chance of achieving 
nutrient goals if GRV is not monitored65
The accuracy of GRV measurement to predict enteral nutrition 
intolerance has not been studied in critically ill children66
Procedures requiring 
fasting, including 
surgery and planned 
extubation
A reduced fasting protocol by use of clear fl uids is safe and 
feasible67
Absence of bowel 
sounds
Auscultation of bowel sounds has limited clinical utility and 
should not be used to guide provision of enteral nutrition68
Fluid 
restriction
Diagnosis dependent, 
often in cardiac or renal 
patients
Use of energy and protein enriched formulas might increase 
the chance of achieving caloric goals69. Interdisciplinary team 
interventions improve nutrition delivery70
GRV, gastric residual volume; RCT, randomised controlled trial
Early parenteral nutrition in critically ill children
Evidence on the impact of (supplemental) parenteral nutrition on clinical outcomes in critically 
ill children is currently lacking6. Some nonrandomised studies, or studies with surrogate 
outcome measures, have pointed toward potential disadvantages of parenteral nutrition in 
this population. In a retrospective study of 204 nonsurgical critically ill children eligible for 
enteral nutrition provision, supplementation of parenteral nutrition was associated with a 
higher nosocomial infection rate than administration of enteral nutrition alone (34.0 vs.10.9%, 
P less than 0.001)73. The use of parenteral nutrition was one of the most significant predictors 
for nosocomial infections in a prospective cohort of 1106 cardiac PICU patients (odds ratio 
1.2, 95% confidence interval 1.1-1.4)74. Use of parenteral nutrition has shown to be the single 
significant factor determining energy intake in mixed-effect modelling and is also identified 
as risk factor for overfeeding1,75, possibly because higher provision of energy is possible, 
while administration is less interrupted compared to enteral nutrition. In septic adolescents, 
metabolic side effects, such as enhanced endogenous glucose production and lipolysis, were 
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encountered with high parenteral protein intake (3 g/kg/day), raising concerns of an increased 
insulin resistance76. High doses of parenteral glucose are associated with side-effects, as 
lipogenesis and hyperglycaemia, which can safely be prevented by amounts of parenteral 
glucose below current guidelines77,78. Therefore, it remains unclear whether insufficient nutrient 
administration by the enteral route should be supplemented with parenteral nutrition. 
The stable and recovery phase of critical illness
The stable phase
The stable phase of critical illness is represented by stabilisation or weaning of vital organ 
support, whereas the different aspects of the stress response are not (completely) resolved. 
In addition to persistent low peripheral hormone levels, this phase is also characterised by a 
central suppression of the different endocrine axes (Fig. 1)14. In contrast to the target organ 
resistance marking the acute phase, peripheral tissues respond to low T3 concentrations by 
increase of local hormone availability and effects79,80. Despite increased effect of this anabolic 
hormone, large amounts of protein continue to be wasted, whereas fat stores remain relatively 
intact81. Plasma cytokine concentrations are substantially decreased, but immune cell function 
remains affected, as shown by persistent alterations in glycoprotein expression. The duration 
of this phase can range from days to weeks, depending on the age and diagnosis of the child82. 
In mixed populations of critically ill children, levels of anabolic hormones such as T3, growth 
hormone and (bioavailable) IGF-1 already increase during the first week of admission36,83. 
Recovery of anabolism appears to be in concert with the resolution of inflammation, as shown 
by the relation between T3 and C-reactive protein (CRP) levels36 and between early metabolic 
markers, such as triglycerides levels, and immunologic parameters such as acute phase CD64+ 
expression on neutrophils24. 
However, despite early normalisation of the catabolic counter-regulatory hormone levels, 
other parameters of the neuro-endocrine, metabolic and immunologic stress response might 
need more time to resolve.
The recovery phase
Clinical mobilisation of the child, that is no longer in need of vital organ support, together 
with resolution of the stress response, marks the onset of the recovery phase. This final phase 
may last weeks to months. Hormone levels gradually return to normal (Fig. 1). The body shifts 
from catabolism to anabolism with protein synthesis exceeding protein breakdown, resulting 
in positive nitrogen balance, tissue repair and (catch-up) growth. Restoration of mitochondrial 
function is achieved with accelerated stimulation of mitochondrial protein (biogenesis)84. 
However, in children with burns a persistent hypermetabolic state is known to delay anabolism 
and growth85, and suppressed insulin receptor signalling can be detected up to 250 days 
postburn86. 
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Despite the improvement of neuro-endocrine, immunologic and metabolic status, clinical 
parameters, such as weight and functional status (measured with the Functional Status 
Scale in medical and cardiac critically ill children), are known to be worse at discharge71,87. 
Profound muscle weakness, due to muscle wasting and critical illness myopathy as observed 
with prolonged duration of the stable phase, contributes to morbidity and adverse outcome 
in the ICU and PICU88,89 and may even cause long-term functional disability beyond hospital 
discharge89. 
Nutrient administration in the stable and recovery phase
The focus of nutritional therapy during the stable and recovery phase should be aimed at 
restoration of lean body mass whereas synthesis of excess fat mass is to be avoided. To prevent 
muscle weakness, the duration of immobilisation should be reduced as much as possible90. A 
combination of optimal nutritional support and physical exercise/mobilisation appears to be a 
logical intervention, but no such studies have been performed in critically ill patients91. 
A recent systematic review and a single centre study in mechanically ventilated children, 
calculated a minimum intake of respectively 57 and 58 kcal/kg/day to achieve a positive 
nitrogen balance92,93. In both studies, a protein intake of 1.5 g/kg/day was required to equilibrate 
nitrogen balance, reflecting a protein-energy ratio of around 10 energy%protein. Since these 
two studies made no distinction between the phases of critical illness, it remains unclear if 
this minimal intake should already be provided in the acute phase or should be reserved for 
subsequent phases. Because nutritional intake during the stable and recovery phase is not 
only aimed at equilibrating nitrogen balance, but also at enabling recovery, growth and catch-
up growth, caloric intake during these phases needs to be inclined from the above mentioned 
minimum intake94,95. Indeed, higher caloric and protein intake (with a sufficient protein-energy 
ratio) via the enteral route are associated with higher 60-day survival2,96, asking for a more 
aggressive feeding approach than in the acute phase. 
Energy expenditure throughout the course of critical illness
Energy requirements for critically ill children vary between individuals and also between 
the phases of critical illness. REE is one component of total energy expenditure (TEE), the 
other components are physical activity, the thermic effect of food, and the energy cost of 
growth. Currently, optimal caloric intake in critically ill children is frequently defined as 90-
110% of REE1,97-99, with an intake below or above this range indicating underfeeding and 
overfeeding, respectively. In order to prevent the detrimental effects associated with these 
two types of malnutrition, REE is advised to guide nutritional therapy throughout the course 
of illness2,4,100-102. Ideally, REE should be measured using indirect calorimetry (IC). With IC, a 
metabolic monitor is attached to the ventilator circuit of the child to derive REE from minute-
to-minute measurements of oxygen consumption (VO
2
) and carbon dioxide production 
(VCO
2
)103. Alternatively, a canopy mode can be used for spontaneously breathing children. The 
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child’s REE can accurately be reflected by a measurement of at least 5 minutes104. However, 
most measurements will take at least 30 minutes, taking into account the time to connect the 
metabolic monitor and the time to reach steady state.
Within-day and between-day variations in REE from the acute phase to the stable phase are 
small in the majority of critically ill children1,94,105-107, so a single measurement early during 
admission may serve to guide nutritional therapy. Since REE remains stable, but requirements 
are likely to change during the different phases of critical illness, the optimal caloric intake in 
relation to REE is likely to vary as well. 
Despite its superiority in predicting REE, only a minority of PICUs uses IC to determine 
energy requirements9, because measurements are time consuming and limited to stabilised 
mechanically ventilated children with mild ventilator settings or spontaneously breathing 
children without need for oxygen. High purchase and maintenance expenses of metabolic 
monitors further limit availability of IC. Alternatively, a simplified metabolic equation using 
ventilator-derived VCO
2
 measurements, could allow measurement of energy expenditure in 
absence of a metabolic monitor108. However, this approach needs to be validated for use in 
critically ill children. 
Due to the limited availability and practice of IC, REE is predominantly predicted by age-
dependent equations based on weight and/or height. These equations, derived from 
measurements in healthy children, do not predict energy requirements accurately in critically 
ill children, resulting in an increased risk of malnutrition during PICU stay105,109,110. Several 
factors, commonly present in the PICU, affect measured REE; fever is found to increase REE, 
while sedatives and muscle relaxants have shown to decrease it111. An increase of REE is also 
seen in children with burns112, septic neonates30,113 and in children after major surgeries, but 
only temporarily31. However, despite these established effects, the application of uniform 
correction factors to REE for the whole PICU population is simplistic and likely to be inaccurate4. 
Therefore, when IC is not possible, it is preferred to derive REE from Schofield’s formula for 
weight, without the addition of stress or activity factors4. 
Respiratory Quotient
The VCO
2
 and VO
2
 values obtained by IC are not solely used to calculate REE. Their ratio (VCO
2
/
VO
2
), known as the respiratory quotient (RQ), reflects the utilisation of different substrates. A 
value >1.0 indicates lipogenesis and can be used to identify carbohydrate overfeeding114-116. A 
high amount of carbohydrates will not always result in an RQ >1.0 because ongoing utilisation 
of fat for energy, as seen in critical illness, will lower the measured RQ117. RQ is also affected by 
hyperventilation and metabolic acidosis. Therefore, a cautious interpretation of this variable 
is necessary before adjusting nutritional practices. The measured RQ value can also function 
as an indicator of caloric overfeeding when it is compared to the predicted RQ based on the 
macronutrients provided (RQ
macr
)118,119. Its adequacy to detect overfeeding is affected by the 
presence of endogenous energy production, as seen in children with caloric intake below 
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measured REE120 and during the acute phase of critical illness117. Therefore, application of this 
parameter may be limited to the stable and recovery phase of critical illness.
In conclusion it can be stated that:
• Low-grade and inconclusive evidence-based guidelines, resulting from a scarcity of 
high-level evidence on all aspects of nutritional support in critically ill children, are 
likely to allow wide variations in nutritional practices between PICUs.
• Understanding the stress response to critical illness and the characteristics of its three 
phases is essential for nutritional recommendations in critically ill children. 
• During the course of critical illness, the enteral route is preferred, but several 
misconceptions concerning the provision of enteral nutrition prevent adequate 
intake. 
• Use of parenteral nutrition in critically ill children is associated with potential 
disadvantages, but clinical outcome studies are lacking. Parenteral nutrient restriction 
early during critical illness might be beneficial for short and long-term outcomes 
by amplifying the acute catabolic stress response and stimulating autophagy and 
muscle integrity. 
• During the stable and recovery phase, inclining caloric and protein requirements 
allow for a more aggressive feeding approach, together with mobilisation, to enable 
recovery, rehabilitation and (catch-up) growth. 
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Outline of this thesis
Part I: Introduction
This thesis aims to provide insight in current nutritional support during stay on the paediatric 
intensive care unit (PICU), concerning the route, timing and amount of artificial nutrition, 
with focus on the identification and risk of caloric overfeeding and the use of (supplemental) 
parenteral nutrition. 
Part II: Current nutritional practices
The second part of this thesis describes daily nutritional practice in the PICU. Chapter 2 
highlights the variation in current clinical practice regarding several aspects of nutritional 
support by an international online survey in 156 PICUs across the world. To compare intended 
with applied nutritional practice, this survey identifies information on local strategies as well 
as their execution in patients by use of point prevalence data.
Part III: Energy expenditure
The third part focuses on the determination of resting energy expenditure (REE) by indirect 
calorimetry in critically ill children. Chapter 3 aimed to validate an alternative method for 
measurement of energy expenditure with indirect calorimetry by use of ventilator-derived VCO
2
 
measurements in 41 mechanically ventilated children. In Chapter 4 different internationally 
used definitions of caloric overfeeding are compared in order to find the most adequate 
method to identify overfeeding. In order to do so, measurements of REE and respiratory 
quotient from 79 mechanically ventilated children are studied in relation to caloric intake.
Part IV: Supplemental parenteral nutrition
In this part the effect of timing of parenteral nutrition in the PICU is investigated. Chapter 5 
reviews the current scarce evidence for the use of parenteral nutrition in the PICU, thereby 
underlining the need for large nutritional RCTs. In Chapter 6 and 7 a multicentre, international 
RCT in 1440 critically ill children at nutritional risk is described. The strategy of withholding 
supplemental parenteral nutrition for one week in the PICU is compared to providing early 
parenteral nutrition. Primary clinical outcomes are the number of patients with new infections 
and length of PICU stay.
Part V: General discussion, including future perspectives, and summary
The last part of this thesis is dedicated to the general discussion and suggestions for future 
research in nutritional support, which can be read in Chapter 8. A summary of the major 
findings of this thesis can be found in Chapter 9 (English and Dutch).
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ABSTRACT
Objective
To assess current nutritional practices in critically ill children worldwide. 
Materials and methods
Members of the World Federation of Pediatric Intensive and Critical Care Societies were asked 
to complete a two-part online, international survey. The first part, the survey, was composed of 
59 questions regarding nutritional strategies and protocols (July-November 2013). The second 
part surveyed the point prevalence of nutritional data of patients present in a subgroup of the 
responding PICUs (May-September 2014). 
Results
We analyzed 189 responses from 156 PICUs in 52 countries (survey). We received nutritional 
data on 295 patients from 41 of these 156 responding PICUs in 27 countries (point prevalence). 
According to the survey, nutritional protocols and support teams were available in 52% and 
57% of the PICUs, respectively. Various equations were in use to estimate energy requirements; 
only in 14% of PICUs, indirect calorimetry was used. Nutritional targets for macronutrients, 
corrected for age/weight, varied widely. Enteral nutrition would be started early (within 24 
hr of admission) in 60% of PICUs, preferably by the gastric route (88%). In patients intolerant 
to enteral nutrition, parenteral nutrition would be started within 48 hours in 55% of PICUs. 
Overall, in 72% of PICUs supplemental parenteral nutrition would be used if enteral nutrition 
failed to meet at least 50% of energy delivery goal. Several differences between the intended 
(survey) and the actual (point prevalence) nutritional practices were found in the responding 
PICUs, predominantly overestimating the ability to adequately feed patients.
Conclusion
Nutritional practices vary widely between PICUs worldwide. There are significant differences 
in macronutrient goals, estimating energy requirements, timing of nutrient delivery, and 
threshold for supplemental parenteral nutrition. Uniform consensus-based nutrition practices, 
preferably guided by evidence, are desirable in the PICU.
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INTRODUCTION
Nutritional support affects recovery and outcome in critically ill children1-3. Although 
undernutrition has been the primary focus, overfeeding in PICUs is also associated with 
increased morbidity4,5. Despite its clinical relevance, there is a scarcity of high-level evidence 
on various aspects of nutritional support in critically ill children6. With grade C as the maximum 
level of evidence, available guidelines for nutrition support in critically ill children are based on 
insufficient data for evidence-based recommendations. 
Consensus-based guidelines provided by expert committees (American Society for Parenteral 
and Enteral Nutrition [A.S.P.E.N.], European Society for Clinical Nutrition and Metabolism 
[ESPEN], and the European Society for Paediatric Gastroenterology Hepatology and Nutrition 
[ESPGHAN]) are based on scant evidence, and are largely driven by expert opinion and 
extrapolations from studies in adults or noncritically ill children7,8. Low-grade or inconclusive 
evidence-based protocols represent a barrier to implementation with differences most 
prominent in areas with the weakest evidence9,10. This allows wide variations in nutritional 
practices for patients in European PICUs as shown in previous studies11,12. The variability in 
timing, amount, and composition of nutrition would inevitably result in underfeeding and/or 
overfeeding, which could potentially impact the clinical outcome of critically ill children and 
overall health care expenses13. While evidence on many aspects of nutrition is lacking, there 
appears to be consensus on the benefits of early enteral nutrition (EN) and the need to prevent 
further nutritional deterioration in this population.
The purpose of our study was to assess the current nutritional practice in PICUs across the world. 
We hypothesized that the limited guidelines available have not been universally implemented, 
and that current practice is heterogeneous and mostly physician based. Since the guidelines 
at least agree on the importance of EN7,14,15, we expected no significant differences in this 
practice between PICUs. Other factors, such as assessment of energy requirements or use of 
parenteral nutrition (PN), are more likely to vary between countries and hospitals given the 
weak recommendations. 
To quantify the variations in clinical practice, we distributed a two-part online survey to PICUs 
across the world. The first part of the survey was composed of questions on various aspects 
of local nutritional practice. The second part was a point prevalence survey on nutritional data 
collected in all patients present in the unit on a single day in a subgroup of the responding 
PICUs. Answers were analyzed, correlated with PICU characteristics, and differences between 
the intended (survey) and the actual (point prevalence) nutritional practices were determined.
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MATERIAL AND METHODS
The local Institutional Review Board of the Erasmus MC in Rotterdam waived the need for 
consent. The participation in this survey was voluntary, and no patient identifiers were 
collected.
The cross-sectional survey was conducted between July and November 2013. The online 
questionnaire was composed of 59 questions regarding local nutritional protocols and 
strategies, and provided in English, French, Spanish and Chinese. The second part, the point 
prevalence, conducted between May and September 2014, involved data collection on 
nutritional practices and intake for the preceding 24 hours. In a subgroup of centers that 
agreed to participate in this portion of the study, respondents were asked to include data for 
all patients present in their PICU; no selection criteria were applied. Both questionnaires are 
available as an online supplement (Supplementary Digital Content: http://links.lww.com/PCC/
A204). 
Testing of clarity, relevance, and clinical sensibility of the English questionnaire was performed 
by independent clinicians in three centers (Sophia Children’s Hospital-Erasmus MC, Rotterdam, 
the Netherlands; University Hospital of Leuven, Belgium; and the Boston Children’s Hospital, 
Boston, MA). Data from this test were not included in the final analysis and survey results. 
Afterward, the questions were translated to French, Spanish, and Chinese by native speakers. 
An invitation to the survey was electronically distributed to members of the World Federation 
of Pediatric Intensive and Critical Care Societies (WFPICCS) by their mailing list and to specific 
members of the European Society of Paediatric and Neonatal Intensive Care (ESPNIC) and 
Society of Critical Care Medicine involved in nutritional management and through the 
newsletter of both the ESPNIC and WFPICCS and the WFPICCS homepage and LinkedIn group. 
A reminder was sent 2 months after the first invitation. Due to incomplete data registration, 
the exact number of PICUs represented by the WFPICCS database is unknown. Respondents 
who provided their contact information in the survey, were approached to participate in the 
point prevalence. 
If more than one questionnaire was returned from a single PICU, the answers were weighted 
by the inverse of the number of completed questionnaires per center, in order to process 
conflicting statements within a single institution without disrupting the weight of the answers 
per PICU. Countries were classified by income according to The World Bank income groups16. 
Individual questions were stratified by continent, income of country, number of PICU beds, 
admissions per year, and percentage of ventilated patients. 
Statistical analysis was performed using IBM SPSS statistics 21 for Windows (IBM, Chicago, 
IL). Descriptive statistics were used to compare differences in respondent characteristics 
and survey responses. Nutritional data obtained in the point prevalence were compared to 
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the survey results for each participating center. Logistic regression, ordinal or multinomial, 
depending on the type of outcome, was used to identify the relation between the answers 
provided and the characteristics of the different PICUs. To correct for cluster effects due to 
multiple returned questionnaires per PICU, generalized estimating equations were used in 
conjunction with robust standard error estimates (Huber sandwich estimator). All statistical 
tests were two-sided, and statistical significance was defined as a p value of less than 0.05.
This trial was registered in the Dutch Trial Register at number 4093 (http://www.trialregister.nl).
RESULTS
Response
After distribution of the first part of the survey, a total of 251 questionnaires were received. 
Fifty-two questionnaires were removed because of missing essential data, defined as 
nutritional data (so only information on PICU characteristics available), and/or data essential for 
distinguishing PICUs from each other without possibility for clarification. Of the remaining 199 
questionnaires, 10 were duplicate replies by the same respondent and therefore deleted. One 
hundred eighty-nine questionnaires were analyzed, representing 156 PICUs in 52 countries 
and six continents as shown in Figure 1. 
For the point prevalence, we collected nutritional data on 295 patients in total, from 41 of 
the responding PICUs (26%) from 27 countries on six continents with a median input of five 
patients (interquartile range [IQR], 2-9) per PICU. Characteristics of responding PICUs for the 
point prevalence were similar compared with the overall survey respondents (Table 1).
Figure 1. One hundred fifty-six PICUs from 52 participating countries (in gray) participated in the survey, 
covering six continents
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Table 1. PICU characteristics of the first (n = 156) and point prevalence part (n = 41) of the survey
                                       No. of PICUs (%)
Characteristic Part 1: Survey
(n = 156)
Part 2: Point prevalence 
(n = 41)
Continent
Asia
Africa
Europe 
North America 
Oceania
South America
37 (24)
5 (3.2)
48 (31)
33 (21)
9 (5.8)
24 (15)
9 (22)
2 (4.9)
16 (39)
3 (7.3)
2 (4.9)
9 (22)
Income category (country)
Low
Lower middle
Upper middle
High
1 (0.6)
20 (13)
49 (31)
86 (55)
0 (0.0)
2 (4.9)
15 (37)
24 (59)
Hospital type
General hospital
University hospital
Children’s hospital
University children’s hospital
31 (20)
51 (33)
20 (13)
48 (31)
7 (17)
15 (35)
4 (9.8)
14 (33)
Type of PICU
Multidisciplinary/mixed
Cardiac
Medical
135 (86)
6 (4.0)
8 (5.1)
35 (85)
2 (4.9)
2 (4.9)
Combination of PICU
With adult ICU
With Neonatal ICU
With adult and neonatal ICU
Not combined
9 (5.8)
25 (16)
3 (2.0)
119 (76)
1 (2.4)
8 (20)
0 (0.0)
32 (78)
Size of PICU
1-10 beds
11-20 beds
21-30 beds
>30 beds
76 (49)
51 (33)
23 (15)
6 (3.5)
20 (49)
13 (32)
7 (17)
1 (2.4)
Admissions (patients/yr)
          Median (interquartile range) 500 (296-793) 450 (350-700)
Ventilated patients
< 25%
25-50%
50-75%
>75%
22 (14)
55 (35)
49 (31)
30 (19)
5 (12)
13 (32)
14 (33)
10 (23)
PICU and patient demographics
The responding PICUs in the first part of the survey represented approximately 90,000 
admissions per year. Fifty-two percent of PICUs were located in North America and Europe. 
Fourteen percent of PICUs were situated in low- or lower-middle-income countries, and 86% 
of PICUs were multidisciplinary. All PICU demographics are shown in Table 1.
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Of the 295 patients included in the point prevalence, 60% were male patients and 58% younger 
than 1 year. Median length of stay (LOS) at moment of data collection was 6 days (IQR, 2-15), 
with a LOS greater than 7 days in 40% of the patients. Median weight was 7 kg (IQR, 4-16), and 
46% of the children were mechanically ventilated. 
Nutritional support
According to the first part of the survey, a nutritional protocol was present in 52% of PICUs; 
protocol characteristics are shown in Table 2. A Nutrition Support Team (NST) was available 
in 57% of the PICUs and 51% of the teams visited the ICU daily. The composition of an NST 
differed; it consisted mostly of dieticians (88%) and pediatric intensivists (51%). 
In the point prevalence part of the study, median caloric intake did not differ in children fed by 
EN exclusively (n = 129) between the following four groups (p = 0.18): 1) PICUs with an NST 
(76 kcal/kg/d), 2) PICUs with a nutritional protocol (76 kcal/kg/d), 3) PICUs with both an NST 
and nutritional protocol (64 kcal/kg/d), and 4) PICUs without an NST and protocol (58 kcal/
kg/d). There was also no difference in the proportion of children receiving EN in PICUs with and 
without an NST and/or protocol.
Table 2. Characteristics of nutritional protocols
Characteristic No. of PICUs (%)
Total 156
Protocol available 82 (52)
Information in protocol
Assessment of energy requirements
Protein requirements
Management of gastric residual volume
Type of EN
Amount of EN
Composition of PN
Amount of PN
72 (89)
65 (81)
57 (71)
72 (89)
75 (94)
71 (88)
72 (89)
Protocol age/weight diff erentiated
Not
For EN
For PN
For both EN and PN
6 (7.7)
8 (10)
7 (8.7)
59 (74)
EN = Enteral Nutrition, PN = Parenteral Nutrition
Nutritional requirements
To predict energy expenditure (EE) different equations were used according to the first part 
of the survey, mainly those published by Schofield17 (25%) and the World Health Organization 
(WHO)18 (25%), but also the Harris-Benedict equation19 (17%). Seventy percent used correction 
factors, as fever (41% of PICUs), diagnosis (54%) and growth (23%) to calculate energy needs. 
Twenty-four percent of respondents did not know which equation was used to calculate EE 
in their unit. Indirect calorimetry (IC) to measure EE was used in 14% of the PICUs. The first 
Chapter 2
38
R1
R0
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
IC measurement was performed if expected stay was longer than 4 days (31% of PICUs), as 
soon as ventilator settings were appropriate (18%), in case of weight loss (15%) or patient 
dependent (11%: obese patients, high risk of malnutrition). 
Age-based protein targets recommended by the A.S.P.E.N. and ESPEN/ESPGHAN guidelines 
(ranging from 0.9 to 3 g protein/kg/d) were followed in 31% and 36% of PICUs, respectively7,8. 
Lipid targets ranged from less than 1.5 to more than 3.5 g/kg/d, where the range of 1.5 to 2.5 
g/kg/d was predominantly used (41%). Sixteen percent and 7.9% of the respondents did not 
know what their protein and lipid targets were, respectively.
In the point prevalence, median caloric intake was 66 kcal/kg/d (IQR, 49-96) for children on EN 
exclusively (n = 129); intake per kg of weight decreased significantly with age as expected 
(p < 0.001) (Fig. 2). In 31% of the children, the caloric intake was lower than basal metabolic 
rate calculated by the weight-based Schofield equation; for the WHO equation, this was 27%. 
Median protein intake was 1.8 g/kg/d (IQR, 1.2-2.6); only 34% of the children met the intended 
target protein intake of their PICU as mentioned in the survey. 
Figure 2. Caloric intake in different age categories in the point prevalence; p < 0.001 when comparing 
intake in the three different age categories (Kruskal-Wallis test). Boxes represent 25th to 75th percentile, 
whiskers by Tukey method
Timing and route of nutrition
In the first part of the survey, an early start (within 24 hr after admission) of EN was mentioned 
for 60% of PICUs (Fig. 3); in 31%, EN would even be started within 12 hours. Fifty-nine percent 
of the respondents had the perception that they were able to feed patients exclusively by 
enteral route within 3 days postadmission. The gastric route was preferred for EN in ventilated 
(67% of PICUs) and nonventilated patients (88%). Prokinetics were prescribed when a patient 
was not tolerating feeds in 70% of PICUs. EN was stopped or decreased due to the following 
reasons: high gastric residuals (73% of PICUs), abdominal distension/pain (85%), diarrhea 
Worldwide survey of nutritional practices in PICUs
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(32%), vomiting (75%), reduced/altered bowel sounds (23%), hemodynamic instability (62%), 
or use of muscle relaxants (12%).
Early PN would be started within 48 hours after admission in 55% of PICUs, while in 3.5% of 
PICUs there would be trials of EN for at least 7 days before starting PN (Fig. 3). When EN was 
insufficient, respondents from 18% of the PICUs would always supplement PN, whereas in 
7.5% supplemental PN would never be utilized. Seventy-two percent supplemented PN if EN 
failed to meet 50% of target calories; 24% if EN failed to meet 80%. PN was stopped in 64% of 
PICUs when EN covered more than 80% of the nutritional targets.
At the moment of our point prevalence 73% of the children received EN (n = 216), predominantly 
by gastric tube (70%). There was no difference in caloric intake (p = 0.82) or in prokinetics use 
(p = 0.47) between children fed by gastric or postpyloric route. Forty-two percent of children 
with LOS less than 24 hours (n = 43) were already receiving EN, and in children with LOS of 2 
days or more (n = 253), EN was provided in 78%. Twenty-one percent of all children received 
PN in some form and 10% received a combination of EN and PN; both groups at a median 
LOS of 6.5 days. The point prevalence showed that the ability to administer exclusive EN was 
overestimated; 40% of children (n = 74) present during the point prevalence achieved exclusive 
EN later than perceived by the respondents from the first part of the survey. 
Figure 3. Time to initiation of enteral nutrition (EN) and parenteral nutrition (PN) based on survey data. 
Boxes represent the percentages of PICUs
Glucose and glycemic control
In the first part of the survey, target intake of glucose during the first 12-24 hours of admission 
varied between less than 2 to more than 6 mg/kg/min for different weight ranges (Fig. 4). In 
62% of the PICUs, a protocol for some form of glycemic control was available. Target blood 
glucoses were defined as less than 10 mmol/L (< 180 mg/dL) in 54% and less than 8 mmol/L 
(< 144 mg/dL) in 23%. Tight glucose control (2.8-4.4 mmol/L or 50-80 mg/dL < 1 year or 3.9-5.5 
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mmol/L or 70-100 mg/dL 1-16 years) as reported by Vlasselaers et al.20 was practiced in 10% of 
PICUs. 
At the time of the point prevalence, 20 children, median weight 8.1 kg, received exclusive 
glucose infusion while being admitted less than 24 hours; median glucose intake was 1.7 mg/
kg/min (IQR, 0.3-2.3). Seventy-five percent received less glucose than their target glucose 
intake (Fig. 4). 
Insulin was administered in 32 children (11%); 24 children on insulin were admitted to a PICU 
with a glucose target less than 10 mmol/L (< 180 mg/dL), five to a PICU that practiced tight 
glucose control as reported by Vlasselaers et al20.
Figure 4. Glucose intake in different weight categories in the first 24 hours after admission based on 
survey data. Intake varied between less than 2 mg/kg/min to more than 6 mg/kg/min in all weight groups. 
Boxes represent the percentages of PICUs
Administration of parenteral lipids and protein
According to the first part of the survey, lipids were supplied in different compositions (Table 
3). In 44% of PICUs, a step-up protocol was used that would start at 50% of the maximal dose. 
Lipid intake was decreased when triglycerides were 3.5-5.5 mmol/L or 310-487 mg/dL (in 69%) 
and stopped when triglycerides exceeded 5 mmol/L or 442 mg/dL (in 70%). In case of sepsis, 
lipid administration was decreased or stopped in 50% of PICUs. Reasons provided to decrease 
or stop the intake of protein were kidney failure (65%) and urea levels more than 15 mmol/L 
or 42 mg/dL (75%).
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Table 3. Parenteral lipid emulsions used in the PICU (> 1 answer possible per PICU)
Type No. of PICUs (%)
100% soy based 105 (67%)
30% soy, 25% olive oil, 15% fi sh oil, 30% MCT 44 (28%)
100% fi sh oil 16 (10%)
80% olive oil, 20% soy 27 (18%)
10% fi sh oil, 40% soy, 50% MCT 5 (2.9%)
50% soy, 50% MCT 3 (1.9%)
MCT = Medium Chain Triglycerides
Geographic and socioeconomic differences
An NST was more often available in PICUs situated in North America (p = 0.014), South America 
(p = 0.005), and Oceania (p = 0.013) than in Europe and in PICUs with more admissions per 
year (p = 0.029). A higher percentage of nutritional protocols (p = 0.006) and support teams (p 
< 0.001) were available in high-income countries than low-middle ones. As expected, protein 
targets in North American PICUs were more often based on A.S.P.E.N. (p = 0.011) and less 
frequently on ESPEN/ESPGHAN guidelines (p < 0.001) than protein targets in Europe. EN was 
started earlier in PICUs in high-income countries (mean, 6-24 hr; 81% within 24 hr) than in 
lower-middle-income countries (mean, 13-48 hr; 74% within 24 hr, p = 0.012). PN was started 
later in PICUs in North America (median, 2-4 d, p = 0.02) and Asia (median, 2-4 days, p = 0.06) 
than in PICUs in Europe (median, < 48 hr) in a child intolerable to enteral feeds. An overview of 
the adjusted odds ratios per continent is provided in Supplementary Table 1.
DISCUSSION
Nutritional practices vary greatly between PICUs worldwide. Several aspects of nutritional 
support differ significantly, such as macronutrient goals, preferred route and timing, estimation 
of energy requirements, and the threshold for supplemental PN use. These differences were 
apparent between PICUs in general and between geographic and socioeconomic regions. 
Many of these areas currently lack evidence. This variability has been described before in PICUs 
in several European countries11,12. In addition, applied nutritional practice (point prevalence) 
deviates from local protocols or strategies (survey) on multiple occasions, increasing the 
variation of clinical nutritional practice even more. Similar results were recently shown by 
Martinez et al.21, describing nutritional practices by detailed prospective data collection in 524 
mechanically ventilated patients from 31 international PICUs. They found a wide variation in 
EN recommendations not in agreement with national guidelines.
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Variation in practice was not only observed between PICUs in our current study; we also received 
conflicting statements within single institutions. We corrected for this issue, by weighting by 
the inverse of the number of completed questionnaires per center. The conflicting statements 
underline the observed variation of nutritional practices, which occurs not only between but 
also within individual institutions. A similar discordance in practice within institutions was 
reported in a U.K. survey of glycemic control in PICUs22.
Globally, guidelines for nutritional support have been released by nutritional organizations. The 
American (A.S.P.E.N). and European (ESPEN/ESPGHAN) societies provide specific guidelines for 
nutrition in critically ill children7,8. However, they do not advise on every aspect of nutritional 
support. Agreements and differences between these guidelines and current practice, as shown 
by our survey, are summarized in Supplementary Table 2.
Overall, the most striking similarity between guidelines and local implementation is the 
preference for EN as the preferred route of nutrient delivery and its early initiation in critically 
ill children. 
A specialized NST and feeding protocol are recommended by the A.S.P.E.N guidelines for 
critically ill children7. Availability of an EN protocol is associated with a lower prevalence 
of hospital-acquired infections3, implementation of an NST with an increase in EN use, and 
decreased reliance on PN23. Our survey showed that a nutritional protocol and/or NST were 
available in approximately half the PICUs. In our point prevalence, we found no significant 
difference in caloric intake and use of EN between patients from centers with and without 
a protocol. However, since this was a secondary analysis, it cannot prove or disprove the 
utility of NST/protocols in general. In single centers, a stepwise EN algorithm has been shown 
to significantly improve the timing of EN initiation and the ability to reach nutrient delivery 
goals24,25. The role of protocols and NSTs in optimizing clinical outcomes in the PICU population 
needs to be further examined in well-designed trials.
The ESPEN/ESPGHAN guidelines prefer the measurement of resting energy expenditure (REE) 
to the use of equations. The A.S.P.E.N. guidelines recommend targeted use of IC in a select 
group of patients with suspected metabolic alterations or malnutrition. Both state that in the 
absence of IC, reasonable values can also be derived from formulas, for example, Schofield17, 
but only when applied without the use of universal correction factors7,8. Several other sources 
state that nutritional therapy should be targeted at REE throughout the course of illness26,27. 
However, due to the limited availability and practice of IC11, and also to inaccurate predictive 
equations26-28, it is difficult to assess REE in critically ill children. Use of the WHO and Schofield 
equations, most commonly used to determine requirements, may lead to underfeeding and 
overfeeding and potentially impacts morbidity and mortality3,4. We confirmed the finding of 
previous studies11 that IC to measure REE is used in a small minority of European (20%) and 
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worldwide (14%) PICUs. In contrast with both guidelines, energy needs were calculated with 
use of correction factors in the majority of PICUs in absence of IC. In the point prevalence, two 
thirds of the children on exclusive EN received more calories than Basic Metabolic Rate (BMR) 
calculated by the Schofield or WHO formula.
Timing of nutrition is not widely covered by the pediatric ESPEN/ESPGHAN and A.S.P.E.N. 
guidelines. The adult guidelines from the same societies agree on the importance of early 
EN but contain contradictory recommendations regarding PN14,15,29. The importance and 
benefits of early EN are generally accepted in previous studies in adults and children1,30-33, 
and in critically ill children, a higher intake by enteral route is associated with a lower 60-day 
mortality3. In our survey as well as in the point prevalence, EN was initiated early; within 24 hours 
after admission to the PICU. Overall, characteristics of EN support were quite similar between 
PICUs, with a preference for the gastric route. Also PN was started early, within 48 hours. The 
mentioned difference in PN initiation time between Europe and North America could reflect 
the contradictory recommendations in adult guidelines in these regions, which agree on the 
importance of early EN but not on the time at which supplemental PN should be started15,29. 
The optimal timing and dose of PN is still under debate34. We are currently conducting a trial 
comparing early versus late supplemental PN in critically ill children who are intolerant of EN 
(ClinicalTrials.gov: NCT 01536275), which is expected to complete enrolment by the end of 
2015.
Prospective data from PICUs on patients receiving EN show that only 38-86% of energy goals 
were administered via this route5,35. A variety of barriers impede EN delivery in the PICU 
setting36,37. Only 60% of the patients of the point prevalence were actually on exclusive EN 
within the time frame mentioned in the survey. Although postpyloric feeding might improve 
caloric intake38, most patients evaluated in our survey and point prevalence were fed by the 
gastric route with no difference in nutrient intake compared to children fed via the postpyloric 
route (point prevalence). The time to feed patients exclusively by the enteral route was short; 
59% of respondents thought their PICU was able to feed their patients within 3 days, but this 
time was overestimated. 
Glucose targets in the ESPEN/ESPGHAN pediatric guidelines are supported by limited evidence; 
A.S.P.E.N. does not provide recommendations on macronutrient intake due to insufficient data. 
In our survey glucose intake targets during the first 12-24 hours tended to range between 2 
and 6 mg/kg/min and decreased with increasing weight. The upper limit of glucose intake 
for critically ill children according to ESPEN/ESPGHAN (5 mg/kg/min, based on the maximal 
oxidation rate) was exceeded by more than 7% of PICUs. Our point prevalence showed that in 
75% of the patients, glucose intake differed from the glucose targets mentioned in the first 
part of the survey. However, we should be very careful to draw conclusions from that number, 
Chapter 2
44
R1
R0
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
because only 20 children received glucose infusion exclusively during the first 24 hours of 
admission. Target blood glucose levels varied between tight control20 and a target glucose 
less than 10 mmol/L or 180 mg/dL. This discrepancy in definitions and implementation in 
glucose management has been highlighted before39,40. The discrepancy in definitions and 
implementation stems from the fact that uncertainties about risks and benefits remain20,41. A 
recent U.K. trial showed no benefit42 and another trial in North America is underway.
The strength of our study is the fact that we surveyed the local nutritional strategies as well as 
their implementation in clinical practice. Furthermore, to our knowledge, it is the first study to 
describe the practices in relation to income characteristics of countries in six continents. 
However, our survey may not provide accurate representations of these geographic regions. 
No response rate can be calculated, since the exact number of PICUs represented by WFPICCS is 
unknown. The total number of PICUs in all countries joined in the WFPICCS, as identified in the 
literature, is at least 969, so our 156 PICUs represent a small proportion of all PICUs worldwide. 
Our point prevalence data represent a small fraction of children in the PICUs per center as well 
as in the cohort invited to participate. 
The smaller number of PICUs in the point prevalence study may have caused an aggravation 
of the selection bias, since it is possible that we mainly received point prevalence data from 
PICUs with a strict protocol adherence. Hence, observations may not depict actual practices 
in these centers. However, characteristics of responding PICUs for the point prevalence were 
similar compared with the overall survey respondents (Table 1). 
Furthermore, many physicians have limited knowledge of nutritional practices in their centers. 
Our study may also be limited by the possibility that nonrespondents of this survey were less 
interested in nutritional practices leading to a selection bias and possible distorted reflection. 
On the other hand, this selection bias may strengthen our conclusion, if even in the nutrition-
minded respondents, adherence to available guidelines is limited. 
Finally, the heterogeneity of the PICU population may have caused some difficulties; many 
of the questions required an unambiguous answer, so only most applicable answers were 
provided. And, as feeding practices differ between populations, answers from combined PICUs 
(with neonates or adults; respectively, 20 and 6% of the responding PICUs in this study) may 
falsely increase the perception of variability.
Nevertheless, our survey clearly demonstrates the international variation in nutritional practice 
in critically ill children and the differences due to the limited available guidelines, especially on 
macronutrient administration and calculation of energy targets. Evidence-based guidelines are 
needed, but are challenging to develop due to a heterogeneous PICU population. Guidelines 
can be either very specific in respect to disease and settings, leading to wide variation of 
practice, or be generally applicable with risk of being unfocused and therefore irrelevant in 
specific situations.
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CONCLUSION
In terms of requirements, timing and route, nutritional practices among critically ill children vary 
greatly between PICUs worldwide. Even the limited available guidelines are not consistently 
followed, and high-level evidence is urgently needed. 
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SUPPLEMENTARY TABLES
Supplementary Table 1. Adjusted Odds Ratios (OR) per continent
PICU variable OR (95% CI) P-value
Nutritional protocol
Asia
Africa
North America
South America
Oceania
Europe (reference)
3.96 (1.53-10.25)
+∞
3.96 (1.35-11.66)
0.95 (0.33-2.76)
0.87 (0.25-3.06)
0.005
*
0.013
0.92
0.83
Nutritional support team
Asia
Africa
North America
South America
Oceania
Europe (reference)
1.2 (0.51-2.83)
+∞
0.32 (0.13-0.79)
0.17 (0.05-0.59)
0.11 (0.02-0.62)
0.68
*
0.14
0.005
0.013
Protein target by A.S.P.E.N.
Asia
Africa
North America
South America
Oceania
Europe (reference)
0.7 (0.27-1.81)
+∞
0.31 (0.12-0.76)
0.72 (0.24-2.17)
1.05 (0.32-3.47)
0.46
*
0.011
0.56
0.94
Protein target by ESPEN/ESPGHAN
Asia
Africa
North America
South America
Oceania
Europe (reference)
3.00 (1.29-6.99)
+∞
15.6 (4.18-58.28)
1.3 (0.53-3.22)
6.4 (1.06-38.84)
0.011
*
<0.001
0.57
0.044
Start of enteral nutrition
Asia
Africa
North America
South America
Oceania
Europe (reference)
1.31 (0.50-3.46)
+∞
2.08 (0.79-5.49)
1.19 (0.42-3.38)
0.17 (0.04-0.67)
0.58
*
0.14
0.74
0.012
Start of parenteral nutrition
Asia
Africa
North America
South America
Oceania
Europe (reference)
3.43 (1.43-8.22)
+∞
3.10 (1.53-6.29)
0.92 (0.36-2.35)
1.50 (0.56-4.01)
0.06
*
0.002
0.85
0.42
Glucose intake children < 10 kg
Asia
Africa
North America
South America
Oceania
Europe (reference)
0.64 (0.19-1.1)
+∞
0.44 (0.21-0.92)
0.73 (0.29-1.87)
0.40 (0.14-1.14)
0.08
*
0.029
0.50
0.085
OR= Odds Ratio, CI= Confidence Interval
*Because the estimated odds ratio converged to 0 or infinity, Wald confidence intervals and p-values 
could not be calculated
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PART III
ENERGY EXPENDITURE 

CHAPTER 3
Validation of ventilator-derived VCO
2
 measurements to determine 
energy expenditure in ventilated critically ill children
Dorian Kerklaan, Marjolein E. Augustus, Jessie M. Hulst, Joost van Rosmalen, 
Sascha C.A.T. Verbruggen, Koen F.M. Joosten
Clinical Nutrition 2016, Jan; Epub ahead of print
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ABSTRACT
Background and aims
Indirect calorimetry (IC) is considered the gold standard to determine resting energy 
expenditure (REE), but its availability in PICUs worldwide is limited. Ventilator-derived VCO
2
 
values could potentially improve the possibility of performing REE measurements. We 
investigated whether ventilator-derived VCO
2
 values are comparable to IC-derived VCO
2
 values 
and can be used in clinical practice to determine REE.
Methods
VCO
2
 values were simultaneously collected in mechanically ventilated children from IC 
(Deltatrac®) and Servo-I® ventilator on a minute base over at least a 10 minute period of 
steady state. REE was calculated using the modified Weir formula (for IC) or REE=5.5*VCO
2
 
(L/min)*1440 (for the Servo-I® values) and compared with frequently used predictive equations 
by Schofield and the WHO to calculate REE.
Results
Measurements were performed in 41 children; median age 2 years. The mean relative difference 
between VCO
2
 measured by IC and Servo-I® was 15.6% (p=0.002), and limits of agreement in 
the Bland-Altman analysis were wide. Comparable measurements, defined as a difference 
≤10% between IC and Servo-I® VCO
2
 values, were seen in 18 children (44%), but this proportion 
was 70% in children ≥15 kg. In this group, REE could be accurately predicted using Servo-
I®-derived VCO
2 
values and this method was superior to the use of predictive equations. The 
Servo-I®-derived VCO
2 
values were not sufficiently accurate for the large proportion of children 
weighing <15kg.
Conclusions
In children ≥15 kg, VCO
2 
measurements of the Servo-I® seem sufficiently accurate for use in 
clinical practice and may be used to determine energy expenditure in the future.
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INTRODUCTION
Adequate nutritional support is essential in the care of children admitted to the paediatric 
intensive care unit (PICU) to prevent the negative consequences of underfeeding and 
overfeeding1,2. Measurement of resting energy expenditure (REE) through indirect calorimetry 
(IC) is the preferred method to determine energy requirements in critically ill children. 
Predictive equations by Schofield3 and the World Health Organization (WHO)4, which are based 
on weight and/or weight/height, do not accurately predict REE in critical illness5,6. Mechanically 
ventilated children are at greater risk of not meeting nutritional needs7. In this group, IC can 
be performed by measurement of O
2
 consumption (VO
2
) and CO
2
 elimination (VCO
2
) using 
metabolic monitors; from this REE is calculated using the modified Weir formula (REE (kcal/
day) = [3.941*VO
2
 + 1.106*VCO
2
]*14408). Worldwide, measurement of REE is limited, because 
IC is only available in 14% of the PICUs9. Recently, we have shown that REE can be calculated 
from only the VCO
2
 values derived from IC instruments in critically ill children by the following 
formula: REE=5.5*VCO
2
 (L/min)*144010. 
Modern ventilators are also able to measure CO
2
 via an infrared sensor and to calculate its 
production per minute (VCO
2
) based on instantaneous flow. Ventilator-derived VCO
2
 values 
provide a continuous measurement and thus a potentially more accurate reflection of the 24 
h metabolic status. Since VCO
2
 values can be automatically subtracted from the ventilator, this 
may be a promising alternative for IC. 
The aim of our study was to investigate whether ventilator-derived VCO
2
 values are comparable 
to IC-derived VCO
2
 values and to determine if ventilator based assessment of REE is more 
accurate than predominantly used equations. 
MATERIALS AND METHODS
Subjects
Children up to the age of 18 years on mechanical ventilation through the Servo-I® with VCO
2
 
module (Maquet, Rastatt, Germany) were included in the study when admitted to our PICU. 
Ventilator settings had to meet the criteria of Deltatrac® Metabolic Monitor usage: inspired 
oxygen fraction (FiO
2
) less than 0.6, tube leakage <10% (determined by comparing inspired 
and expired tidal volumes) and Positive End Expiratory Pressure (PEEP) < 10 cmH
2
0. Patients 
on High Frequency Oscillation (HFO), Extra Corporeal Membrane Oxygenation (ECMO) and 
Nitric Oxide (NO) support were excluded. The institutional review board of the Erasmus MC 
approved the study protocol (MEC-2014-169), and (parental) informed consent was obtained 
before the study was started. The study has been performed in accordance with the ethical 
standards laid down in the 1964 Declaration of Helsinki and its later amendments.
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Measurements
VCO
2
 values were simultaneously collected over 1 min intervals from IC (Deltatrac II® Datex-
Ohmeda, Finland) and ventilator (Servo-I® with the Capnostat-III sensor, Maquet, Rastatt, 
Germany) over at least a 10-min period during steady state (less than 10% fluctuation in VCO
2
 
and VO
2 
by IC). Before each study, the calorimeter was calibrated with a reference gas mixture 
(95% O
2
, 5% CO
2
, Datex Division Instrumentarium Corp.) The properties of the Deltatrac® 
metabolic monitor have been described before11. Per-minute measurements from IC with an 
RQ < 0.67 or >1.3 or ventilator-derived VCO
2
 values of 0 were discarded, since these values are 
physiologically impossible.
REE by IC was calculated using the modified Weir formula (REE (kcal/day)=[3.941*VO
2
 + 
1.106*VCO
2
]*14408). For the Servo-I®-derived VCO
2
 values REE was calculated using the 
following formula: REE=5.5* VCO
2
 (L/min)*144010.
REE was calculated using the following predictive equations: Schofield-weight, Schofield-
weight/height3 and the WHO (based on weight)4. The following clinical data were recorded 
from the Patient Data Management System (PDMS) for all patients: sex, age, weight and height, 
diagnosis category, ventilation mode and settings, ICU stay and survival, FiO
2
, temperature, 
PRISM score on admission, use of catecholamines/sedatives/muscle relaxants and beta 
blockers and length of stay at moment of measurement.
Statistical analysis
Descriptive statistics were expressed as means ± standard deviations (SD) in case of normally 
distributed data; otherwise data are expressed as medians with interquartile ranges (IQR). 
Relative differences between IC and other methods were calculated as follows: ((value
 
IC - 
value other method)/ value
 
IC)*100%. Paired samples t-tests were performed to check if there 
was a difference in mean values between methods. Spearman’s correlation coefficient (ρ) was 
used to describe the association between methods of measurement in case of non-normality. 
This correlation coefficient was also used to describe the association between patient weight 
and the absolute value of the relative difference between methods. Linear regression analysis 
was performed to detect proportional and fixed bias between Servo-I®-derived VCO
2
 values 
and IC-derived VCO
2
 values. This method was chosen because the predictor (IC-derived VCO
2
 
values) is expected to be free of error (due to steady state measurements). 
Bland-Altman analysis was used to assess the agreement 1) between Servo-I® and IC-derived 
VCO
2
 values and 2) between IC-derived REE values and calculated REE values (Servo-I® and 
predictive equations)12. Accuracy was also quantified by the proportion of comparable 
measurements, defined as a relative difference ≤10% between values derived from the Servo-I® 
or predictive equations, and those of IC, to be clinically useful. Inaccuracy was quantified by the 
proportion of measurements with a relative difference >30%, to determine the prevalence of 
large errors13. Differences between the children with and without comparable measurements 
were analysed using independent samples t-tests, Mann-Whitney tests or chi-square tests, 
depending on the outcome used.
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The statistical analyses were performed using IBM SPSS statistics 21 for Windows (IBM, Chicago 
IL, USA). All statistical tests were two-sided and statistical significance was defined as a p-value 
<0.05.
RESULTS
Measurements were performed in 41 children, the median age was 2.3 years (IQR 0.3 to 8.4) and 
56% were male. Seventy-two percent of the children were admitted with a medical diagnosis, 
mostly due to respiratory insufficiency (39%). Patient characteristics are shown in Table 1a. A 
controlled ventilation mode was used in 66% of the children; median fractional inspired O
2
 
was 0.26 (IQR 0.21 to 0.31). Metabolic measurements, performed on the 2nd day of ICU stay 
(median), lasted 30 minutes on average. Ventilator settings and metabolic measurement data 
are shown in Table 1b.
Table 1a. Patient characteristics for all children and for subgroups based on compatibility of the indirect 
calorimetry (IC) and ventilator method (defined as a difference ≤10% or >10% between IC and ventilator-
derived VCO
2
 values 
All children
N=41
Difference ≤10%
N=18
Difference >10%
N=23
P-value
Age (yr)
Age < 3 year
Median (IQR)
%
2.3 (0.3-8.4)
51.2
7.4 (3.3-11.9)
22.2
0.6 (0.2-4.6)
73.9
<0.001b
0.002c
Male sex % 56.1 55.6 56.5 0.95c
Weight (kg)
Weight < 10 kg
Median (IQR)
%
12.7 (6.1-28.5)
46.3
22.5 (14-41.8)
16.7
6.3 (4.6-16)
69.6
0.001b
0.002c
Height (cm) Median (IQR) 88
(63-135)
121 
(103-150)
65
(54-98)
<0.001b
Diagnosis
Surgery
Medical
- Respiratory
%
29.3
71.7
38.7
27.8
72.2
30.4
69.6
0.85c
PRISM score Median (IQR) 10 (5-16) 12 (7-16) 9 (5-17) 0.44b
LOS ICU (days) Median (IQR) 7 (4-17) 9 (4-24) 7 (4-11) 0.76b
Survival % 92.7 94.4 91.3 0.70c
Temperature (ºC) Mean ± SD 37.3 ± 1.0 37.6 ± 1.2 37.1 ± 0.7 0.18a
Use of medication
Sedatives
Catecholamines
Muscle relaxants
Beta blockers
%
87.8
24.4
7.3
0
88.9
27.8
11.1
0
87.0
21.7
4.3
0
0.85c
0.66c
0.41c
1.00c
P-values are calculated for differences between the two subgroups using the following tests: aIndependent 
samples t-test, bMann-Whitney test, cChi-square test. 
IQR= Interquartile Range, PRISM= Paediatric Risk of Mortality, LOS= Length of Stay, ICU= Intensive Care 
Unit, SD= Standard Deviation
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Table 1b. Ventilator settings and metabolic measurement data for all children and for subgroups based on 
compatibility of the indirect calorimetry (IC) and ventilator method (defined as a difference ≤10% or >10% 
between IC and ventilator-derived VCO
2
 values) 
All children
N=41
Difference 
≤ 10%
N=18
Difference 
>10%
N=23
P-value
Ventilation mode 
Support
Control
%
34.1
65.9
33.3
66.7
34.8
65.2
0.94c
FiO2 Median (IQR) 0.26 
(0.21-0.31) 
0.28 
(0.21-0.36)
0.25 
(0.21-0.30)
0.57b
Tidal volume (ml)
Inspiratory
Expiratory
Median (IQR)
89 (34-157)
91 (34-180)
142 (96-185)
143 (95-198)
36 (20-90)
35 (19-97)
0.002b
0.001b
Tube leak (%)
(inspiratory-expiratory tidal 
volume)
Mean ± SD -1.9 ± 8.6 -4.8 ± 10.2 0.3 ± 6.4 0.07a
Respiratory rate (/min) Median (IQR) 38 (25-47) 26 (23-35) 43 (38-50) 0.02b
Heart rate (/min) Median (IQR) 116 
(103-139)
113 
(99-124)
128 
(101-142)
0.27b
LOS at moment of 
measurement (days)
Median (IQR) 2 (1-4) 2 (1-4) 2 (1-4) 0.75b
Length of measurement (min) Mean ± SD 30 ± 9.5 34 ± 8 33 ± 11 0.71a
VCO2 Deltatrac (ml/min) Median (IQR) 75.2 
(41.6-116.1)
108.6 
(94-132.9)
45.9 
(28.3-78.6)
<0.001b
VCO2 Servo-I (ml/min) Median (IQR) 74.0 
(27.5-118.0)
111.6 
(94.8-135.9)
33.4 
(12.6-75.3)
<0.001b
P-values are calculated for differences between the two subgroups using the following tests: aIndependent 
samples t-test, bMann-Whitney test, cChi-square test. 
IQR= Interquartile Range, FiO
2
= Fraction inspired Oxygen, LOS= Length of Stay, SD= Standard Deviation
Correlation between Servo-I®-derived VCO
2 
values and IC-derived values was excellent [ρ=0.965 
(95% CI: 0.935 to 0.981)]. However, despite being a necessary condition for agreement, high 
correlation does not automatically imply good agreement. Figure 1a shows the Bland-Altman 
plot for agreement between the two methods for measuring VCO
2 
values. Measurements were 
not comparable with a mean relative difference of 15.6% (p=0.002, one-sample t-test), due to 
underestimation of VCO
2
 values by the Servo-I®. The 95% limits of agreement were wide (-42.4 
% and 73.6%). Linear regression of Servo-I®-derived VCO
2 
values on IC-derived values showed 
a regression line with a slope of 1.15 (95% CI: 1.07 to 1.23) and an intercept at -15.66 (95% CI: 
-23.32 to -8.01). The slope of this regression line was significantly different from 1 (p<0.001), 
and the intercept was significantly different from 0 (p<0.001), reflecting both proportional and 
fixed bias. 
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Comparable measurements, defined as a difference ≤10% between Servo-I®-derived VCO
2 
values and those of IC to be clinically useful, were seen in 18 children (44%). When comparing 
these 18 children to the 23 children with a difference >10%, it was shown that children with 
comparable measurements were significantly older (median 7.4 vs. 0.6 years, p<0.001), and 
taller (median 121 vs. 65 cm, p < 0.001) with higher weight (median 23 vs. 6.3 kg, p=0.001), 
suggesting that the size of the differences between the methods decreases with age and 
weight (Table 1a). There was no significant difference in diagnosis, PRISM score, heart rate, 
temperature, use of medication, ventilation mode or supplied oxygen fraction between these 
2 groups of children. Median VCO
2 
values of the Servo-I® (112 vs 33 ml/min, p<0.001) and of IC 
(109 vs 46 ml/min, p<0.001) were significantly higher, as were the median inspiratory (142 vs 
36 ml, p=0.002) and expiratory (143 vs 35 ml, p=0.001) tidal volumes and the respiratory rate 
(Table 1b). Measurements with a difference >30% between Servo-I®-derived VCO
2 
values and 
those of IC were seen in 11 children (27%).
Since ventilator settings are weight-based, we plotted the relative difference between VCO
2
 
values derived from IC and Servo-I® by weight in kg (Fig. 1c). As shown in this figure, in children 
weighing less than 15 kg (n=21), there was a substantial bias with only 19% of measurements 
being comparable (difference ≤10%). In children weighing 15 kg or more (n=20), 14 children 
(70%) had comparable measurements (difference ≤10%). Among this group there was no 
significant correlation (Spearman’s ρ=-0.222, p=0.347) between weight and the absolute value 
of the relative difference between the two methods, suggesting that the accuracy does not 
depend on weight for children weighing more than 15 kg (see also Fig. 1c). Five percent of 
measurements in children weighing 15 kg showed a difference >30%. Therefore a weight of 15 
kg could be a clinically acceptable threshold for reliability of the Servo-I®-derived VCO
2
 values. 
We used this threshold in the remaining analyses. 
REE values derived from IC were compared to REE values calculated from Servo-I®-derived 
VCO
2 
values. Correlation was high [ρ=0.954 (95%CI: 0.915 to 0.975)]. There was a mean relative 
difference of 19% with wide 95% limits of agreement; -36.3% and 74.4% as shown in Figure 1b. 
The linear regression analysis showed both fixed (p=0.001) and proportional bias (slope 1.09, 
p=0.038). 
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A B
C
Figure 1. Bland-Altman plots for agreement a) between VCO
2
 values derived from indirect calorimetry 
(IC) and Servo-I® measurements with a mean relative difference of 15.6% (panel A), b) between REE values 
derived from IC and Servo-I® measurements with a mean relative difference of 19% (Panel B), and relative 
differences between VCO
2
 values derived from IC (Deltatrac®) and Servo-I® measurements by weight (kg) 
(panel C). The mean relative difference is represented by the solid horizontal line; dotted lines indicate 
95% limits of agreement (panels A and B) or 10% difference between methods (panel C)
In the 20 children weighing 15 kg or more, the agreement of the REE values on the Bland-
Altman plot was considerably better. The mean relative difference between methods was 1.3% 
(p=0.668), with 95% limits of agreement of -24.6% and 27.2% (Fig. 2a). 
This mean relative difference in children ≥15 kg was significantly smaller than that of the 
Schofield-weight (-13.4%, p=0.03), Schofield-weight/height (-13.2%, p=0.03) and WHO (-15.0%, 
p=0.07) equations. As shown by the Bland-Altman plots (Fig. 2), limits of agreement were 
narrowest for Servo-I® based REE when compared with the REE based on predictive equations. 
In children ≥15 kg, the proportion of comparable measurements (difference ≤10% with IC-
derived REE) was highest, whereas the proportion of measurements with a difference >30% 
was lowest for the Servo-I® based REE, when compared with proportions of the equations-
based REE (Fig. 3). 
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Figure 2. Bland-Altman plots for agreement between REE values derived from indirect calorimetry 
(IC: Deltatrac®) and REE values derived a) from Servo-I® measurements, b) from the Schofield-weight 
equation, c) from the Schofield-weight/height equation and d) from the WHO equation. The mean relative 
difference is represented by the solid horizontal line; dotted lines indicate 95% limits of agreement
чϭϬйĂĐĐƵƌĂĐǇ
хϯϬйŝŶĂĐĐƵƌĂĐǇ
Figure 3. Accuracy and inaccuracy quantified by the proportions of measurements with a relative 
difference ≤10% and >30% when comparing REE derived from Servo-I® and predictive equations with 
indirect calorimetry derived REE in children ≥15 kg
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DISCUSSION
In this study we compared the VCO
2 
values by IC (Deltatrac®) and ventilator (Servo-I®) in 41 
mechanically ventilated critically ill children; VCO
2 
values were highly correlated, but not 
comparable due to underestimation of VCO
2 
values by the Servo-I®. 95% limits of agreement in 
the Bland-Altman analysis were wide, showing poor agreement. Clinically useful measurements 
(difference ≤10% between VCO
2 
values of the Servo-I® and those of IC) were seen in children 
with higher weight. In the 20 children weighing ≥15 kg, VCO
2 
measurements were comparable 
between IC and Servo-I® and the derived REE values were more precise than predominantly 
used predictive equations with a smaller difference and narrower limits of agreement. In 81% 
of the children weighing <15 kg, measurements by the Servo-I® deviated >10% from those of 
IC, which made the use of measurements in these children very limited.
The wide limits of agreement may be due to the technical specifications of the sampling 
methods; especially the underestimation by the Servo-I® in children <15 kg may be affected 
by the characteristics of the sensor. VCO
2 
is the volume of eliminated
 
CO
2 
calculated over 
one minute.
 
CO
2 
is mainly measured in the exhaled breath of alveoli (phase 2 and 3 of the 
capnogram, Fig 4), while breath from the upper airways is void of CO
2
 (dead space, phase 1 of 
capnogram). 
Figure 4. Capnogram divided in 4 phases. Phase I represents airway dead space. It is the CO
2
 -free portion 
of the exhaled breath from the conducting airways. Phase II (expiratory upstroke) represents the mixing of 
airway dead space gas with alveolar gas, and is characterised by a significant rise in CO
2
. The steep slope is 
due to fast-emptying alveoli. Phase III is the alveolar plateau; it reflects the level of effective ventilation of 
the alveoli. The gradual rise in the slope is due to late-emptying alveoli. Phase IV is the inspiratory down 
stroke, the beginning of the next inspiration
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The value of CO
2 
depends on the technical performance and location of the CO
2 
sensor. In the 
Servo-I® the CO
2
 fraction is measured mainstream simultaneously with the airway flow by an 
infrared sensor attached to the endotracheal tube.
 
Tidal volume CO
2
 (TVCO
2
) is then calculated 
based on the fraction and the instantaneous flow over a single breath. When the transition 
from phase 2 to phase 3 of the capnogram cannot be clearly identified by the sensor, or if 
there is no alveolar plateau in phase 3, this detection method fails and CO
2
 values may be 
underestimated or even absent. 
This is predominantly a problem in small lungs14, and is also affected by the exhalation 
time of the child. If the exhalation time is too short as compared to the rise time of the CO
2
 
analyser, the alveolar plateau is not reached and CO
2
 is underestimated. This might have 
been a problem in our study; we found significantly higher respiratory rates in children with 
non-comparable measurements leading to decreased exhalation time and therefore worse 
detection of the alveolar plateau. Next to that, adding the Capnostat® airway adapter to the 
ventilation circuit leads to an increase in dead space and even to extra turbulence due to the 
difference in diameter. In smaller children with smaller airways, this increase is relatively large, 
resulting in blending of inspired and expired gasses leading to inaccurate measurements. A 
last explanation for the underestimation of VCO
2
 values in smaller children, is the difficulty of 
distinguishing the inspiratory and expiratory phase in children with higher respiratory rates. 
Since the CO
2 
in inspired gas is approximately 0, false interpretation of this gas for expired gas, 
will underestimate the true CO
2 
values. The method of measurement is different for IC by the 
Deltatrac® device, which uses an air-dilution method, which is independent of the tidal volume 
and exhalation time of the patient measured15. This might explain the wide limits of agreement 
between the two methods. 
In theory, the ventilation mode might also influence the technical performance of the two 
methods, mainly since respiratory rates vary between the different modes. We did not find 
a significant difference in ventilator mode between children with and without clinically 
comparable measurements; this is in accordance with findings of previous studies where no 
significant influence of ventilator mode on VCO
2 
measurements were found in critically ill 
children and adults16,17. 
REE could be accurately predicted based on ventilator-derived VCO
2 
values (mean relative 
difference of 11.3% with narrow limits of agreement), but only in children with a weight ≥15 
kg (n=20). This prediction was more precise than those by the frequently used predictive 
equations to determine REE in critically ill children. The use of weight ≥15 kg could therefore 
be a clinically acceptable threshold.
Our study is limited by its specific study population, due to the restriction of Deltatrac® 
usage to mechanically ventilated children with an FiO
2
 <0.6 and tube leak <10% and without 
additional nitric oxide therapy. Secondly, in the smallest children many VCO
2 
values needed to 
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be discarded because the values were 0 due to the inaccuracy of the device. Larger prospective 
studies on the validation of Servo-I®-derived VCO
2 
values in children weighing ≥15 kg are 
needed.
However, our results show that in clinical practice, the measurement of VCO
2 
values by the 
Servo-I® is a promising option for the determination of energy requirements in children ≥15 kg 
on mechanical ventilation. 
CONCLUSION
Measuring VCO
2 
by use of a ventilator (Servo-I®) is feasible. In children weighing ≥15 kg, VCO
2 
measurements and derived REE predictions of the Servo-I® seem sufficiently accurate for use 
in clinical practice, since their performance is superior to the performance of frequently used 
predictive equations. This method is not suitable for the large proportion of children weighing 
<15kg. In clinical practice VCO
2
 measurements derived from the ventilator can be used to 
calculate REE to guide nutritional therapy in children weighing ≥15kg.  
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ABSTRACT
Objectives
Overfeeding during critical illness is associated with adverse effects such as metabolic 
disturbances and increased risk of infection. Because of the lack of sound studies with clinical 
endpoints, overfeeding is arbitrarily defined as the ratio caloric intake/measured resting 
energy expenditure (mREE) or alternatively as a comparison of measured respiratory quotient 
(RQ) to the predicted RQ based on the macronutrient intake (RQ
macr
). We aimed to compare 
definitions of overfeeding in critically ill mechanically ventilated children based on mREE, RQ 
and caloric intake to find an appropriate definition.
Methods
Indirect calorimetry measurements were performed in 78 mechanically ventilated children, 
median age 6.3 months. Enteral and/or parenteral nutrition was provided according to the 
local guidelines. Definitions used to indicate overfeeding were the ratio caloric intake/mREE of 
>110% and >120% and by the measured RQ>RQ
macr
 + 0.05. 
Results
The proportion of patients identified as overfed varied widely depending on the definition 
used, ranging from 22% (RQ>RQ
macr
+ 0.05), to 40% and 50% (caloric intake/mREE of >120% and 
>110% respectively). Linear regression analysis showed that all patients would be identified as 
overfed with the definition RQ>RQ
macr
+ 0.05 when the ratio caloric intake/mREE exceeded 165%.
Caloric intake was higher in children with a standard deviation score weight for age <-2.
Conclusions
The proportion of mechanically ventilated patients identified as overfed ranged widely 
depending on the definition applied. These currently used definitions fail to take into account 
several relevant factors affecting metabolism during critical illness and are therefore not 
generally applicable to the pediatric intensive care unit population.
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 INTRODUCTION
Nutritional support affects outcome in critically ill children1-3. Undernutrition has long been the 
primary focus for nutritional research, but overfeeding is also prevalent in pediatric intensive 
care units (PICUs)1,4-6. Caloric overfeeding is associated with increased mortality in critical ill 
adults7. It may lead to liver dysfunction by increasing the risk for hepatobiliary complications, 
such as steatosis and cholestasis, and might increase the risk of infection secondary to 
hyperglycemia8. Overfeeding of glucose leads to lipogenesis with an increase in carbon 
dioxide9, resulting in a difficulty to wean from the ventilator10,11. Furthermore, overfeeding 
during critical illness might evoke a phenotype of autophagy deficiency as a potentially 
important contributor to mitochondrial, organ and skeletal muscle damage, particularly when 
amino acid enriched parenteral nutrition (PN) is provided12,13. Also in critically ill children, 
unintended consequences of overfeeding are likely to occur14.
To prevent these detrimental effects, nutritional therapies are ideally guided by resting energy 
expenditure (REE) throughout the course of illness15. REE can be measured (mREE) by indirect 
calorimetry or predicted by use of equations, and might be affected by the type, severity and 
stage of disease16-18. Because there is a lack of studies using clinical endpoints to determine 
the optimal caloric intake in critically ill children, recommendations on minimum caloric 
intake are often based on equilibrating energy or protein balances19,20. So far, however, no 
clinical endpoint or (surrogate) marker has been studied to determine the optimal maximum 
caloric intake in this population. Overfeeding is arbitrarily defined as a ratio caloric intake/
REE >110%7,21-23 or >120%14,24-28 (see related studies in Table 1). As an alternative method 
the comparison of measured respiratory quotient (RQ) to the predicted RQ based on the 
macronutrient intake (RQ
macr
) is suggested29,30. The measured RQ is derived from the ratio of 
CO
2
 production over O
2
 consumption and reflects the use of different substrates. An RQ value 
>1.0 indicates lipogenesis, and is frequently used to identify carbohydrate overfeeding29. 
RQ
macr
 is the weighted average of the RQs of the different macronutrients administered, which 
can be obtained from the modified Lusk table. A difference >0.05 between RQ and RQ
macr
 has 
been proposed to define overfeeding29,30. 
The aim of the present study was to compare different definitions of overfeeding in critically 
ill mechanically ventilated children based on measurements of mREE, RQ and caloric intake 
and to find an appropriate definition to study the effect of overfeeding on clinical endpoints 
in future trials.
Chapter 4
72
R1
R0
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39 Ta
bl
e 
1.
 O
ve
rv
ie
w
 o
f c
lin
ic
al
 st
ud
ie
s c
on
ce
rn
in
g 
ov
er
fe
ed
in
g 
in
 c
rit
ic
al
ly
 il
l c
hi
ld
re
n
St
u
d
y
D
es
ig
n
, P
at
ie
n
ts
A
p
p
lie
d
 d
efi
 n
it
io
n
 
ov
er
fe
ed
in
g
 
%
 o
ve
rf
ee
d
in
g
R
is
k 
fa
ct
o
rs
 fo
r 
ov
er
fe
ed
in
g
O
u
tc
o
m
e
Ta
yl
or
 e
t a
l.,
 C
lin
 N
ut
r. 
20
03
 N
ut
rit
io
na
l 
su
p
p
or
t i
n 
cr
iti
ca
lly
 il
l c
hi
ld
re
n 
 
Re
tr
os
p
ec
tiv
e 
st
ud
y 
in
 9
5 
ch
ild
re
n 
in
 
PI
C
U
 ≥
3 
da
ys
M
ed
ia
n 
ag
e 
7.
7 
(r
an
ge
 1
-1
8.
6)
 y
ea
rs
Ra
tio
 c
al
or
ic
 in
ta
ke
/
p
RE
E 
(S
ch
ofi
 e
ld
-
w
ei
gh
t)
 >
11
0%
18
%
 (n
=
13
5)
 
p
at
ie
nt
 d
ay
s 
Pa
re
nt
er
al
 n
ut
rit
io
n
H
ul
st
 e
t a
l.,
 N
ut
rit
io
n.
 2
00
5 
A
de
qu
at
e 
fe
ed
in
g 
an
d 
th
e 
us
ef
ul
ne
ss
 o
f t
he
 re
sp
ira
to
ry
 
qu
ot
ie
nt
 in
 c
rit
ic
al
ly
 il
l c
hi
ld
re
n
Pr
os
p
ec
tiv
e 
st
ud
y 
in
 9
8
m
ec
ha
ni
ca
lly
 v
en
til
at
ed
 c
hi
ld
re
n,
 
m
ed
ia
n 
ag
e 
14
.6
 d
ay
s 
(r
an
ge
 0
-1
5.
2 
y)
Ra
tio
 c
al
or
ic
 in
ta
ke
/
m
RE
E 
>
12
0%
69
%
 p
at
ie
nt
 d
ay
s
N
on
e 
id
en
tifi
 e
d
O
os
te
rv
el
d 
et
 a
l.,
 P
ed
ia
tr
 C
rit
 C
ar
e 
M
ed
. 2
00
6 
 
En
er
gy
 e
xp
en
di
tu
re
 a
nd
 b
al
an
ce
 fo
llo
w
in
g 
p
ed
ia
tr
ic
 in
te
ns
iv
e 
ca
re
 u
ni
t a
dm
is
si
on
: a
 
lo
ng
itu
di
na
l s
tu
dy
 o
f c
rit
ic
al
ly
 il
l c
hi
ld
re
n
O
b
se
rv
at
io
na
l s
tu
dy
 in
 4
6 
ch
ild
re
n,
 
m
ed
ia
n 
ag
e 
4 
(IQ
R 
0-
18
) y
ea
rs
Ra
tio
 c
al
or
ic
 in
ta
ke
/
m
RE
E 
>
11
0%
28
%
 p
at
ie
nt
 d
ay
s
Pa
re
nt
er
al
 n
ut
rit
io
n
D
e 
N
ee
f e
t a
l.,
 C
lin
 N
ut
r. 
20
08
N
ut
rit
io
na
l g
oa
ls
, p
re
sc
rip
tio
n 
an
d 
de
liv
er
y 
in
 
a 
p
ed
ia
tr
ic
 in
te
ns
iv
e 
ca
re
 u
ni
t
Pr
os
p
ec
tiv
e 
st
ud
y 
in
 8
4 
m
ec
ha
ni
ca
lly
 
ve
nt
ila
te
d 
ch
ild
re
n 
in
 P
IC
U
 ≥
3 
da
ys
, 
m
ed
ia
n 
ag
e 
4.
7 
(IQ
R 
0.
9-
18
.9
) m
on
th
s
Ra
tio
 c
al
or
ic
 in
ta
ke
/
p
RE
E 
(W
H
O
)>
11
0%
26
.5
%
 p
at
ie
nt
 d
ay
s
N
on
e 
id
en
tifi
 e
d
M
eh
ta
 e
t a
l.,
 P
ed
ia
tr
 C
rit
 C
ar
e 
M
ed
. 2
01
1 
En
er
gy
 im
b
al
an
ce
 a
nd
 th
e 
ris
k 
of
 o
ve
rf
ee
di
ng
 
in
 c
rit
ic
al
ly
 il
l c
hi
ld
re
n
Pr
os
p
ec
tiv
e 
st
ud
y 
in
 3
3
m
ec
ha
ni
ca
lly
 v
en
til
at
ed
 c
hi
ld
re
n,
 
m
ed
ia
n 
ag
e 
2 
(r
an
ge
 0
.1
-2
5.
8)
 y
ea
rs
Ra
tio
 c
al
or
ic
 in
ta
ke
/
m
RE
E 
>
12
0%
83
%
 (n
=
24
) 
ch
ild
re
n
A
ge
 <
 1
 y
ea
r 
Ky
le
 e
t a
l.,
 J 
Ac
ad
 N
ut
r D
ie
t. 
20
12
   
N
ut
rit
io
n 
su
p
p
or
t i
n 
cr
iti
ca
lly
 il
l c
hi
ld
re
n:
 
un
de
rd
el
iv
er
y 
of
 e
ne
rg
y 
an
d 
p
ro
te
in
 
co
m
p
ar
ed
 w
ith
 c
ur
re
nt
 re
co
m
m
en
da
tio
ns
Re
tr
os
p
ec
tiv
e 
st
ud
y 
in
 2
40
 c
hi
ld
re
n 
in
 
PI
C
U
 >
2 
da
ys
Ra
tio
 c
al
or
ic
 in
ta
ke
/
p
RE
E 
(S
ch
ofi
 e
ld
-
w
ei
gh
t)
 >
11
0%
30
%
 (n
=
34
4)
 
p
at
ie
nt
 d
ay
s
N
on
e 
id
en
tifi
 e
d
D
ok
ke
n 
et
 a
l.,
 JP
EN
 J 
Pa
re
nt
er
 E
nt
er
al
 N
ut
r. 
20
15
In
di
re
ct
 c
al
or
im
et
ry
 re
ve
al
s 
th
at
 b
et
te
r 
m
on
ito
rin
g 
of
 n
ut
rit
io
n 
th
er
ap
y 
in
 p
ed
ia
tr
ic
 
in
te
ns
iv
e 
ca
re
 is
 n
ee
de
d
Pr
os
p
ec
tiv
e 
st
ud
y 
in
 3
0 
m
ec
ha
ni
ca
lly
 
ve
nt
ila
te
d 
ch
ild
re
n,
 m
ed
ia
n 
ag
e
15
.5
 (r
an
ge
 3
-1
68
) m
on
th
s
Ra
tio
 c
al
or
ic
 in
ta
ke
/
m
RE
E 
>
12
0%
60
.5
%
 (n
=
63
) 
p
at
ie
nt
 d
ay
s
N
on
e 
id
en
tifi
 e
d
de
 B
et
ue
 e
t a
l. 
Cl
in
 N
ut
r. 
20
15
A
ch
ie
vi
ng
 e
ne
rg
y 
go
al
s 
at
 d
ay
 4
 a
ft
er
 
ad
m
is
si
on
 in
 c
rit
ic
al
ly
 il
l c
hi
ld
re
n;
 p
re
di
ct
iv
e 
fo
r o
ut
co
m
e?
 
Pr
os
p
ec
tiv
e 
st
ud
y 
in
 3
25
 c
hi
ld
re
n 
at
 
da
y 
4 
af
te
r a
dm
is
si
on
, m
ed
ia
n 
ag
e 
0.
14
 (r
an
ge
 0
-1
8)
 y
ea
rs
Ra
tio
 c
al
or
ic
 in
ta
ke
/
p
RE
E 
(S
ch
ofi
 e
ld
-
w
ei
gh
t)
 >
12
0%
74
%
 o
f c
hi
ld
re
n 
on
 P
N
 a
nd
 E
N
 
co
m
b
in
ed
 (n
=
24
0)
43
%
 o
f c
hi
ld
re
n 
on
ly
 o
n 
EN
 (n
=
14
0)
Yo
un
ge
r c
hi
ld
re
n,
M
al
no
ur
is
hm
en
t
M
ul
tiv
ar
ia
te
 a
na
ly
si
s:
 b
ei
ng
 o
ve
rf
ed
 n
ot
 a
ss
oc
ia
te
d 
w
ith
 c
ha
ng
e 
in
 n
o.
 o
f d
ay
s 
un
til
 d
is
ch
ar
ge
d 
al
iv
e,
 n
o.
 o
f d
ay
s 
on
 th
e 
ve
nt
ila
to
r, 
no
. o
f d
ay
s 
on
 
an
tib
io
tic
s,
 n
o.
 o
f n
ew
 in
fe
ct
io
ns
 o
r s
ite
 o
f i
nf
ec
tio
n
IQ
R 
=
 In
te
rq
ua
rt
ile
 R
an
ge
, P
IC
U
 =
 P
ed
ia
tr
ic
 In
te
ns
iv
e 
C
ar
e 
U
ni
t, 
m
RE
E 
=
 m
ea
su
re
d 
Re
st
in
g 
En
er
gy
 E
xp
en
di
tu
re
, p
RE
E 
=
 p
re
di
ct
ed
 R
es
tin
g 
En
er
gy
 E
xp
en
di
tu
re
, W
H
O
 =
 W
or
ld
 
H
ea
lt
h 
O
rg
an
iz
at
io
n,
 E
N
 =
 E
nt
er
al
 N
ut
rit
io
n,
 P
N
 =
 P
ar
en
te
ra
l N
ut
rit
io
n
Use of indirect calorimetry to detect overfeeding
73
4
R1
R0
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
METHODS
Neonates and children up to the age of 18 years admitted to our level III multidisciplinary PICU 
were consecutively included in the study when they met the criteria for indirect calorimetric 
measurements: mechanical ventilation with a Servo ventilator (Siemens-Elema, Solna, 
Sweden); FiO
2
 <0.6, tube leakage <10% and hemodynamic stable condition (blood pressure 
and heart rate within 2 standard deviation (SD) of age-related values). 
The institutional review board of the Erasmus MC approved the study protocol, and written 
parental informed consent was obtained before children entered the study. Data, including 
age, sex, weight, primary diagnosis, surgical status, days on mechanical ventilation, length of 
ICU stay, route of nutritional support, and energy and macronutrient intake were recorded. The 
severity of illness on admission was assessed by the Pediatric Risk of Mortality score (PRISM)31. 
Nutritional status on admission was defined by weight for age (WFA) SD-scores using Dutch 
Growth Standards32; children were categorized as underweight if their WFA SD-score was <-2.
Indirect calorimetry measurements were performed as soon as possible after admission. Oxygen 
consumption (VO
2
) and carbon dioxide production (VCO
2
), standardized for temperature, 
barometric pressure, and humidity were measured for at least 2 hours using the Deltatrac® 
(Datex Division Instrumentarium, Helsinki, Finland) metabolic monitor. Measured REE (mREE) 
was calculated with the modified Weir formula33. The properties of the Deltatrac® metabolic 
monitor have been described previously34. The RQ was calculated from the measured VO
2 
and 
VCO
2 
levels24. 
Children were fed enterally and/or parenterally according to the local feeding protocol25 and 
the judgement of the attending physician. A glucose infusion was provided during the first 12 
to 24 hours after admission aimed at a carbohydrate intake of 4 to 6 mg/kg/min (children<30kg) 
or 2 to 4 mg/kg/min (>30kg)35,36. Enteral nutrition (EN), consisting of human milk or standard 
formula, was started as soon as possible in all patients, either continuously or intermittently 
through a postpyloric or nasogastric tube. PN was started within 48 hours after admission in 
case of insufficient EN, either by peripheral infusion or by central venous access. Fluid and 
electrolyte intakes were adjusted to individual requirements. 
Energy goals for EN were based on the body weight-based Schofield equation37 on the first day 
of admission and on the Recommended Dietary Allowances for the subsequent length of stay 
(Dietary Reference Intake: energy, protein and digestible carbohydrates, 2001, Health Council 
of the Netherlands: The Hague). Parenteral energy goals were based on the weight-based 
guidelines of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition 
(ESPGHAN) throughout PICU stay38. Actual total daily intake of energy, carbohydrate, protein 
and fat were derived from patient records on the day of calorimetry. 
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An RQ of administered macronutrients (RQ
macr
) was calculated based on the modified Lusk 
table after determination of the ratio of carbohydrate to fat for the total nonprotein calories 
of the intake provided on the day of the measurement29. The measured RQ was compared 
to the RQ
macr
. The RQ was assumed to approximate the RQ
macr
, if RQ = RQ
macr
 ± 0.0529,30. 
No corrections were made for losses of macronutrients in stools when EN was given39.
The following definitions of energy overfeeding were used and compared:
1) Caloric intake/mREE >110%
2) Caloric intake/mREE >120%
3) RQ > RQ
macr
 + 0.05 
Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 21.0 
(Released 2012. SPSS Armonk, NY: IBM Corp.). Results are expressed as proportion, mean and 
standard deviation, or median and interquartile range (IQR). Differences between groups were 
analyzed by use of the Mann-Whitney and Kruskal-Wallis test. Pearson’s correlation coefficient 
(r) was used to evaluate the strength of the relation between RQ and carbohydrate intake, and 
between the continuous variables on which the definitions are based: RQ-RQ
macr
 and the ratio 
caloric intake/mREE. Linear regression analysis was used to further define the relation between 
RQ-RQ
macr
 and the ratio caloric intake/mREE. Two-tailed P-values <0.05 were considered 
significant. 
RESULTS
Patients
Measurements were performed in 78 children (51 boys). Clinical and nutritional characteristics 
are shown in Table 2. Median age was 6.3 (Interquartile Range [IQR]1.5 to 29.3) months. An 
SD-score for WFA<-2 was found in 23 children (30%). The reason for admission was medical in 
77% of the children, with 32% respiratory insufficiency. The median length of stay at the time 
of measurement was 1 day (IQR 1 to 3) after PICU admission. All children were mechanically 
ventilated and sedated with midazolam and/or morphine. Seventy-four percent of the children 
received EN; 57% were fed by EN exclusively; and 18% received a mixture of EN and PN. Total 
PN was provided in 15% of the children; 10% of the children received only glucose infusion at 
time of measurement.
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Table 2. Clinical and nutritional characteristics of the patients
N = 78
Male sex N (%) 51 (54%)
Age 
Months
Age < 1 year
Median (IQR)
N (%)
6.3 (1.5-29.3) 
46 (59)
Weight (kg) Median (IQR) 6.4 (3.9-12.6)
SD-score WFA 
< -2
Mean (±SD) 
N (%)
-1.3 (±1.8)
23 (30)
Diagnosis
Medical
Surgery
N (%)
60 (77)
18 (23)
PICU length of stay (days) Median (IQR) 8 (5-13.5)
Mortality N (%) 3 (7)
PRISM score Median (IQR) 10 (5-16)
mREE
Total
Per kg
Median (IQR)
Mean (±SD)
312 (217-640)
48 (±9.6)
RQ
Measured
RQ > 1
Macronutrients
Mean (±SD) 
N (%)
Median (IQR)
0.88 (± 0.08)
5 (6.4)
0.90 (0.86-0.96)
Body temperature
Temp ≥ 38.5ºC
Mean (±SD) 
N (%)
37.5 (± 0.6)
7 (9)
Day of measurement
Day > 7
Median (IQR)
N (%)
1 (1-3)
8 (10)
Route of nutrition
Exclusive EN
Exclusive PN
EN and PN combined
Glucose only
N (%)
44 (57)
12 (15)
14 (18)
8 (10)
Intake
Kcal/kg/day
Caloric intake>mREE
Protein (g) per kg
Fat (g) per kg
Carbohydrates mg/kg/min
Mean (±SD)  
N (%)
Median (IQR)
Median (IQR)
Mean (±SD)
52 (±29)
45 (58)
1.1 (0.5-2.1)
1.3 (0.4-2.7)
5.4 (±2.8)
IQR = Interquartile Range, SD = Standard Deviation, WFA = Weight for Age, PICU = Pediatric Intensive Care 
Unit, PRISM = Pediatric Risk of Mortality score (maximum total score 74), mREE = measured Resting Energy 
Expenditure, RQ = Respiratory Quotient, EN = Enteral Nutrition, PN = Parenteral Nutrition
Energy overfeeding
Table 3 shows patient demographics and nutritional characteristics in relation to the different 
definitions of energy overfeeding studied.
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For the total population, mean mREE was 48 (±9.6) kcal/kg compared to a mean caloric 
intake of 52 (±29) kcal/kg/day. The mean RQ was 0.88 (±0.08). Fifty percent of the children 
(n=39) were provided with >110% of mREE and 40% (n=31) with >120%. These children had a 
significant lower SD-score WFA (-1.8 vs -0.5, p=0.004) and, as expected, had a significant higher 
intake of calories (p<0.001), protein (p<0.001), fat (p<0.001), and carbohydrates (p<0.001) per 
kilogram compared to the children without overfeeding. Children with an SD-score WFA<-2 
had a significant higher intake of calories per kilogram than children with an SD-score WFA≥-2 
(61 vs 48 kcal/kg/d, p=0.031). The ratio caloric intake/mREE was 119% in children with an SD-
score WFA<-2 and 100% in the children with an SD-score ≥-2 (p=0.091).
In 22% of the children (n=17) RQ was higher than RQ
macr
 + 0.05. Fourteen of these children (82%) 
were also identified as overfed according to the ratio caloric intake/mREE >120% definition. 
Children identified as overfed by RQ had a significant higher intake of calories (71 vs 44 kcal/
kg/d, p=0.001), protein (2.2 vs 0.9 g/kg/d, p<0.001), and fat (2.9 vs 0.9 g/kg/d, p<0.001) per 
kilogram and a higher ratio caloric intake/mREE (71 vs 44 kcal/kg/d, p<0.001) compared with 
the children with an RQ<RQ
macr
 ± 0.05. There was a significant positive correlation between 
RQ-RQ
macr
 and the ratio caloric intake/mREE (r=0.627, p<0.001) (Fig. 1). Caloric overfeeding as 
defined by RQ (RQ exceeding RQ
macr
+ 0.05) occurred if the ratio caloric intake/mREE exceeded 
165%, reflecting a mean caloric intake of 79 kcal/kg/day in our population. 
Table 3. Characteristics of children identified as overfed according to predefined definitions 
Caloric intake/
mREE
>110%
N = 39
Caloric intake/
mREE
>120%
N = 31
RQ>RQmacr+0.05
N = 17
Male sex N (%) 22 (56) 18 (58) 7 (41)
Age (months) Median (IQR) 3.6 (1.0-17) 3.7 (1.0-18) 4.6 (1.7-15)
Weight (kg) Median (IQR) 4.2 (3.4-8.8) 4.2 (3.4-8.8) 4.5 (3.5-8.4)
SD-score WFA
<-2
Mean (±SD)
N (%)
-1.9 (±1.8)
14 (36)
-1.8 (±1.7)
11 (36)
-1.8 (-3.8- -1.3)
8 (47)
mREE/kg Mean (±SD) 50 (±8.3) 52 (±8.8) 50 (40-54)
RQ measured Mean (±SD) 0.90 (± 0.08) 0.90 (± 0.08) 0.95 (0.93-0.98)
Intake
Kcal/kg/d
Protein g/kg/d
Fat g/kg/d
Carbohydrates mg/kg/min
Mean (±SD)  
Median (IQR)
70 (±25)
1.7 (1.0-2.5)
2.5 (1.3-3.5)
6.8 (5.4-8.6)
71 (±24)
2.1 (±0.9)
2.9 (±1.5)
6.9 (5.7-8.6)
71 (53-92)
2.2 (1.3-2.5)
2.9 (2.0-4.1)
6.5 (3.7-8.4)
Route of nutrition
Exclusive EN
Exclusive PN
EN and PN 
Glucose only
N (%)
26 (67)
6 (15)
6 (15)
1 (3)
21 (68)
4 (13)
6 (19)
-
11 (65)
2 (12)
4 (24)
-
IQR = Interquartile Range, SD = Standard Deviation, WFA = Weight for Age, PICU = Pediatric Intensive Care 
Unit, mREE = measured Resting Energy Expenditure, RQ = Respiratory Quotient, EN = Enteral Nutrition, 
PN = Parenteral Nutrition
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Figure 1. Correlation between RQ-RQ
macr
 and caloric intake/mREE (r=0.627, p<0.001). Dotted line 
represents the generally applied cut-off value for overfeeding
RQ = Respiratory Quotient, mREE = measured Resting Energy Expenditure
DISCUSSION
This study showed that when different definitions indicating overfeeding were applied to a 
group of critically ill mechanically ventilated children, a wide variation in the proportion of 
children identified as overfed was found, ranging from 23% to 50%. RQ exceeded RQ
macr
 +0.05 
from a ratio caloric intake/mREE of 165%.  
Overfeeding in critically ill children has been predominantly reported with the definition 
based on the ratio caloric intake/REE (Table 1)14,21-25,27,28. The proposed and frequently used 
upper limits of 110% or 120% are, however, consensus based and not derived from sound 
studies with clinical endpoints. A recent systematic review in which 9 studies were summarized 
and a recent single-center study by Jotterand Chaparro et al., investigated the influence of 
energy and protein intake on protein balance in critically ill children. It was found that a 
minimum intake of respectively 57 and 58 kcal/kg/day and of 1.5 g protein/kg/day were 
required to achieve a positive protein balance19,20. Taking into account a ratio caloric intake/
mREE >110% and >120%, a subgroup analysis of our study showed that 36% and 23% of the 
children, respectively, did not achieve this minimal energy intake of 57 kcal/kg/day but would 
be identified as being overfed. This identification of a patient as being overfed while they can 
be presumed to have a negative protein balance would be a contradiction, regardless of the 
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fact that a positive protein balance should be interpreted as an intermediate and not a clinical 
outcome measure40. Based on our data the upper limit of caloric intake was found to be 165% 
of the ratio caloric intake/mREE based on RQ-RQ
macr, 
reflecting a caloric intake of 79 kcal/kg/day. 
This upper limit is more in line with the identified minimum intakes than the most frequently 
used limits of 110% and 120%.
An age-dependent definition of overfeeding, however, might be necessary. In the single-
center study by Jotterand Chaparro et al., it was shown that nitrogen balance was equilibrated 
with a caloric intake close to mREE in children younger than 3 years, and 122% of mREE in 
children older than 3 years19. 
Another reason to question the use of the ratio caloric intake/mREE to identify overfeeding 
throughout the course of PICU stay is the effect of the phase of critical illness. Several studies 
have shown that REE remains stable during the first week after admission16,21,41. This implies 
that, when using this ratio to guide nutritional therapy, the upper limit of caloric intake remains 
stable in this period as well, even if the patient is recovering, and extra energy is presumed 
necessary for tissue repair and growth. Furthermore, REE is measured in rest, whereas the 
patient in the recovery phase will be mobilizing. These patients have a higher energy need 
than patients who are not able to mobilize, but this increase in caloric requirements cannot be 
identified with current methods.
So far, only one study, with a limited number of surgical infants, investigated the relation 
between caloric intake and the phases of the metabolic stress response using an RQ>1.0, 
reflecting lipogenesis, to define overfeeding11; it was found that the rate of overfeeding was 
lower in the resolving stress group, defined by a C-reactive protein (CRP) level of 2 mg/dL or 
less, compared to the acute stress group (CRP >2 mg/dL) (33.4 vs 69.2%, p<0.001). Although 
inflammatory parameters such as a CRP level might be used to guide caloric intake, it is not 
clear how soon energy intake can be increased without the risk of overfeeding, because no 
single metabolic or hormonal markers or parameters have consistently shown to indicate the 
start of the anabolic phase. When the child is in the recovery phase and is able to mobilize, 
optimal caloric intake might be as high as the recommended intake for healthy children24 or 
even higher to compensate for catch-up growth.
The risk of overfeeding might also be affected by the nutritional status of the child. More 
attention is paid to nutritional support of malnourished children or children at nutritional 
risk42 and absolute weight-based intake goals are lower for malnourished patients than 
nonmalnourished peers25. Also in our study, caloric intake was higher in children with an 
SD-score WFA<-2. Therefore nutritional goals are more easily reached in this population, 
but with a concomitant increased risk of overfeeding. Besides the increased caloric intake, 
malnourishment is likely to affect energy expenditure by an altered body composition. In a 
recent study, mREE in malnourished critically ill children was found to be 80% of predicted43, 
highlighting the need for measurement of energy requirements to identify overfeeding in 
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this specific group of children. This hypometabolic state was reflected in an increased ratio 
caloric intake/mREE of 145%43. We also found that children identified as being overfed by the 
ratio caloric intake/mREE, had a significantly lower SD-score, compared to children without 
overfeeding. This contrasting combination of lowered mREE and caloric overfeeding described 
in malnourished children, might be linked to an amplification of mitochondrial dysfunction 
associated with the stress response43,44. Therefore the effect of nutritional status on the risk of 
overfeeding may be intertwined with the phases of critical illness.
Because the difference of RQ-RQ
macr 
reflects the use of different macronutrients within a 
patient, it acts as a more functional parameter to describe overfeeding throughout the course 
of illness and for different age groups. The use of this parameter might be, however, limited 
when caloric intake is less than mREE45 and during the acute phase of critical illness when 
endogenous energy production is present, even with adequate energy provision46. RQ is also 
affected by factors unrelated to feeding29.
Our study is further limited by the small number of patients, the lack of clinical endpoints, 
and the fact that we only performed single measurements. Therefore, it should be followed 
by larger prospective studies on the effect of intake on clinical outcomes, preferably with a 
longitudinal design. 
To conclude, the proportion of mechanically ventilated patients identified as overfed ranged 
widely from 23% to 50% depending on the criteria applied. The currently used definitions to 
describe overfeeding fail to take into account several relevant factors associated with critical 
ill children and are therefore not generally applicable to the PICU population. We advocate the 
development of a definition for overfeeding dependent on age, nutritional status and phase 
of illness, preferably based on clinical outcome measures. 
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PART IV
SUPPLEMENTAL PARENTERAL NUTRITION

CHAPTER 5
Evidence for the use of parenteral nutrition 
in the pediatric intensive care unit
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ABSTRACT
Background and aims
During hospitalization in a pediatric intensive care unit (PICU), critically ill children are fed 
artificially. Administered via the preferred enteral route, caloric targets are often not reached. 
Hence, parenteral nutrition is given to this patient population. In this review we analyzed the 
available evidence from randomized controlled trials (RCTs) that supports the use of parenteral 
nutrition in children during critical illness. 
Methods
A search strategy in Ovid MEDLINE and Ovid EMBASE was created and trial registries were 
screened to identify the relevant RCTs. Studies were included if they were randomized 
controlled trials, involved pediatric patients admitted to PICU, and compared different dosing/
compositions of parenteral nutrition. Descriptive studies and reviews were excluded.
Results
Of the 584 articles identified by the search strategy, only 114 articles were retained after title 
screening. Further abstract and full text screening identified 6 small RCTs that compared 
two dosing/composition strategies of parenteral nutrition. These trials reported differences 
in surrogate endpoints without an effect on hard clinical endpoints. The RCTs observed 
improvements in these surrogate endpoints with the use of more calories or when parenteral 
glutamine or fish oil was added.
Conclusions 
The few RCTs suggest that surrogate endpoints can be affected by providing parenteral 
nutrition to critically ill children, but the studies were not statistically powered to draw 
meaningful clinical conclusions. Large RCTs with clinically relevant outcome measures are 
urgently needed to support the current nutritional guidelines that advise the use of parenteral 
nutrition in the PICU.
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INTRODUCTION
For critically ill children who require an admission to the Pediatric Intensive Care Unit (PICU), 
nutritional support is advised as soon as possible to prevent or reduce catabolism, with the 
intention to enhance recovery while allowing normal growth1. The enteral route is preferred 
as it has been suggested that feeding via the gut maintains gut integrity and may reduce the 
risk of infection, in comparison with feeding via the parenteral route1. However, when only 
enteral nutrition (EN) is provided during PICU stay, caloric targets are often not reached. This is 
explained by intestinal dysfunction as part of the critical illness, the administered medication 
that affects the gastrointestinal tract, frequent interruptions of enteral feeding and the need 
for fluid restriction2. Hence, a caloric deficit quickly builds up in critically ill children, the 
severity of which has been associated with poor outcomes and impaired growth3,4. Children 
are particularly vulnerable for accumulating a pronounced caloric deficit as their relative 
energy requirements are 2-3 times higher than those of adults. Reaching the preset caloric 
targets is easier when parenteral nutrition (PN) is administered. However, feeding children 
via the parenteral route has shown to increase the risk of metabolic disturbances such as 
hyperglycemia and dyslipidemia and to be associated with more nosocomial infections5. 
Therefore, the question remains if, and when, PN should be initiated for critically ill children 
in the PICU. 
The currently available guidelines are not very specific on how energy requirements should be 
determined for critically ill children nor on how the caloric deficit should best be prevented. 
The European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Society 
for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) guidelines state that the 
initiation of PN depends on the clinical condition and the age and size of the infant or child6. 
These guidelines advocate to start PN in infants shortly after admission to PICU whenever 
EN fails, but in older children and adolescents longer periods of inadequate nutrition may 
be tolerated. The American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) guidelines 
make no specific recommendations for the use and dosing of PN for children treated in the 
PICU1. However, the A.S.P.E.N. guidelines state that for older children, a caloric deficit can be 
tolerated for up to one week. These different and rather non-specific recommendations have 
resulted in nutritional practices that vary widely among PICUs worldwide7.
Therefore, we performed an up to date review to assess all available evidence from randomized 
controlled trials (RCTs), with hard clinical as well as surrogate endpoints, that supports the use 
of parenteral nutrition in children during critical illness.
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METHODS
An extensive search strategy in both Ovid MEDLINE and Ovid EMBASE was created and trial 
registries were screened to identify the relevant RCTs. Studies were included if they were 
randomized controlled trials, involved pediatric patients admitted to PICU, and compared 
different dosing/compositions of parenteral nutrition. Parenteral nutrition was defined as 
intravenously administered macronutrients (carbohydrates, lipids, proteins) of which dosing 
differed between treatment groups in the included RCTs.
The time frame of the search strategy was from the inception of these databases up to 
September 7, 2015. Also non-English language studies were taken into account. In addition, 
trial registries were screened and reference lists of all potentially relevant studies were analyzed 
manually. The detailed search strategies are described in Supplementary Table 1. We included 
only randomized controlled trials, and any eventual post-hoc analyses thereof, of pediatric 
patients admitted to the PICU that compared different dosing/compositions of parenteral 
nutrition. Descriptive studies and reviews were excluded. Also studies involving the adult or 
premature newborn population were excluded. We focused on timing and dosing as well as 
composition of parenteral macronutrients and did not address other nutritional aspects in the 
PICU. The initial focus was on studies with hard clinical outcome measures (such as infections, 
length of PICU stay, or mortality). However, a systematic review from 2009 revealed that one 
study used a clinical outcome measure. Therefore, we also included studies with surrogate 
endpoints (such as nitrogen balance or markers of inflammation). The quality assessment of 
the individual studies was based on the Jadad score8 and the Black and Downs score9.
Two authors (TF, DK) independently screened the search results. Two selection criteria were 
premised for title and abstract screening. First, the study population had to consist of term 
neonates, infants, children or adolescents treated in the PICU. Secondly, the studies needed 
to investigate parenteral nutritional support during hospitalization in PICU. For the full text 
screening, these criteria were further narrowed to (a) an age range of 37 weeks gestational 
age to 18 years of age and (b) to randomized controlled trials in which dosing and/or timing 
of mixed-bag PN or one of its components (amino acids, lipids, glucose) differed between the 
randomly allocated groups. Hence, studies comparing EN strategies were excluded. TF and DK 
independently determined eligibility. In case of discrepancy, SV and KJ decided on inclusion 
by consensus.
RESULTS
After title screening, 114 articles were retained (Fig. 1). The main reasons for these initial 
exclusions were (a) non-PN related aspects of nutrition, such as dosing of EN and (b) non-
randomized controlled trials. After further screening of the abstracts and an additional manual 
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search, 8 articles were retained10-17. Of these, full text reading resulted in exclusion of another 
2 articles, one that was related to EN instead of PN and one was not a RCT15,16. Table 1 gives 
an overview of the 6 trials, of which 1 was a post-hoc analysis of one of 5 RCTs11, that were 
identified as relevant for this review. As the retained studies used different interventions and 
outcome measures they could not be analyzed in a formal meta-analysis. 
MEDLINE 
213 articles 
NICU                                   17 
Not PN related                                    247        
Not PICU related            31 
Adult population       15 
Study on glycemic control          3  
Adult population                                   33 
NICU                                                          18 
Descriptive studies                                31 
Review                                                      24 
114 articles 
8 articles 
6 articles 
No RCT                                                        1 
Not PN related                                          1 
Text screening 
EMBASE 
468 articles 
584 articles 
Hand search  
2 articles 
Duplicates                99  
Title screening 
Abstract screening 
Figure 1. Flowchart of screening process
NICU=Neonatal Intensive Care Unit, PN=Parenteral Nutrition, RCT=Randomized Controlled Trial
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The RCT by Larsen et al., as well as the post-hoc analysis of this RCT, investigated 32 infants 
undergoing elective open-heart surgery with cardiopulmonary bypass and compared the 
effect of the pre- and post-operative administration of two types of parenteral lipid formulas, 
namely Intralipid® (LCT soybean oil) in the control group and Lipoplus® (50% MCT, 40% LCT, 
10% Fish oil) in the intervention group11,17. In the primary trial17, the authors report significantly 
lower plasma concentrations of TNF-alpha and IL-6 (primary outcome measures) on the first 
postoperative day in the treatment group receiving Lipoplus®. On day 7, the plasma TNF-
alpha and IL-6 concentrations were no longer different. Also duration of stay in PICU/hospital, 
incidence of sepsis, inotrope scores or ventilator days (secondary outcome measures) were 
similar in both groups. The post-hoc analysis11 also reported lower levels of other inflammation 
biomarkers (procalcitonin, leukotriene B4, lymphocytes) in the Lipoplus® group.
Two RCTs by Chaloupecky et al. were studies of 29 and 37 infants, respectively, undergoing 
cardiac surgery, in which the impact on proteolysis and plasma amino acid profiles of early 
parenteral administration of a higher dose of amino acids and of glucose as compared with 
a low dose maintenance glucose infusion on the first postoperative day was investigated10,12. 
Thereafter, all patients received enteral nutrition in equal amounts. The authors reported 
less negative nitrogen balances, less proteolysis as suggested by urinary 3-methylhistidine 
excretion, and higher levels of plasma amino acids during the first postoperative day in the 
intervention group who received more parenteral amino acids and glucose. Although clinical 
outcome measures were not explicitly described, the authors report no severe complications 
such as low cardiac output syndrome, renal failure, sepsis or mortality in any of the groups. 
Duration of intubation and inotropic support did not differ between treatment groups.
The RCT by Jordan et al. investigated 98 children suffering from severe sepsis or admitted 
after major surgery who were identified as requiring parenteral nutrition. The study compared 
the impact of glutamine-supplemented parenteral nutrition in the intervention group 
with standard parenteral nutrition in the control arm13. The authors report that glutamine-
supplemented parenteral nutrition evoked a higher plasma concentration of heat shock 
protein 70 on day 5, whereas plasma concentrations of IL-6 and IL-10 were not affected. Clinical 
outcome measures were not significantly different in the 2 study groups.
The RCT by Lekmanov et al. studied 40 children with severe thermic burns and concomitant 
injuries and compared the effect of glutamine-supplemented total parenteral nutrition during 
at least one week in the intervention group to standard total parenteral nutrition in the control 
group14. The authors reported no significant differences between the two groups for the serum 
levels of protein, albumin and glutamine on day 5 and 7 of PICU stay, but found a significantly 
shorter duration of mechanical ventilation in the intervention group (7 days versus 12 days in 
the control group). This result should be interpreted with caution, since the methods section 
was incomplete without information on the statistical analyses. Also plasma concentrations of 
glutamine were not significantly different between the two groups. 
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Quality assessment revealed low scores for the 2 RCTs by Chaloupecky et al.; namely a Jadad 
score of 1 and a Black Downs score of 9/31 for both trials, and the RCT by Lekmanov et al.; 
Jadad score of 2 and Black Downs score of 4/31. The study by Larsen et al. had a higher Jadad 
score of 3 but the Black and Downs score was only 17/31. The trial of Jordan et al. scored the 
highest with a Jadad score of 5 and a Black and Downs score of 27/31. As only 6 studies were 
retained, a funnel plot to assess publication bias could not be created.
DISCUSSION
This systematic review could identify only 6 small RCTs that investigated the impact of a 
different dose or composition of PN in critically ill infants or children treated in the PICU. Of 
these 6 studies, 4 investigated infants after cardiac surgery and two included children with 
sepsis or after other major surgery, or burns respectively. The focus of these few studies was 
on intermediate or surrogate endpoints, such as nitrogen balances and inflammation markers, 
which appeared to be beneficially affected by providing more or altered parenteral nutrition 
early during critical illness. As the studies were small, all were statistically underpowered to 
detect a clinically relevant effect on patient-centered endpoints. Only the RCT by Lekmanov 
et al. reported a significant reduction of the duration of mechanical ventilation in children 
receiving glutamine-supplemented parenteral nutrition. However, with limited information 
on the used methodology which lacked a statistical analysis plan, the accuracy of these results 
cannot be determined. Hence, strong clinical conclusions cannot be drawn from these studies. 
As a result, no recommendations can be made regarding the optimal timing for initiation and 
composition of parenteral nutrition for use in critically ill infants and children.  
The lack of large RCTs on the use of parenteral nutrition in critically ill infants and children is 
striking. However, this is an observation that is not limited to the nutritional field. Indeed, there 
are only 7 randomized controlled trials of PICU patients that have addressed a clinical question 
with a large enough sample size to be able to detect a difference in patient-centered, hard 
clinical outcomes18-25, of which 3 are related to metabolic aspects19,20,23. This overall lack of large 
RCTs in PICU patients suggests difficulties in recruiting large numbers of patients, due to the 
fact that the number of PICU patients and the size of the PICUs worldwide are smaller than for 
adult intensive care. 
All the trials retained by the search strategy of this systematic review focused on surrogate 
endpoints, such as nitrogen balances and inflammation markers. This may hold some risks. 
Surrogate nutritional outcome measures are often used to describe mechanistic effects of 
an intervention. However, there is often a weak relationship, if any, between these surrogate 
endpoints and the important patient-centered clinically relevant outcomes. Sometimes 
surrogate endpoints can be misleading as they may inadvertently suggest a benefit whereas 
the clinical outcomes indicate harm. For example, a large well-designed RCT of critically ill adults 
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found that the administration of growth hormone, with the intention to improve anabolism 
and outcome, improved nitrogen balances but increased mortality26. Also another large trial 
showed that early PN in adult ICU patients reduced markers of inflammation while it increased 
infections, weakness and organ failure and slowed down recovery27. Surrogate outcome 
measures are also the main focus of limited pediatric studies on glutamine-supplemented 
parenteral nutrition, that failed to show any advantage in critically ill children, just as enteral 
supplementation of glutamine28. Glutamine supplementation is no longer supported in adult 
critical care, based on the results of recent large high-quality RCTs that showed either no effect 
on morbidity or revealed and increased late mortality with glutamine supplementation29-31. 
In contrast to the PICU, there appears to be a greater consensus in the neonatal ICU, in favor of 
early parenteral supplementation. However, again the evidence generated by large RCTs with 
hard clinical endpoints is quite limited. In a Cochrane review, Trivedi et al32 included 7 RCTs 
comparing the effect of intravenous early amino acid administration (within 24 hours after 
admission) with late initiation (>24 hours) in 394 low-birth-weight neonates on short-term 
in-hospital outcomes including mortality, early and late growth or neurodevelopment. There 
were no differences in length and occipitofrontal circumference, however nitrogen balance 
improved with early administration of amino acids. The impact on other outcomes was not 
reported. Only with early initiation of parenteral lipids, an improved neonatal growth has been 
suggested by two RCTs of very-low-birth-weight infants33,34. 
In contrast with the pediatric critically ill patient population, recent large and high quality trials 
have provided more evidence to support nutritional recommendations for adult critically ill 
patients27,35-37. The EPaNIC (the impact of early parenteral nutrition completing enteral nutrition 
in adult critically ill patients trial) compared early parenteral supplementation of insufficient 
enteral feeding with tolerating the caloric deficit that accumulates when only EN is given in 4640 
adult ICU patients27. This study found that not using PN during the first week in ICU resulted 
in fewer new infections, less ICU acquired weakness with earlier weaning from mechanical 
ventilation38, less liver dysfunction39 and reduced need for renal replacement therapy, together 
resulting in an earlier live discharge from the ICU and from the hospital27. The SPN (the impact 
of supplemental parenteral nutrition on infection rate, duration of mechanical ventilation and 
rehabilitation in ICU patients) trial compared the initiation of PN on day 4, when adult patients 
were not yet receiving 60% of their caloric needs, with tolerating a nutritional deficit with EN 
until day 837. The SPN trial showed no differences in the clinically relevant outcomes. The early 
Parenteral Nutrition trial investigated whether PN should be started very early in critically ill 
patients when there was a short-term relative contra-indication to EN and apart from a shorter 
duration of mechanical ventilation (which was a tertiary outcome measure) there were no 
other clinical benefits36. The evidence generated from these trials has resulted in a change in 
clinical practice of adult intensive care, with a tendency to delay initiation of PN and to accept 
the macronutrient deficits for up to one week in ICU40. 
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While the evidence from high quality RCTs no longer supports the early use of PN for critically 
ill adult patients, and while the literature may suggest the opposite for preterm newborns, 
there is currently no evidence to support any of the current PN practices for critically ill patients 
from term neonates to adolescents. Although several observational studies of large cohorts 
of critically children have shown a relation between the adequacy of feeding and of protein 
intake during the first 10 days of admission and lower risk of death4,41, the adult literature 
calls for caution in assuming that this association is causal. Hence, whether and for how long 
the substantial macronutrient deficit that accumulates in critically ill infants and children on 
enteral feeding only can be tolerated remains an open question. 
Further research is therefore necessary to address this question and to determine the role of 
PN in the PICU population. In order to answer this important question, the study should be 
large enough to have enough statistical power to detect relevant differences in hard clinical 
endpoints. The results of the currently ongoing multicenter randomized controlled PEPaNIC 
trial (Clinical Trials.gov NCT 01536275), will hopefully elucidate some of the controversial 
topics. The PEPaNIC trial is a study of 1440 critically ill infants and children, and compares 
the effects of early PN with no PN for up to one week in PICU on several patient-centered 
clinical endpoints such as new infections and the duration of PICU dependency, besides safety 
endpoints including mortality42. 
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Supplementary Table 1. Search strategy
Ovid MEDLINE search strategy
((Critically ill OR critical illnesses OR “Critical Care”[Mesh:NoExp] OR critical care[tiab] 
OR “Intensive Care”[Mesh:NoExp] OR intensive care[tiab] OR icu[tiab] OR “Intensive 
Care Units”[Mesh:NoExp] OR burn unit OR burn center* OR sepsis) AND (children OR 
toddler*[tiab] OR “Infant”[Mesh:NoExp] OR infant[tiab] OR infants[tiab] OR “Infant, 
Newborn”[Mesh:NoExp] OR newborn[tiab] OR newborns[tiab] OR neonate[tiab] OR 
neonates[tiab] OR newborn[tiab] OR newborns[tiab] OR babies[tiab] OR baby[tiab] 
OR adolescents OR teen[tiab] OR teenager[tiab] OR teenagers[tiab] OR youth[tiab] OR 
pediatric[tiab] OR paediatric[tiab])) OR “Intensive Care Units, Pediatric”[Mesh:NoExp] OR 
PICU[tiab]
86939
AND
(“Parenteral Nutrition”[Mesh:NoExp] OR “Parenteral Nutrition, Total”[Mesh:NoExp] 
OR parenteral feeding*[tiab] OR intravenous feeding*[tiab] OR “Parenteral Nutrition 
Solutions”[Mesh])
1339
AND
(“randomized controlled trials as topic”[MeSH Terms] OR (“randomized”[All Fields] AND 
“controlled”[All Fields] AND “trials”[All Fields] AND “topic”[All Fields]) OR “randomized 
controlled trials as topic”[All Fields] OR (“randomized”[All Fields] AND “controlled”[All 
Fields] AND “trial”[All Fields]) OR “randomized controlled trial”[All Fields])
131
Alternative:
(Randomized Controlled Trials as Topic OR Random Allocation OR Double Blind Method OR 
Single Blind Method OR clinical trial OR clinical trial, phase i[Publication Type] OR clinical 
trial, phase ii[Publication Type] OR clinical trial, phase iii[Publication Type] OR clinical trial, 
phase iv[Publication Type] OR controlled clinical trial[Publication Type] OR randomized 
controlled trial[Publication Type] OR multicenter study[Publication Type] OR clinical trial 
[Publication Type] OR Clinical Trials as topic OR (clinical AND trial*) OR ((singl* OR doubl* 
OR treb* OR tripl*) AND (blind* OR mask*)) OR placebos OR placebo* OR randomly 
allocated OR (allocated AND random*))
213
Ovid EMBASE search strategy
#56
#54 AND #55
468
#55
‘clinical trial’/exp OR ‘clinical trial’ OR ‘randomized controlled trial’/exp OR ‘randomized 
controlled trial’ OR ‘randomization’/exp OR’randomization’ OR ‘single blind procedure’/
exp OR ‘single blind procedure’ OR ‘double blind procedure’/exp OR ‘double blind 
procedure’ OR ‘crossover procedure’/exp OR ‘crossover procedure’ OR ‘placebo’/exp 
OR ‘placebo’ OR (randomi?ed AND controlledAND trial* AND [embase]/lim) OR (rct AND 
[embase]/lim) OR (‘random allocation’/exp OR ‘random allocation’ AND [embase]/lim) OR 
(‘randomly allocated’ AND [embase]/lim) OR (‘allocated randomly’ AND [medline]/lim) OR 
(allocated NEAR/2 random AND [embase]/lim) OR (‘single blind$’ AND [embase]/lim) OR 
(‘double blind$’ AND [embase]/lim) OR ((treble OR triple) NEAR/2 blind$ AND [embase]/
lim) OR (placebo$ AND [embase]/lim) OR ‘prospective study’/exp OR ‘prospective 
study’ NOT (‘case study’/exp OR ‘case study’ OR (‘case report’/exp OR ‘case report’ AND 
[embase]/lim) OR ‘abstract report’/exp OR ‘abstract report’ OR ‘letter’/exp OR ‘letter’)
1,607,926
#54
#52 AND #53
2,848
#53
#40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48
42,795
#52
#38 OR #39 OR #51
99,572
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#51
#49 AND #50
98,815
#50
#17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 
OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34OR #35 OR 
#36 OR #37
3,186,376
#49
#1 OR #4 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16
421,442
#48
‘amino acid mixture plus electrolyte solution’/exp
11
#47
‘parenteral solution’:ab,ti
204
#46
‘peripheral parenteral nutrition’/exp
51
#45
‘parenteral solution’/exp
838
#44
‘intravenous feeding’:ab,ti
519
#43
‘intravenous feeding’/exp
965
#42
(parenteral NEXT/1 feeding*):ab,ti
1,670
#41
‘parenteral nutrition’:ab,ti
21,366
#40
‘parenteral nutrition’/exp
38,418
#39
‘pediatric intensive care nursing’/exp
123
#38
picu:ab,ti
4,994
#37
paediatric:ab,ti
56,331
#36
pediatric:ab,ti
234,760
#35
youth:ab,ti
43,555
#34
teenagers:ab,ti
11,785
#33
teenager:ab,ti
2,643
#32
teen:ab,ti
4,479
#31
‘adolescents’:ab,ti
148,727
#30
‘adolescent’:ab,ti
98,521
#29
‘adolescent’/de
1,246,280
#28
babies:ab,ti
37,712
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#27
baby:ab,ti
38,356
#26
‘neonates’:ab,ti
64,110
#25
‘neonate’:ab,ti
26,829
#24
‘newborn’:ab,ti
121,130
#23
‘newborn’/exp
479,511
#22
‘infants’:ab,ti
237,450
#21
‘infant’:ab,ti
150,122
#20
‘infant’/exp
886,678
#19
toddler*:ab,ti
8,002
#18
children:ab,ti
972,537
#17
‘child’/exp
2,153,189
#16
‘sepsis’:ab,ti
92,883
#15
‘sepsis’/exp
177,007
#14
(burn NEXT/1 center*):ab,ti
1,806
#13
‘burn unit’:ab,ti
1,238
#12
‘burn unit’/exp
638
#11
‘intensive care unit’/exp
91,129
#10
‘icu’:ab,ti
58,026
#9
‘intensive care’:ab,ti
126,347
#8
‘intensive care’/de
93,067
#7
‘critical care’:ab,ti
28,770
#6
‘critical illness’:ab,ti
6,656
#4
‘critically ill’:ab,ti
39,234
#1
‘critically ill patient’/exp
21,467
Supplementary Table 1. Continued
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ABSTRACT
Background
The state-of-the-art nutrition used for critically ill children is based essentially on expert 
opinion and extrapolations from adult studies or on studies in non-critically ill children. In 
critically ill adults, withholding parenteral nutrition (PN) during the first week in ICU improved 
outcome, as compared with early supplementation of insufficient enteral nutrition (EN) with 
PN. We hypothesized that withholding PN in children early during critical illness reduces the 
incidence of new infections and accelerates recovery.
Methods/design
The Pediatric Early versus Late Parenteral Nutrition in Intensive Care Unit (PEPaNIC) study is 
an investigator-initiated, international, multicenter, randomized controlled trial (RCT) in three 
tertiary referral pediatric intensive care units (PICUs) in three countries on two continents. This 
study compares early versus late initiation of PN when EN fails to reach preset caloric targets in 
critically ill children. In the early-PN (control, standard of care) group, PN comprising glucose, 
lipids and amino acids is administered within the first days to reach the caloric target. In the 
late-PN (intervention) group, PN completing EN is only initiated beyond PICU day 7, when EN 
fails. For both study groups, an early EN protocol is applied and micronutrients are administered 
intravenously. The primary assessor-blinded outcome measures are the incidence of new 
infections during PICU stay and the duration of intensive care dependency. The sample size 
(n = 1,440, 720 per arm) was determined in order to detect a 5% absolute reduction in PICU 
infections, with at least 80% 1-tailed power (70% 2 tailed) and an alpha error rate of 5%. Based 
on the actual incidence of new PICU infections in the control group, the required sample size 
was confirmed at the time of an a priori planned interim-analysis focusing on the incidence of 
new infections in the control group only. 
Discussion 
Clinical evidence in favor of early administration of PN in critically ill children is currently 
lacking, despite potential benefit but also known side effects. This large international RCT will 
help physicians to gain more insight in the clinical effects of omitting PN during the first week 
of critical illness in children. 
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BACKGROUND
Nutritional support for children in intensive care
The state-of-the-art nutrition used for critically ill children is essentially based on expert 
opinion, small studies with surrogate endpoints and extrapolations from adult studies or from 
studies in healthy children outside the Intensive Care Unit (ICU). It is widely accepted that in 
healthy children, nutrition not only serves to maintain body tissues but also allows growth, 
which is considered of particular importance during infancy and adolescence1,2. In hospitalized 
children, especially in the young, the current European and American guidelines for nutrition 
recommend early parenteral nutrition (PN) to prevent/correct malnutrition and to sustain 
appropriate growth when enteral nutrient (EN) supply is insufficient3,4. Observational studies 
suggest that about a quarter of children, most notably infants, admitted to pediatric intensive 
care units (PICUs) develop a pronounced caloric deficit1. The stores of energy, fat and protein 
in children are limited, leaving children to rely on muscle mass to provide necessary substrates 
for metabolism. The energy deficit observed with acute critical illness in children has been 
associated with adverse outcome5. Based hereon, it is current practice in PICUs to start PN in 
the acute phase of critical illness to supplement insufficient EN with the intention to avoid 
underfeeding3,4. However, overfeeding may also be harmful6-9. It is difficult to administer the 
correct amount of nutrition, avoiding overfeeding as well as underfeeding. 
Varying nutritional guidelines and clinical practices 
It is currently advised to assess energy expenditure considered to reflect energy requirements, 
through the use of indirect calorimetry during the course of critical illness and to use this 
technique for determining individualized targets to guide nutritional therapy10. However, a 
European survey conducted in 2004 showed that only 17% of the PICUs use this technique11 
and the technique itself has not been well standardized12,13. In the most critically ill, major 
caveats are present, such as respiratory support with more than 60% oxygen and the use 
of uncuffed tubes resulting in unpredictable measurements. The use of standard equations 
to predict energy expenditure and/or requirements also carries the risk of overfeeding and 
underfeeding14-16.
Experts worldwide agree that there are insufficient data to make evidence-based 
recommendations for the optimal target of caloric intake in critically ill children and for the 
optimal time after onset of critical illness by which this target should be reached. The lack 
of widely accepted caloric targets for critically ill children results in nutritional strategies that 
vary substantially across centers. The current European and American guidelines for nutrition 
in hospitalized children recommend PN to prevent or correct malnutrition and to sustain 
appropriate growth when EN supply is insufficient10,17. Most guidelines advise to do this early 
so that the recommended daily allowances for children are reached on day 2 or 3 after PICU 
admission. These recommendations are based on evidence from cohort studies without a 
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control group, case series or expert opinion (Grade D level). 
The ongoing controversy on optimal amount, composition and timing of administration of PN 
in critically ill children may in fact conceal the fact that there is no hard evidence for any use of 
PN in critically ill children. Supported by the results of a Cochrane systematic review, Joffe et 
al. concluded that randomized trials investigating the role of intravenous nutritional support 
during the first week of critical illness in children should be performed and should include a 
control arm in which no nutritional support is administered or hypocaloric goals (below basal 
metabolic rate) for nutritional support are used18.
Rationale of the study and study hypothesis
A recent randomized controlled trial (RCT) in critically ill adults19 showed that the early 
provision of PN worsened rather than improved outcomes as compared with withholding PN 
and thus tolerating a substantial caloric deficit up to 1 week in ICU. Also, other studies did 
not show clinical benefit of early PN in adult ICU patients20,21. Hitherto, no well-designed RCT 
has been performed in critically ill children. The aim of the PEPaNIC trial (the acronym stands 
for Pediatric version of the effect of Early Parenteral Nutrition to complete insufficient enteral 
nutrition in ICU patients) is to investigate whether a strategy of withholding PN during the first 
7 days in the PICU (late PN) provides clinical benefit over the current practice of early PN in 
critically ill children. We hypothesize that withholding PN for 1 week in the PICU reduces new 
infections and shortens the duration of PICU stay. 
This hypothesis is currently being tested in a multicenter superiority RCT performed in three 
large, tertiary referral PICUs (University Hospitals Leuven, Leuven, Belgium; Erasmus Medical 
Center, Sophia Children’s Hospital, Rotterdam, The Netherlands; Stollery Children’s Hospital, 
Edmonton, AB, Canada). The centers were invited to participate based on a self-declared 
routine use of early PN in the PICU. It was anticipated that this routine use of early PN differs 
among centers. This was considered to be an asset as it contributes to the external validity of 
the PEPaNIC trial. 
METHODS/DESIGN
Ethical approval
The study protocol and (deferred) informed consent forms were approved by the institutional 
ethical review boards in Leuven, Belgium (ML8052 Amend-ID0005), Rotterdam, The Netherlands 
(NL38772.000.12) and Edmonton, AB, Canada (Pro00038098). Informed consent is given in 
writing by the parents or the legal guardians, confirmed by the child when older than 7 years, 
after providing all information orally in plain language and in writing. For planned admissions, 
informed consent is obtained prior to surgery/procedure. For unplanned admissions, informed 
consent is obtained within 24 hours after admission on the PICU (deferred informed consent as 
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the nutritional therapy should be initiated from PICU admission onward). 
Patients’ eligibility – Inclusion criteria
Upon admission to the participating PICUs, all critically ill children are screened for nutritional 
risk and eligibility for inclusion in the PEPaNIC clinical study22. All non-eligible patients, 
identified by the local investigators, are logged. 
Critically ill children, newborn to 17 years (inclusive or exclusive depending on the local 
definition of a pediatric patient) old, with a STRONGkids (Nutritional risk score) score of 2 
points or more and who are likely to stay in the PICU for more than 24 hours, are eligible for 
inclusion22. 
Exclusion criteria 
Patients fulfilling one or more of the following criteria are excluded:
• STRONGkids score lower than 2 on PICU admission22
• Not critically ill (for example, anticipated oral intake within 24 hours)
• Non-pediatric patients (aged 17 or older, compare with above) 
• Premature newborns (<37 weeks gestational age upon admission in the PICU)
• ‘Do not resuscitate’ code at the time of PICU admission
• Expected death within 12 hours
• Readmission to PICU after already having been randomized 
• Enrollment in another intervention trial
• Transfer from another PICU or neonatal ICU after a stay of more than 7 days
• Ketoacidotic or hyperosmolar coma 
• Inborn metabolic diseases requiring specific diet
• Short bowel syndrome or other conditions requiring PN for more than 7 days prior to 
PICU admission 
Data collection at study entry
At baseline, data on demographic (age, gender, race/ethnicity, (pre-)admission bodyweight 
and height) and clinical characteristics of the patients are obtained. For all patients, severity 
of illness scores are calculated such as the PEdiatric Logistic Organ Dysfunction (PELOD) 
score and, for cardiac surgery patients, the Risk-Adjustment in Congenital Heart Surgery or 
RACHS score. The Pediatric Risk of Mortality (PRISM) score cannot be used for this study as the 
nutritional management is expected to affect the highest blood glucose concentration during 
the first 24 hours. In addition, co-morbidities prior to admission are noted. These comprise, 
among others, the presence of a genetic syndrome, gestational age at birth, presence/history 
of cancer, diabetes mellitus, kidney failure and infection upon admission.
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Randomized treatment allocation
Randomization procedure
Randomization to early PN or late PN in a 1:1 ratio, is performed centrally (KU Leuven, Belgium) 
by use of a dedicated computerized system, accessible in all centers around the clock, 7 days 
a week. The computer algorithm allocates every consecutive, eligible patient per center to 
one of the two treatment arms in a blinded fashion by use of permuted blocks per diagnostic 
stratum to create parallel groups. The block size is unknown to bedside physicians, nurses and 
members of the research team. Patients are stratified per study site according to age groups 
(<1 year and ≥1 year) and the following primary diagnostic categories on admission:
I.  Medical PICU admissions (infectious or non-infectious): (a) neurological (b) other.
II.  Surgical PICU admissions (elective or emergency) according to referral discipline (a) 
cardiac surgery (b) other.
Treatment allocation and blinding 
Concealed allocation to the randomized treatment was realized by use of the computerized 
randomization system described above. It was considered not feasible to blind treating 
physicians and patients for the allocated treatment during the time window of the randomized 
intervention. After discharge to the normal ward, all treating physicians are unaware of the 
randomized treatment allocation. All outcome assessors and investigators not directly 
involved in the patients care, such as statisticians, infectious disease specialists and laboratory 
personnel, are fully blinded to treatment allocation. 
Common strategy for early EN in both study arms
The initiation and increase of EN, and the use of gastroprokinetics are prescribed in the standing 
orders for EN in each center. Both groups receive micronutrients (trace elements, minerals and 
vitamins) intravenously from day 2 onwards until the amount of EN given reaches 80% of the 
caloric target.
Randomized interventions
Patients randomized to the early-PN strategy (standard of care or control group) receive 
this type of nutrition according to current management in each of the participating centers, 
which were recruited based on a routine use of early PN. For patients randomized to the 
late-PN group (intervention group), all PN is withheld during the first week in the PICU. The 
international setting of the trial brings some variation in the control group (see study rationale 
and hypothesis), while the intervention group is strictly standardized (‘no PN during the first 
week in PICU’). 
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Standard of care or control group: early-PN
In the Leuven (BE) PICU, patients randomized to the early-PN group receive a mixture of glucose 
30% and Vaminolact® (Fresenius, Uppsala, Sweden) in equal amounts upon admission to 
PICU, comprising 150 mg/ml glucose and 4.7 mg/ml nitrogen. For patients who require fluid 
restriction, total fluid intake is 50 ml/m²/h on days 1 and 2 (the day after admission and further 
referred to as day 2), and 60 ml/m²/h on day 3. Patients not requiring fluid restriction receive 
100 ml/kg/day for the first 10 kg bodyweight, 50 ml/kg for the next 10 kg, and 20 ml/kg for 
the bodyweight over 20 kg, to be reached within 3 days. For all patients on intravenous (IV) 
nutrition, and within the fluid limitation described above, lipids (SMOFlipid® (20g/100ml) 
Fresenius, Uppsala, Sweden) are added from the second morning after admission, initially at 
a dose of 1.5 g/kg/day, increasing to a maximum of 3 g/kg/day, depending on the age. On 
the third morning after admission, pharmacy-prepared PN preparations are prescribed, unless 
adequate enteral nutritional intake is expected. PN preparations contain a mixture of glucose 
50% and SMOFlipid® covering respectively 60 to 70% and 40 to 30% of calculated energy target 
and a 1.5 to 2.5 g/kg protein intake, according to age, by Vaminolact®. If the body weight is 
above 5 kg, Vaminolact® is replaced by Vamin 18® (Fresenius, Uppsala, Sweden). Any enterally-
delivered energy is taken into account twice daily to reduce the energy delivered by PN. When 
EN covers 80% of optimal calculated caloric needs, PN is stopped. When the patient starts to 
take oral nutrition, the PN and/or EN is reduced and eventually stopped. Whenever enteral or 
oral intake falls below 50% of calculated caloric needs, the PN is restarted. 
In the Rotterdam (NL) PICU, patients randomized to the early-PN group receive a continuous 
glucose infusion upon admission to PICU (<30 kg; 4 to 6 mg/kg/min, >30 kg; 2 to 4 mg/kg/min). 
From day 2 onwards the glucose intake is increased for all children on IV nutrition to 8.3 mg/
kg/min (5 to 10 kg), 6.9 mg/kg/min (10 to 30 kg) or 4 mg/kg/min (>30 kg). Primene® (Baxter, 
Kobaltweg 49, 3542 CE Utrecht) (5.5 to 5.7 mg/ml nitrogen) is added from day 2 onward at 25 
ml/kg/day (<10 kg) or 20 ml/kg/day (10 to 30 kg). From day 2 onwards, Intralipid® (Fresenius, 
Uppsala, Sweden) is added initially at a dose of 10 ml/kg/day (<10 kg) or 7.5 ml/kg/day (10 to 
30 kg), increasing to 20 or 15 ml/kg/day respectively. For patients who require fluid restriction, 
intake is adjusted accordingly. Children >30 kg on IV nutrition receive from day 2 onwards 
Olimel N5 (Baxter, 5.2 mg/ml nitrogen, 115 mg/ml glucose) when central lines are in place or 
Olimel N4 (Baxter, 4.0 mg/ml nitrogen, 75 mg/ml glucose) when only peripheral lines are in 
place; the dose is 48 ml/kg/day. Any enterally-delivered energy is assessed twice daily and the 
energy delivered by PN is reduced accordingly. Energy goals for enteral nutrition are based on 
the body weight-based Schofield equation23 (first day of admission) and on the Recommended 
Dietary Allowances (RDA, Dutch Health Council) for the subsequent length of stay (Dietary 
Reference Intake: energy, protein and digestible carbohydrates, 2001, Health Council of the 
Netherlands: The Hague). Energy goals and composition of parenteral nutrition are based on 
the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) 
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guidelines4. When EN covers 80% of calculated caloric needs, PN is stopped. When the patient 
starts with oral nutrition, PN and/or EN is reduced and eventually stopped. Whenever enteral 
or oral intake falls below 50% of calculated caloric needs, PN is restarted.
In the Edmonton (CA) PICU, the patient’s energy expenditure is assessed upon admission by 
a registered dietitian when possible. Nutritional support is initiated as soon as possible, with 
the goal to match energy expenditure (measured or estimated resting energy expenditure 
of the child). The urgency of initiation of nutrition support is dependent on nutritional risk 
prior to admission, disease state and age. If indirect calorimetry cannot be done, 65% of basal 
metabolic rate by the Food and Agriculture Organization-World Health Organization (FAO-
WHO) is used to determine caloric requirement. This number is adjusted daily by the dietitian 
based on the acute phase response and clinical picture of the child. If nutritional requirements 
cannot be met enterally, PN is added to achieve caloric target. On admission to PICU, patients 
receive a glucose infusion of approximately 3 to 4 mg/kg/minute taking into account the total 
fluid prescribed by medical staff. At that time EN is initiated when possible. On the morning 
of day 2, if the patient is not already on full enteral feeding, 20% IV lipids are initiated at 0.5 
g/kg/day. On the morning of day 3, if the patient is not already on full enteral feeding, lipid 
infusion is increased to 1 g/kg/day and a solution of amino acids and concentrated glucose is 
added. The caloric goal is Basal Metabolic Rate when the patient is intubated and Total Energy 
Expenditure when the patient has been extubated.  
Intervention group: late-PN
In the 3 centers, patients randomized to the late-PN group receive a mixture of glucose 5% and 
NaCl 0.9% at, respectively, 60% and 40% of the total flow rate that is required to obtain optimal 
hydration, as prescribed by the attending physician, taking into account the volume of EN that 
is being delivered. No other forms of PN (lipid or protein infusions) are administered. When the 
amount of EN that is administered still covers less than 80% of the calculated targets after 1 
week in the PICU, supplemental PN is initiated on day 8 according to the current PN protocols 
in each center. 
The medical and nursing staff of the PICU were all informed and trained extensively during 
regular meetings before the start of the trial and were familiarized with the protocol. In order to 
optimize protocol compliance, the protocol was programmed in the patient data management 
system (PDMS). The use of this program was explained to every nurse, trainee and resident on 
the PICU and was always supervised by the senior staff. 
Adherence to the protocol in Leuven and Rotterdam was guaranteed by using a PDMS guided 
system and by careful follow-up by study nurses. In Edmonton, a paper protocol was used and 
adherence checked by an independent study nurse and physician. 
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Criteria for stopping the study intervention
When in the intervention arm (late-PN group), blood glucose concentration falls spontaneously 
(without exogenous insulin) below 50 mg/dl, the standard infusion of glucose 5% is switched to 
10% glucose until blood glucose concentration is higher than 80 mg/dl and stable. Thereafter, 
the infusion of glucose 10% is stopped again and switched back to glucose 5%.
Blood glucose management
In Leuven, patients in both study groups receive continuous insulin infusion to target blood 
glucose levels of 50 to 80 mg/dl when aged <1 year and 70 to 100 mg/dl when aged ≥ 1 year. 
Blood glucose and potassium are monitored systematically every 1 to 4 hours on the blood 
gas analyzer (ABL Radiometer, Copenhagen, Denmark) using undiluted arterial blood samples 
drawn via a VAMP® system (Edwards Lifescience Pontbeekstraat 4 1702 Groot-Bijgaarden)24 and 
insulin infusion is adjusted when needed.
In Rotterdam, patients in all age groups receive continuous insulin infusion using a step-
wise nurse-driven glucose control protocol to target blood glucose levels of 72 to 145 mg/dl, 
except for patients with traumatic brain injury for whom the target is set at 108 to 145 mg/dl25. 
Blood glucose and potassium are monitored systematically every 1 to 3 hours on the blood 
gas analyzer (ABL 625; Radiometer, Copenhagen, Denmark) using arterial or capillary blood 
samples.
In Edmonton, patients in all age groups receive continuous insulin infusion at the discretion of 
the attending physician when blood glucose levels exceed 180 mg/dl. The attending physician 
sets the lower target range limit.
Other procedures and guidelines
Other medical treatments are not described by the study protocol. Patients are weaned from 
the ventilator and from hemodynamic support according to standardized guidelines used in 
each participating PICU. End-of-life decisions, when further intensive care is considered to be 
futile, are taken in consensus by senior PICU physicians and the referring specialist. 
Handling of re-admissions to the PICU
Patients who are readmitted to the PICU after a participation in PEPaNIC are not eligible for 
reinclusion. Patients who are readmitted to the PICU within 48 hours of discharge and who are 
still within the 7 days’ time window of the initial randomization receive the nutrition strategy 
they were randomly assigned to during the initial PICU admission. Patients readmitted more 
than 48 hours after PICU discharge will be fed at the discretion of the attending physician 
(standard care).
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Outcome measures
Primary endpoints
The two primary endpoints of this RCT are: (i) the incidence of new infections during PICU 
stay and (ii) the duration of PICU dependency. The latter will be reported as the crude number 
of PICU stay days and as the time to live discharge from PICU, to account for mortality as a 
competing risk. 
Also, the proportion of patients from the intention-to-treat population who stayed 8 days or 
more in PICU will be reported. This is not only reflecting the proportion of prolonged critically 
ill patients but also examines effects of the randomized intervention beyond the time window 
of the randomized intervention in PICU.
The incidence of new infections for all patients in the three centers will be scored in consensus 
by the same two assessors (infectious disease specialists), who are blinded for treatment 
allocation. This assessment is based on an a priori drafted protocol19, which makes use of 
prescribed antibiotics and clinical infection and inflammation data. 
As the timing of PICU discharge to a regular ward may be affected by the availability of beds on 
regular wards, which could induce bias, we a priori decided to analyze ‘time to discharge from 
PICU’ as ‘time to ready for discharge from PICU’. A patient is considered ‘ready for discharge’ as 
soon as all clinical conditions for PICU discharge have been fulfilled (no longer in need for, or 
at risk of, vital organ support). 
Secondary safety endpoints
Secondary safety endpoints comprise: (i) death during PICU stay and during the time window 
of the randomized intervention (up to day 8), (ii) the proportion of patients with at least 1 
episode of severe hypoglycemia (<40 mg/dl), (iii) in-hospital mortality and (iv) 90-day mortality. 
As a specific Serious Adverse Event (SAE), hypoglycemia resistant to bolus administration of 
glucose during the time window of the randomized intervention will be reported for both 
groups.
Secondary efficacy endpoints
1. Time to (live) discharge from hospital and duration of hospital stay, for both the index 
hospitalization and total hospitalization including stay in the referred hospital.
2. Time to final (live) weaning from mechanical respiratory support and duration of 
mechanical ventilation. 
3. Kidney failure. Proportion of patients in need for renal replacement therapy (RRT) 
during PICU stay and the duration of RRT (for those patients requiring RRT). Also, the 
further analysis of the maximum and daily serum level of creatinine and urea during 
the intervention window and during PICU stay will be reported. Other plasma and urine 
markers of kidney function will be investigated.
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4. Need for pharmacological or mechanical hemodynamic support during PICU stay and 
duration of such need. In addition, time to final (live) weaning from all pharmacological 
or mechanical hemodynamic support in PICU will be analyzed. 
5. Number of readmissions to the PICU. The proportion of patients readmitted within 48 
hours after discharge will be recorded. Also the proportion of patients readmitted to the 
PICU beyond 48 hours during their index hospital stay will be reported, as these patients 
will have been excluded from treatment allocation and will receive standard care. 
6. Liver dysfunction. Markers of liver function will be measured and proportion of patients 
with abnormal tests will be compared.
7. Inflammation. Effect of the intervention on inflammation will be analyzed by comparing 
markers of inflammation. Both peak values and time courses will be analyzed.
8. Duration of antibiotic treatment. The duration of antibiotic treatment (whenever given) 
within the intervention window and during the PICU stay will be compared between the 
groups. 
9. Nutrition delivered during PICU stay. The macronutrients and calories administered during 
the intervention window and thereafter during PICU stay will be compared between the 
treatment groups. Total amount of macronutrients, as well as the amounts administered 
parenterally and enterally, will be reported. 
10. Structural and functional differences in muscle tissue during PICU stay. By ultrasonography, 
skeletal muscle thickness of the quadriceps, as a marker of muscle wasting, will be 
reported in a subset of patients. In addition, handgrip strength will be measured in a 
subset of patients older than 6 years. 
11. Intolerance to enteral feeding during PICU stay. Markers of tolerance to enteral feeding will 
be determined in a subset of patients. Markers in blood, stool and buccal swab samples 
will be investigated.
Further pre-planned studies (execution depending on further funding), of which the detailed 
protocols and the methods for statistical analysis will be reported separately, are here listed 
below:
1. Direct healthcare-related costs. Total, direct healthcare costs during index PICU stay will be 
compared between the treatment groups26. 
2. Mechanistic studies. Explanations of any observed effects of delayed administration of 
PN as compared with standard of care will be assessed. These will comprise, among 
others, metabolic, endocrine, inflammation and (epi)genetic analyses, the investigation 
of the role of severity of illness, the use of indirect calorimetry, the type of blood glucose 
management, and post-randomization factors such as type and dose of administered 
macronutrients, and disease evolution27.
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3. Long-term follow-up. This will include developmental and neurocognitive assessments, 
metabolic, endocrine, inflammation and (epi)genetic studies, with a healthy matched 
control group investigated over time in parallel. 
Data collection following recruitment
All systemically applied medications received by the patients during the stay in PICU are 
registered. Every day the quantities of kilocalories, carbohydrates, lipids and proteins delivered 
by either PN or EN are calculated and entered into the electronic Case Record Form (eCRF). 
The need for and the number of days of mechanical ventilatory support, of mechanical and 
pharmacological hemodynamic support, of renal replacement therapies, days on antibiotics 
and days requiring a central line are recorded. Blood, urine, buccal mucosa swabs and hair 
samples are taken upon PICU admission and during PICU stay. Such samples are appropriately 
handled (collected on ice when required) and immediately stored (at room temperature or 
at -20°C/-80°C as appropriate) for future measurements. Analyses on blood and urine for the 
primary clinical analyses include routine chemistry, hematology, and markers of inflammation. 
Further metabolic, endocrine, inflammatory and (epi)genetic measurements on stored 
samples in the context of mechanistic analyses are planned. For mechanistic and exploratory 
studies, ultrasound evaluation of the skeletal muscle, in combination with muscle strength 
measurements will be performed in a subset of patients28-30. Quality of life on admission and 
after 4 to 6 months is recorded through a validated, semi-structured questionnaire, filled out 
by the parents, which is repeated at 2 and 4 years after enrollment in the PEPaNIC trial. 
Data handling and record keeping
Data are collected electronically in an anonymized eCRF, unambiguously linked to the source 
file. Data are manually transferred and checked for accuracy into the eCRF by the clinical research 
assistants’ team on a daily basis. Extensive range and consistency checks are performed by the 
study monitor. All original records, such as consent forms, eCRFs and relevant correspondence, 
will be archived at the participating centers, according to the local regulations. Vital status at 
90 days (and at later follow-up times) will be recorded for all patients, by the National Death 
Registries. When this information is not available, vital status will be checked through the 
hospital information system or the regional network of pediatricians and general practitioners.
All data are stored anonymously. Investigators involved in the trial do not have direct access 
to the database. In addition, the study monitor has logged the use of the database. After the 
trial, the study monitor will store all data in a secured file that is only accessible by the study 
monitor himself. 
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Trial organization
The sponsor (KU Leuven) provides direct access to the eCRF, the source data and the study 
master file for monitoring, for review by the independent ethics committee and regulatory 
inspection. The sponsor established an independent data safety monitoring board (DSMB). 
The sponsor appointed one monitor. The monitor verifies that the trial is performed in 
accordance to the protocol as described in the European Medicine Agency’s ‘Note for guidance 
on good clinical practice CPMP/ICH/135/95.’ as well as the Declaration of Helsinki. Monitoring is 
performed and reported according to the sponsor’s standard operating procedures. The clinical 
research team guarantees a daily follow-up of patient screening and inclusion, availability of 
requested clinical data in the clinical patient files and protocol compliance. Non-compliance to 
the protocol and other questions or problems are reported to the study monitor and discussed 
with the principal investigators and trial steering committee. SAEs are reported to the study 
sponsor and, if needed, to the local ethics committee. The study monitor regularly provides the 
sponsor and the DSMB with reports on inclusions and SAEs. Regular meetings are organized 
with principal investigators and clinical research teams to discuss the daily progression of the 
PEPaNIC trial.
The protocol has been instructed in each hospital to all clinical medical and nursing staff 
through frequent teaching sessions and clinical feedback rounds. The protocol decision 
support is integrated into the PICU PDMS in Leuven and Rotterdam, facilitating the prescription 
of the exact amounts of PN and EN according to protocol and clinical evolution.
In order to achieve adequate participant enrollment to reach target sample size, regular 
meetings and site visits take place every 3 months together with the Rotterdam team and via 
teleconferences with the Edmonton team.
Regular data auditing is done by the administrative trial team, the DSMB and by the central 
independent audit procedure in place at the University Hospital of Leuven in compliance with 
the European Trials Directives. 
Statistical analysis plan
One Consolidated Standards of Reporting Trials (CONSORT) diagram will be reported.
Protocol compliance will be documented by comparing the actual amounts of PN and EN 
during the intervention window and this will be reported as absolute numbers of calories and 
weight units. 
For the primary and secondary endpoints taking place during PICU stay all data will be available. 
In case of request for discontinuation of the study intervention by patients, parents or legal 
guardians, this will be respected, but all data will be analyzed. In case of consent withdrawal, 
the parents will be asked whether the data can be used for analysis. In case this would not be 
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allowed, all data of that patient will be removed from the database, and this will be reported 
in the CONSORT diagram. At all time, the intention-to-treat principle will be respected and 
reported. No data imputation will be undertaken for any of the primary or secondary outcomes.
Variables will be summarized as frequencies and percentages, means and standard errors of 
the means, or medians and interquartile ranges, as appropriate. 
Results will be analyzed with the use of chi-square testing, Student’s t-test or non-parametric 
testing (Wilcoxon rank-sum test, Van der Waerden test or Median test), as appropriate. Kaplan-
Meier plots will be used to document time-to-event effects, and the time-to-event effect size 
will be estimated with the use of Cox proportional-hazard analysis. All time-to-event analyses 
will also be performed on data censored at 90 days. As death is a competing risk for duration 
of care outcomes, non-survivors will be censored beyond the longest duration of such care 
required for survivors19. All outcomes will be analyzed both with and without adjustment for 
baseline risk factors, including the diagnostic and age groups, severity of illness, severity of 
nutritional risk and center. The latter is considered necessary to account for the differences 
among centers in nutrition given to the control group and the variation in blood glucose 
control targets. For these analyses, P-values will be considered significant when at or below 
0.05 without correction for multiple comparisons. To assess whether any eventual impact of 
the intervention on the primary endpoints is affected by the baseline risk factor subgroups, 
interaction P-values will be calculated (logistic regression or Cox proportional hazard analysis) 
with a threshold for significance of interaction set at a P-value of <0.1. All analyses will be 
conducted on an intention-to-treat basis.
Sample size calculation and interim analyses
In the design phase of the PEPaNIC trial, and based on the previous adult EPaNIC trial results, 
the sample size (N = 1,440, 720 patients per arm) was determined in order to detect a reduction 
in the incidence of new infections during PICU stay from 20 to 15% (Absolute Risk Reduction 
5%), with at least 80% 1-tailed power and at least 70% 2-tailed power and at an alpha error 
of 5%. With this sample size, the trial can also detect a major safety issue, such as a doubling 
of the PICU mortality rate from 4% (the baseline mortality in the Leuven center) to 8% with a 
statistical power of 89% in a 2-sided test with an alpha error of 5%. This sample size will also 
allow to detect a reduction in mean duration of stay in PICU of 1 day with at least 90% power 
(2-tailed) and 95% certainty.
Two interim analyses of the safety endpoints (except 90-day mortality) only were planned (after 
inclusion of 480 upon specific request of the DSMB, and after inclusion of 50% of the study 
population). It was a priori decided to determine the actual incidence of new infections during 
PICU stay in the 3 centers, as this was not known exactly for each of the participating centers 
prior to trial initiation. In order to allow statistical repowering and to judge the necessity of 
inclusion of more trial sites, the assessment of incidence of new infections during PICU stay 
PEPaNIC trial: study protocol
119
6
R1
R0
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
in the control group took place after inclusion of 750 patients. Based on this actual incidence 
of new PICU infections in the control group, the hypothesized absolute risk reduction of 5% 
and an alpha error rate of 5%, the sample size of 1,440 patients (720 patients in each arm) was 
found sufficiently large to yield a statistical power of 77% 2-sided and of 85% 1-sided. As these 
interim analyses did not assess any of the efficacy endpoints, no adjustments of the P-values 
are needed. 
DISCUSSION
The clinical evidence for the administration of PN in critically ill children is missing18. Thousands 
of children are annually exposed to this non-evidence-based treatment, which is assumed to 
result in faster recovery (benefit). This large international RCT will help PICU physicians to obtain 
more insight on the possibility of the omission of PN during the first week of critical illness. A 
significant difference in the safety and/or efficacy endpoints will provide important evidence 
for optimizing clinical patient care. Also a neutral result will provide important insight, as this 
would mean that clinicians can safely withhold PN in all comparable patients during the first 
week of ICU stay, which would have an impact on healthcare spending in the PICU.
TRIAL STATUS 
The study was initiated as planned on 18 June 2012. At the time of the safety interim analyses 
(after 480 and 750 study patients discharged from PICU), the DSMB advised the continuation of 
the trial and ratified the initial sample size of 1,440 patients as adequate to test the hypothesis. 
On 1 December 2014, 1,130 patients have been included into the PEPaNIC trial. Recruitment of 
the last patient is expected for October 2015. 
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ABSTRACT 
Background
Recent trials have questioned the benefit of early parenteral nutrition in adults. The effect of 
early parenteral nutrition on clinical outcomes in critically ill children is unclear. 
Methods
We conducted a multicenter, randomized, controlled trial involving 1440 critically ill children to 
investigate whether withholding parenteral nutrition for 1 week (i.e., providing late parenteral 
nutrition) in the pediatric intensive care unit (ICU) is clinically superior to providing early 
parenteral nutrition. Fluid loading was similar in the two groups. The two primary end points 
were new infection acquired during the ICU stay and the adjusted duration of ICU dependency, 
as assessed by the number of days in the ICU and as time to discharge alive from ICU. For the 
723 patients receiving early parenteral nutrition, parenteral nutrition was initiated within 24 
hours after ICU admission, whereas for the 717 patients receiving late parenteral nutrition, 
parenteral nutrition was not provided until the morning of the 8th day in the ICU. In both 
groups, enteral nutrition was attempted early and intravenous micronutrients were provided.
Results
Although mortality was similar in the two groups, the percentage of patients with a new 
infection was 10.7% in the group receiving late parenteral nutrition, as compared with 18.5% 
in the group receiving early parenteral nutrition (adjusted odds ratio, 0.48; 95% confidence 
interval [CI], 0.35 to 0.66). The mean (±SE) duration of ICU stay was 6.5±0.4 days in the group 
receiving late parenteral nutrition, as compared with 9.2±0.8 days in the group receiving early 
parenteral nutrition; there was also a higher likelihood of an earlier live discharge from the 
ICU at any time in the late-parenteral-nutrition group (adjusted hazard ratio, 1.23; 95% CI, 
1.11 to 1.37). Late parenteral nutrition was associated with a shorter duration of mechanical 
ventilatory support than was early parenteral nutrition (P=0.001), as well as a smaller 
proportion of patients receiving renal-replacement therapy (P=0.04) and a shorter duration 
of hospital stay (P=0.001). Late parenteral nutrition was also associated with lower plasma 
levels of γ-glutamyltransferase and alkaline phosphatase than was early parenteral nutrition 
(P=0.001 and P=0.04, respectively), as well as higher levels of bilirubin (P=0.004) and C-reactive 
protein (P=0.006). 
Conclusion
In critically ill children, withholding parenteral nutrition for 1 week in the ICU was clinically 
superior to providing early parenteral nutrition. 
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INTRODUCTION 
Critically ill children cannot normally be fed by mouth, and as a result a pronounced 
macronutrient deficit often develops after a few days. This macronutrient deficit has been 
associated with infections, weakness, prolonged mechanical ventilation, and delayed 
recovery1-3. In order to prevent or limit the development of this macronutrient deficit, current 
guidelines, which are based largely on small studies with surrogate end points and on expert 
opinion, advise care providers to initiate nutritional support soon after a child’s admission to 
the pediatric intensive care unit (ICU)4-6. The preferred route for the administration of nutritional 
support in the pediatric ICU is the nasogastric tube7, but enteral nutrition is often delayed or 
interrupted8,9. Since nutrition should equal basic metabolic needs and in children should allow 
for growth, children require relatively more macronutrients than adults. Hence, the current 
standard of pediatric intensive care is to meet these requirements early7,10. When enteral 
nutrition fails, parenteral nutrition is advised5,6, but current nutritional practices in pediatric 
ICUs vary owing to concerns about the overdosing of parenteral nutrition8,11. 
There is a dearth of adequately powered, randomized, controlled trials that address the effects 
of parenteral nutrition on clinical outcomes in critically ill children12. With respect to critically 
ill adults, recent large, randomized, controlled trials have questioned the benefit of early 
parenteral nutrition13-15.
Therefore, in this international, multicenter, randomized, controlled trial, we investigated 
whether a strategy of withholding parenteral nutrition up to day 8 (late parenteral nutrition) 
in the pediatric ICU is clinically superior to the current practice of early parenteral nutrition. 
METHODS
Design and oversight
The Early versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit (PEPaNIC) trial 
was a multicenter, prospective, randomized, controlled, parallel-group superiority trial16. The 
institutional review board at each participating site approved the protocol (available with the 
full text of this article at NEJM.org)16. The first and last authors vouch for the fidelity of the study 
to the protocol and for the accuracy and completeness of the reported data.
From June 18, 2012, through July 27, 2015, all children (from term newborns to children 17 years 
of age) who were admitted to one of the participating pediatric ICUs were eligible for inclusion 
if a stay of 24 hours or more in the ICU was expected, if they had a score on the Screening 
Tool for Risk on Nutritional Status and Growth (STRONGkids) of 2 or more (with a score of 0 
indicating low risk of malnutrition, a score of 1 to 3 indicating medium risk, and a score of 4 
to 5 indicating high risk)17, and if none of the criteria for exclusion were met (See Table S1 in 
the Supplementary Appendix). Written informed consent was requested from parents or legal 
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guardians before elective admission to the pediatric ICU. For emergency admissions, consent 
was requested within 24 hours after the child’s admission to the pediatric ICU.
At each center, consecutive, eligible patients were randomly assigned to one of the two 
treatment groups in a 1:1 ratio. Concealment of group assignment was ensured by use of a 
central computerized randomization system. The randomization was stratified in permuted 
blocks of 10 according to age (<1 year or ≥1 year) and diagnosis on admission (medical-
neurologic, medical-other, surgical-cardiac, or surgical-other). The block size was unknown to 
the medical and research teams. Outcome assessors and investigators who were not directly 
involved in ICU patient care were unaware of the treatment assignments. 
An independent data and safety monitoring board planned to perform two interim analyses 
of the safety end points, one after 480 patients had been enrolled and a second after 50% 
of all patients had been enrolled. The board advised that recruitment could be continued to 
completion. 
Procedures
All participating centers used early parenteral nutrition as the standard of care. Among 
patients assigned to receive early parenteral nutrition, parenteral nutrition was initiated within 
24 hours after admission to the pediatric ICU. The dose and composition varied according to 
local guidelines (Table S2 in the Supplementary Appendix)16; parenteral nutrition was used 
to supplement any enteral nutrition that was provided, with a goal toward meeting local 
macronutrient and caloric targets (Table S3 in the Supplementary Appendix). 
Among patients assigned to the late-parenteral-nutrition group, parenteral nutrition was 
withheld up to the morning of day 8 in the pediatric ICU. A mixture of intravenous dextrose 
(5%) and saline was administered to the late-parenteral-nutrition group to match the amount 
of intravenous fluid administered in the early-parenteral-nutrition group16. When blood 
glucose levels spontaneously dropped below 50 mg per deciliter (2.8 mmol per liter) in the 
late-parenteral-nutrition group, the standard 5% dextrose solution was replaced with a 10% 
dextrose solution until blood glucose exceeded 80 mg per deciliter (4.4 mmol per liter) and 
remained stable16.
In both study groups, enteral nutrition was initiated early and was increased in accordance with 
local guidelines. Both study groups also received intravenous micronutrients (trace elements, 
minerals, and vitamins) starting from day 2 and continuing until the enteral nutrition provided 
reached 80% of the caloric targets. Starting from the morning of day 8 in the pediatric ICU, 
supplementary parenteral nutrition was provided for patients in both groups who were not 
yet receiving 80% of the caloric target enterally. In Leuven, Belgium, an insulin infusion was 
started in both groups to target blood glucose levels of 50 to 80 mg per deciliter (2.8 to 4.4 
mmol per liter) in infants (<1 year of age) and 70 mg per deciliter (3.9 mmol per liter) to 100 mg 
per deciliter (5.6 mmol per liter) in children (≥1 year of age). In Rotterdam, The Netherlands, all 
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patients received an insulin infusion designed to target blood glucose levels of 72 to 145 mg per 
deciliter (4.0 to 8.0 mmol per liter), with the exception of patients with traumatic brain injury, 
for whom the target was 108 mg per deciliter (6.0 mmol per liter) to 145 mg per deciliter. In 
Edmonton, Canada, patients received an insulin infusion when blood glucose levels exceeded 
180 mg per deciliter (10.0 mmol per liter). No specific lower boundary was set.
Data collection
All patient data were stored in a logged database that was closed 90 days after enrollment of 
the last patient. Because the treatment assignment affected the blood glucose level during 
the first 24 hours after admission, as expected, the Pediatric Risk of Mortality score could not 
be used to account for the severity of illness at baseline, and the Pediatric Logistic Organ 
Dysfunction (PELOD) score (which ranges from 0 to 71, with higher scores indicating more 
severe illness) was used instead. The risk of malnutrition at admission was quantified with use 
of the STRONGkids score17. The determination of the presence of infection on admission to the 
pediatric ICU or infection acquired after randomization was based on the consensus opinion 
of two infectious disease specialists, who made their decision on the basis of guidelines in the 
study protocol (Table S4 in the Supplementary Appendix)13; both specialists were unaware of 
the study-group assignments. During the time patients were in the ICU, daily records were kept 
regarding all procedures, treatments, nutrition provided, and results of laboratory analyses. 
Information on vital status at 90 days was obtained from national death registries, hospital 
information systems, and regional networks of pediatricians and general practitioners. 
End points
The two primary end points were new infection acquired during the ICU stay and the duration 
of ICU dependency, which was adjusted for five prespecified baseline risk factors (diagnostic 
group, age group, severity of illness, risk of malnutrition, and treatment center)16. Among 
patients with a new infection, the duration of antibiotic treatment was compared between 
the study groups. The duration of pediatric ICU dependency was quantified as the number of 
days in the pediatric ICU and as the time to discharge alive from the pediatric ICU, to account 
for death as a competing risk. Discharge from the pediatric ICU was defined a priori as the 
moment when a patient was ready for discharge from the pediatric ICU (i.e., no longer required 
or was no longer at risk for requiring vital organ support)16.
Secondary safety end points were death during the first 7 days in pediatric ICU, during the total 
stay in the pediatric ICU, during the stay in the index hospital, and at 90 days after admission to 
the pediatric ICU and randomization; the number of patients with hypoglycemia (glucose level 
<40 mg per deciliter [2.2 mmol per liter]); and the number of readmissions to the pediatric ICU 
within 48 hours after discharge. 
Secondary efficacy outcomes were the time to final (live) weaning from mechanical ventilatory 
support, the duration of pharmacologic or mechanical hemodynamic support, the proportion 
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of patients receiving renal-replacement therapy, markers of liver dysfunction and inflammation, 
and the time to (live) discharge from the hospital. 
Statistical analysis
We calculated that with a sample of 1440 patients (approximately 720 patients per group), 
the study would have at least 70% power to detect a 5-percentage-point lower rate of new 
infection in the late-parenteral-nutrition group than in the early-parenteral-nutrition group, 
assuming an estimated rate of 20% in the early-parenteral-nutrition group, with the use of a 
two-tailed test at an alpha error rate of 5%. All analyses were conducted on an intention-to-
treat basis. 
Variables were summarized as frequencies and percentages, medians and interquartile ranges, 
or means and standard errors. Univariable comparisons were performed with use of the chi-
square test (Fisher’s exact test) and the Wilcoxon rank-sum test. Kaplan-Meier plots were used 
to illustrate time-to-event effects with univariable significance that were analyzed by means 
of log-rank testing. The time-to-event effect size was estimated with use of Cox proportional-
hazards analysis, with data censored at 90 days. To take into account death as a competing risk 
for outcomes related to duration of care, data for non-survivors were censored at 91 days (i.e., 
beyond the date for censoring of data for all survivors). These time-to-event outcomes were 
assessed univariably and with adjustment for the baseline risk factors (diagnostic groups, age 
group, severity of illness, risk of malnutrition, and treatment center). The adjusted multivariable 
analysis of the effect of the intervention on dichotomized outcomes was performed with the 
use of logistic regression.
All P values were two-sided, and P values of less than 0.05 were considered to indicate 
statistical significance. No corrections were made for multiple comparisons. Because efficacy 
end points were not assessed in the interim analyses, no adjustment of the P value threshold 
for significance was required. 
To determine whether the effect of the intervention on the primary end points was influenced 
by baseline risk factors, P values for interaction were calculated with the use of multivariable 
logistic-regression analyses and multivariable Cox proportional-hazard analyses with a 
threshold for significance of interaction set at a P<0.10.  
All analyses were performed with the use of JMP software, version 11.2.0 (SAS Institute).
RESULTS 
Patients
A total of 1440 patients underwent randomization and were included in the analysis (Fig.1). 
At baseline, the characteristics of the patients were similar in the two groups (Table 1). Caloric 
and macronutrient intake per day up to day 16 in the pediatric ICU, which illustrates adherence 
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to the protocol, is shown in Figure 2, as well as in Figures S1 and S2 in the Supplementary 
Appendix.
7519 Children (newborn to 17 years of age)
 were assessed for eligibility
723 Were assigned to early 
parenteral nutrition
723 Were included in the analysis 717 Were included in the analysis
717 Were assigned to late 
parenteral nutrition
1440 Underwent randomization
 6079 Were excluded 
3592 Were not ill enough to 
necessitate nutritional 
support 
928 Had STRONGkids score <2 
408 Were readmissions  
178 Were enrolled in another 
trial 
 109 Were transferred from  
another neonatal or 
pediatric ICU 
95 Were premature newborns 
73 Had short-bowel syndrome 
or other condition requiring 
parenteral nutrition 
62 Had inborn metabolic 
diseases 
56 Had ketoacidotic or 
hyperosmolar coma 
46 Had  DNR code at 
admission 
32 Had expected death within 
12 hr 
18 Were >17 years of age 
158 Had other reasons 
324 Did not have consent 
Figure 1. Screening and randomization
The scores on the Screening Tool for Risk on Nutritional Status and Growth (STRONGkids) range from 0 to 
5, with a score of 0 indicating low risk of malnutrition, a score of 1 to 3 indicating medium risk, and a score 
of 4 to 5 indicating high risk17. DNR denotes do not resuscitate, and ICU intensive care unit.
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Table 1. Baseline characteristics*
Early Parenteral 
Nutrition
Late Parenteral 
Nutrition
Characteristic (N=723) (N=717)
Median age (IQR) - yr 1.4 (0.3-6.1) 1.5 (0.2-7.2)
Age <1 yr – no. (%) 328 (45.4) 325 (45.3)
Male sex -  no. (%) 415 (57.4) 415 (57.9)
Median weight (IQR) - kg 10.0 (4.8-20.0) 10.3 (4.5-21.5)
      Median standard deviation score (IQR)† -0.5 (-1.4-0.5) -0.4 (-1.4-0.5)
Median height (IQR) - cm 80 (58-113) 80 (56-120)
      Median standard deviation score (IQR)† -0.3 (-1.5-0.8) -0.3 (-1.4-0.8)
Median BMI (IQR) 15 (14-17) 15 (14-17)
      Median standard deviation score (IQR)† -0.5 (-1.5-0.5) -0.5 (-1.6-0.6)
STRONGkids risk level - no. (%)‡
     Medium 644 (89.1) 644 (89.8)
     High 79 (10.9) 73 (10.2)
Median PELOD score, fi rst 24 hr in pediatric ICU (IQR)§ 21 (11-31) 21 (11-31)
Emergency admission -  no. (%) 383 (53.0) 400 (55.8)
Diagnostic group -  no. (%)
     Surgical
          Abdominal 53 (7.3) 60 (8.4)
          Burns 5 (0.7) 5 (0.7)
          Cardiac 279 (38.6) 268 (37.3)
          Neurosurgery – traumatic brain injury 63 (8.7) 53 (7.3)
          Thoracic 34 (4.7) 27 (3.8)
          Transplantation 7 (1.0) 17 (2.4)
          Orthopedic surgery - trauma 28 (3.9) 26 (3.6)
          Other 21 (2.9) 27 (3.8)
     Medical
          Cardiac 30 (4.1) 31 (4.3)
          Gastrointestinal-hepatic 2 (0.3) 4 (0.6)
          Oncologic-hematologic 8 (1.1) 7 (1.0)
          Neurologic 51 (7.1) 52 (7.3)
          Renal 1 (0.1) 1 (0.1)
          Respiratory 99 (13.7) 96 (13.4)
          Other 42 (5.8) 43 (6.0)
Condition on admission -  no. (%)
          Mechanical ventilation required 639 (88.4) 622 (86.8)
          ECMO or other assist device required 19 (2.6) 25 (3.5)
          Infection 287 (39.7) 271 (37.8)
* There were no significant differences in characteristics between treatment groups at baseline. BMI 
denotes body-mass index (the weight in kilograms divided by the square of the height in meters), ECMO 
extracorporeal membrane oxygenation, and ICU intensive care unit.
† Age- and gender-specific standard deviation scores were calculated with the use of reference data from 
the World Health Organization18.
‡ Scores on the Screening Tool for Risk on Nutritional Status and Growth (STRONGkids) range from 0 to 5, 
with a score of 0 indicating a low risk of malnutrition, a score of 1 to 3 indicating medium risk, and a score 
of 4 to 5 indicating high risk.
§ Pediatric Logistic Organ Dysfunction (PELOD) scores range from 0 to 71, with higher scores indicating 
more severe illness.
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Figure 2. Daily caloric and macronutrient intake 
The daily amount of energy (kilocalories per day) and substrate (grams per day) provided by the enteral 
route, the parenteral route, or both (total) are shown for participants’ first 16 days in the pediatric intensive 
care unit (ICU). Bars indicate the mean, and whiskers indicate the standard error of the mean. PN denotes 
parenteral nutrition. 
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Primary outcomes
The rate of acquisition of a new infection was 7.8 percentage points lower (95% confidence 
Interval [CI], 4.2 to 11.4) among children receiving late parenteral nutrition than among children 
receiving early parenteral nutrition (adjusted odds ratio, 0.48; 95% CI, 0.35 to 0.66) (Table 2). This 
result was attributable primarily to the fact that fewer patients in the late-parenteral-nutrition 
group acquired an airway or blood stream infection (Table 2). Late parenteral nutrition was 
also associated with a shorter stay in the pediatric ICU by a mean of 2.7 days (95% CI, 1.3 to 
4.3) (Table 2), with a higher likelihood of an earlier discharge alive from the pediatric ICU at any 
time (adjusted hazard ratio, 1.23; 95% CI, 1.11 to 1.37) (Table 2 and Fig. 3, and Fig. S3 and Table 
S5 in the Supplementary Appendix). 
Figure 3. Kaplan-Meier plots for the time to discharge and for survival up to 90 days
Panels A, B, and C show the cumulative proportions of patients discharged from the pediatric ICU, the 
index hospital, and all hospitals (index and transfer hospitals), respectively. Data for surviving patients 
were censored at 90 days, whereas data for non-survivors were censored at the time of death. For the sake 
of clarity, only the first 30 days are shown. Panel D shows the survival rate up to 90 days. 
P values were adjusted for diagnostic group, age group, severity of illness, risk of malnutrition, and 
treatment center.
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There were no significant interactions (P<0.10) between treatment assignment and any 
of the prespecified risk factors (Table S6 in the Supplementary Appendix). However, for the 
interaction between treatment assignment and risk of malnutrition, the P value was 0.11, with 
a lower odds of infections with late parenteral nutrition than with early parenteral nutrition 
among children at high risk of malnutrition (odds ratio, 0.28; 95% CI, 0.10 to 0.70) than among 
those at medium risk of malnutrition (odds ratio, 0.54; 95% CI, 0.38 to 0.76). There was also a 
higher likelihood of an earlier discharge alive from pediatric ICU with late parenteral nutrition 
among the children at high risk of malnutrition (hazard ratio, 1.61; 95% CI, 1.12 to 2.31) than 
among the children at medium risk of malnutrition (hazard ratio, 1.19; 95% CI, 1.06 to 1.33) 
(P=0.19 for the interaction). 
Similarly, there was no significant interaction between treatment assignment and age group. 
A post hoc subgroup analysis of the 209 term neonates who were less than 4 weeks of age at 
the time of study inclusion revealed that the benefits of late parenteral nutrition were similar 
to or greater than those for children 4 weeks of age or older (odds ratio for new infections, 0.47 
[95% CI, 0.22 to 0.95] among neonates and 0.48 [95% CI, 0.33 to 0.69] among older children; 
P=0.99 for the interaction; hazard ratio for the likelihood of earlier live discharge from the 
pediatric ICU, 1.73 [95% CI, 1.27 to 2.35] among neonates vs. 1.17 [95% CI 1.04-1.31] among 
older children; P=0.03 for the interaction). 
In addition, the effect of late parenteral nutrition on primary outcomes was unaltered after 
adjustment for the amount of enteral nutrition provided (Table S7 in the Supplementary 
Appendix).    
Secondary outcomes
Mortality was similar in the two groups at all prespecified time points (Table 2 and Fig. 3). The 
percentage of patients with an episode of hypoglycemia (glucose level <40 mg per deciliter) 
was higher in the group receiving late parenteral nutrition than in the group receiving early 
parenteral nutrition (Table 2). Adjustment for hypoglycemia did not alter the effect size of 
late parenteral nutrition on the primary outcomes (odds ratio for new infection, 0.45 [95% CI, 
0.32 to 0.62] and adjusted hazard ratio for the likelihood of an earlier live discharge from the 
pediatric ICU, 1.26 [95% CI, 1.13 to 1.41]) (Table S7 in the Supplementary Appendix). Rates 
of readmission to the pediatric ICU within 48 hours after discharge and of the occurrence of 
serious adverse events were similar in the two study groups (Table 2). 
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The duration of mechanical ventilatory support was shorter and the likelihood of being 
weaned alive earlier from mechanical ventilation was higher among patients receiving late 
parenteral nutrition than among those receiving early parenteral nutrition (Table 2, and 
Table S5 in the Supplementary Appendix), whereas there was no significant between-group 
difference in the duration of hemodynamic support. After adjustment for prespecified risk 
factors, late parenteral nutrition was also associated with a lower need for renal-replacement 
therapy (Table 2, and Table S5 in the Supplementary Appendix). The peak plasma total 
bilirubin levels were higher in the late-parenteral-nutrition group than in the early-parenteral-
nutrition group during the first 7 days in the pediatric ICU (Table 2) and during the duration 
of the pediatric ICU stay (Table S8 in the Supplementary Appendix), whereas the peak plasma 
γ-glutamyltransferase and alkaline phosphatase levels were higher with early parenteral 
nutrition (Table 2). There were no significant between-group differences in the results of other 
liver tests (Table 2). Although there were fewer new infections with late parenteral nutrition 
than with early parenteral nutrition, the peak plasma levels of C-reactive protein were higher 
with late parenteral nutrition during the first 7 days in the pediatric ICU (Table 2).
The mean duration of stay in the index hospital was 4.1 days shorter (95% CI, 1.4 to 6.6), and 
the likelihood of an earlier discharge alive from the hospital was higher (adjusted hazard ratio, 
1.19; 95% CI, 1.07 to 1.33) in the late-parenteral-nutrition group than in the early-parenteral-
nutrition group (Table 2 and Fig. 3, and Table S5 and Fig. S3 in the Supplementary Appendix). 
This effect of late parenteral nutrition remained significant when any eventual additional stay 
in a transfer hospital was taken into account (Table 2 and Fig. 3, and Table S5 and Fig. S3 in the 
Supplementary Appendix).
Adjustments for hypoglycemia or for the amount of enterally administered nutrition did not 
alter the effect of late parenteral nutrition on any of the secondary outcomes (Table S7 in the 
Supplementary Appendix). 
DISCUSSION
The results of our trial showed that withholding parenteral nutrition for 1 week in the pediatric 
ICU was clinically superior to providing early parenteral nutrition; late parenteral nutrition 
resulted in fewer new infections, a shorter duration of dependency on intensive care, and a 
shorter hospital stay. 
The clinical superiority of late parenteral nutrition was shown irrespective of diagnosis, severity 
of illness, risk of malnutrition, or age of the child. The observation that critically ill children at 
the highest risk of malnutrition benefited the most from the withholding of early parenteral 
nutrition was unexpected. However, this finding was reinforced by the apparently greater 
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benefit of this strategy for critically ill term neonates than for older children. Indeed, immediate 
initiation of nutrition is currently advised for neonates because they are considered to have 
lower metabolic reserve7.
The benefits of late parenteral nutrition were evident irrespective of the variability in nutritional 
care and blood-glucose management across participating centers. Late parenteral nutrition 
resulted in more instances of hypoglycemia than were seen with early parenteral nutrition, but 
this higher rate did not affect the overall effect of the intervention on the outcome. In addition, 
in earlier studies, such brief episodes of hypoglycemia in critically ill children or in premature 
or mature newborns were not shown to have a negative effect on long-term neurocognitive 
outcomes19-21.
The finding that the rate of new infections was substantially lower with late parenteral 
nutrition than with early parenteral nutrition but that the rate of inflammation (as indicated by 
elevated plasma levels of C-reactive protein) was higher illustrates the limitation of surrogate 
end points in clinical trials22-26. As was seen in a previous study involving adults, plasma levels 
of γ-glutamyltransferase and alkaline phosphatase were lower in children who received late 
parenteral nutrition than in those who received early parenteral nutrition, a finding that was 
suggestive of less cholestasis in children in the late-parenteral-nutrition group13,27,28. However, 
late parenteral nutrition resulted in higher plasma bilirubin levels than did early parenteral 
nutrition in these critically ill children, as it has in adult patients, which provides further support 
for the concept that increases in plasma bilirubin levels in response to critical illness may be 
partially adaptive29.
The underlying mechanisms of the clinical benefits observed when there is a substantial 
macronutrient deficit early in critical illness in children remain speculative. Preservation of 
autophagy may play a role, given its importance for innate immunity and for quality control in 
cells with a long half-life, such as myofibers30-32.
A limitation of this study is that the patients, their parents, and the staff providing intensive 
care were aware of the treatment assignments. However, outcome assessors and caregivers on 
the pediatric wards were unaware of the treatment assignments. The strength of the study is 
its external validity, given the multicenter study design. 
In conclusion, in critically ill children, withholding parenteral nutrition for 1 week while 
administering micronutrients intravenously was clinically superior to providing early parenteral 
nutrition to supplement insufficient enteral nutrition. 
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Supplementary Figure 1. Caloric and macronutrient intake per kg
Daily amount of energy in kcal/kg/day, and the daily amounts of substrates in g/kg/day, for the first 16 
days of pediatric intensive care unit (PICU) stay provided by the enteral route, the parenteral route or both 
(total). Bars represent the mean and the whiskers represent the standard error of the mean (SEM). The red 
bars represent the late parenteral nutrition (PN) group; the blue bars represent the early PN group.
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Supplementary Figure 2. Caloric intake per kg for weight categories
Daily amount of energy in kcal/kg/day, for three weight categories (<10 kg, 10-20 kg and >20 kg), for the 
first 16 days of pediatric intensive care unit (PICU) stay provided by the enteral route, the parenteral route 
or both (total). Bars represent the mean and the whiskers represent the standard error of the mean (SEM). 
The red bars represent the late parenteral nutrition (PN) group; the blue bars represent the early PN group. 
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Supplementary Figure 3. Kaplan-Meier plots for the time to (live) discharge from the PICU and the 
hospital and for survival up to 90 days
Panels A to F represent the cumulative proportions of patients discharged from the PICU (A), discharged 
live from the PICU (B), discharged from the hospital [index (C) and total (E)] and discharged live from 
the hospital [index (D) and total (F)]. For the analyses of the time to discharge, data for all patients were 
censored at 90 days, while non-survivors were censored at time of death. For the analyses of the time to 
live discharge, data were censored at 90 days with non-survivors censored at 91 days to account for death 
as a competing risk. For sake of clarity, only the first 30 days are shown in panels A-F. Panel G illustrates 
survival up to 90 days. The red lines represent the late PN group; the blue lines represent the early PN 
group. 
*univariable log-rank P-value; $ P-value adjusted in multivariable analysis.
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SUPPLEMENTARY TABLES
Supplementary Table 1. Exclusion criteria for study participation
Not critically ill enough to necessitate nutritional support
STRONGkids score lower than 2 on PICU admission1
Non-pediatric patients (aged 17 or older)
Premature newborns (<37 weeks gestational age upon admission in the PICU)
‘Do not resuscitate’ code at the time of PICU admission
Expected death within 12 hours
Readmission to PICU after already having been randomized
Enrollment in another intervention trial
Transfer from another PICU or neonatal ICU after a stay of more than 7 days
Ketoacidotic or hyperosmolar coma
Inborn metabolic diseases requiring specifi c diet
Short bowel syndrome or other conditions requiring PN for more than 7 days prior to PICU admission
PICU=Pediatric Intensive Care Unit, PN=Parenteral Nutrition 
Supplementary Table 2. Local protocols for initiation of PN in early PN group, in all participating centers EN 
was attempted as soon as possible
Center On admission Day 2 Day 3 Subsequent Stay
Leuven, 
Belgium
Mixture of glucose 
30% and Vaminolact® 
(Fresenius)
Addition of lipids 
(SMOFlipid® 
Fresenius)
All replaced by 
mixture of glucose 
50% and SMOFlipid® 
with Vaminolact® or 
Vamin 18®.
Glucose 50% and 
SMOFlipid® with 
Vaminolact® or Vamin 
18®
Rotterdam, 
The Nether-
lands
Continuous glucose 
infusion with glucose 
intake 4-6 mg/kg/
min (< 30 kg) or 2-4 
mg/kg/min (> 30 kg)
Pharmacy-made PN: 
mixture of glucose, 
Primene® (Baxter) 
and Intralipid® 
(Fresenius, 50% of 
fi nal dose). Children 
>30 kg Olimel® 
(Baxter, N5 or N4 
depending on central 
or peripheral line)
Increase of lipids to 
100%
Pharmacy-made PN: 
mixture of glucose, 
Primene® (Baxter) 
and Intralipid® 
(Baxter, 100% of fi nal 
dose). Children >30 
kg Olimel® (Baxter, 
N5 or N4 depending 
on central or 
peripheral line)
Edmonton, 
Canada
Continuous glucose 
infusion with glucose 
intake 3-4 mg/kg/
min
Addition of 20% IV 
lipids (50% of fi nal 
dose)
Increase of lipids to 
100%
Mixture amino acids 
and concentrated 
glucose 
Mixture amino acids, 
concentrated glucose 
and 20% IV lipids 
EN=Enteral Nutrition, IV=Intravenous, PN=Parenteral Nutrition
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Supplementary Table 3. Macronutrient and caloric targets per center
Center First day Subsequent stay
Leuven, Belgium First 10 kg: 100 kcal/kg
10-20 kg: + 50 kcal/kg
>20 kg: + 20 kcal/kg
(adjusted downward when fl uid restriction required)
Rotterdam, 
The Netherlands
EN: basal metabolic rate by Schofi eld-
weight2
PN: ESPGHAN3
EN: Recommended Dietary 
Allowances4
PN: ESPGHAN3
Edmonton, Canada Resting energy expenditure by indirect 
calorimetry
If indirect calorimetry impossible: 65% 
of basal metabolic rate (FAO-WHO5)
Adjusted daily by the dietitian based 
on clinical information
EN=Enteral Nutrition, PN=Parenteral Nutrition
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Supplementary Table 4. Protocol for scoring of infections   
1. Data export 
All patients receiving antimicrobial agents were identified by the data manager, who provided 
an export of all patient numbers with all the information on antimicrobial agents given as well 
as the duration of such treatment.
2. Identification of patients with infections
The infectious disease specialists, who were blinded for treatment allocation, selected all 
patients receiving antimicrobial agents for more than 48h, after excluding all patients who 
received prophylaxis. Each patient who fulfilled the criteria for infection, as well as the type 
of infection, was identified as such based on thorough review of the medical record6. Patients 
for whom antimicrobials were initiated prior to PICU admission or within the first 48 hours of 
admission while the criteria for infection were fulfilled, were labeled as “having an infection upon 
admission”. When antimicrobial agents were initiated after randomization and beyond the first 
48 hours in the PICU, and were given for more than 48 hours while the criteria for infection were 
fulfilled, the patient was labeled as “having a new infection”6. 
Supplementary Table 5. Logistic regression and Cox proportional hazards analyses
OR or HR
unadjusted 
(95% CI)
Late PN vs. 
Early PN
P-value 
unadjusted
OR or HR 
adjusted* 
(95% CI)
Late PN vs. 
Early PN
P-value
adjusted
Primary Outcomes
Odds for New Infection 0.53 (0.39-0.71) < 0.001 0.48 (0.35-0.66) < 0.001
Likelihood of Earlier Live Discharge 
from PICU 
1.14 (1.02-1.27) 0.01 1.23 (1.11-1.37) < 0.001
Safety Outcomes
Odds for Death
   Within 8 days in PICU 0.91 (0.48-1.71) 0.76 0.73 (0.34-1.51) 0.39
   During PICU Stay 0.89 (0.55-1.45) 0.64 0.73 (0.42-1.28) 0.27
   During Hospital Stay 0.84 (0.53-1.32) 0.44 0.72 (0.43-1.19) 0.20
   Within 90 days after enrollment 0.77 (0.49-1.19) 0.23 0.64 (0.39-1.05) 0.07
Secondary Effi  cacy Outcomes
Likelihood of Earlier Live Weaning 
from Mechanical Ventilatory Support
1.11 (1.00-1.24) 0.04 1.19 (1.07-1.32) 0.001
Odds for Renal Replacement Therapy 0.69 (0.37-1.26) 0.23 0.49 (0.24- 0.96) 0.03
Likelihood of Earlier Live Discharge 
from Index Hospital
1.14 (1.03-1.27) 0.01 1.19 (1.07-1.33) 0.001
Likelihood of Earlier Live Discharge 
from Hospital (Index and Transferral 
Hospital)
1.14 (1.02-1.27) 0.02 1.21 (1.08-1.34) < 0.001
All duration of care outcomes were censored at 90 days with non-survivors censored at 91 days. OR=Odds 
Ratio, HR=Hazard Ratio, PN=Parenteral Nutrition, 95% CI= 95% confidence intervals, PICU=Pediatric 
Intensive Care Unit
* Adjusted for the following risk factors: center, age group, diagnosis group, PELOD score (first 24h)7 and 
STRONGkids category1
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Supplementary Table 6. P-values for interaction between randomized treatment allocation and the 
predefined baseline risk factors on the primary outcomes
P-value
Patients with New Infections1
  PELOD score fi rst 24h in PICU 0.80
  Age group 0.55
  Diagnostic group 0.25
  STRONGkids score1 0.11
  Center 0.72
Time to live discharge from the PICU2
  PELOD score fi rst 24h in PICU 0.80
  Age group 0.65
  Diagnostic group 0.73
  STRONGkids score1 0.19
  Center 0.56
PELOD=PEdiatric Logistic Organ Dysfunction7, PICU=Pediatric Intensive Care Unit 
1 Multivariable Logistic Regression Analysis censored at 90 days with non-survivors censored at 91 days
2 Multivariable Cox Proportional Hazard Analysis censored at 90 days with non-survivors censored at 91 
days
Supplementary Table 7. Adjusted Odds Ratios and Hazard Ratios further corrected for hypoglycemia (plasma 
concentration glucose < 40 mg/dL) and for the average amount of enteral feeding (kcal/kg/day) during 
randomisation window 
OR or HR adjusted*
(95% CI)
Late PN vs. Early PN
(adjusted
for
hypoglycemia)
P-value OR or HR adjusted*
(95% CI)
Late PN vs. Early PN
(adjusted
for
enteral kcal/kg/d)
P-value
Primary Outcomes
Patients with New Infections 0.45 (0.32-0.62) < 0.001 0.47 (0.34-0.65) < 0.001
Likelihood Earlier Live PICU Discharge 1.26 (1.13-1.41) < 0.001 1.24 (1.12-1.38) < 0.001
Secondary Effi  cacy Outcomes
Likelihood Earlier Live Weaning 
from Mechanical Ventilatory Support
1.21 (1.09-1.35) < 0.001 1.19 (1.07-1.32) 0.001
Renal-Replacement Therapy 0.49 (0.24-0.97) 0.03 0.52 (0.25-1.03) 0.06
Likelihood Earlier Live Hospital 
Discharge 
1.22 (1.09-1.36) < 0.001 1.19 (1.07-1.33) 0.001
All duration of care outcomes were censored at 90 days with non-survivors censored at 91 days. OR=Odds 
Ratio, HR=Hazard Ratio, PN=Parenteral Nutrition, 95% CI= 95% Confidence Intervals, PICU=Pediatric 
Intensive Care Unit
* Adjusted for the following risk factors: center, age group, diagnosis group, PELOD score first 24h7, 
STRONGkids category1 and hypoglycemia (plasma concentration glucose < 40 mg/dL) or amount of 
enterally administered kcal per kg per day.
In both analyses, experiencing hypoglycemia and receiving a higher amount of enterally administered 
kcal per kg per day were independent risk factors for infections and for a delayed live discharge from PICU 
(all P-values ≤0.004).
Chapter 7
148
R1
R0
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Supplementary Table 8. Highest plasma concentrations during PICU stay for markers of liver dysfunction and 
inflammation. Mean plasma glucose concentration during PICU stay
Early PN Late PN P-value
Highest plasma concentration during PICU stay N=723 N=717
Liver dysfunction - mean (SEM)
    Highest plasma bilirubin – mg/dL (N = 1261) 1.6 (0.1) 1.9 (0.2) 0.006
    Highest plasma Alkaline Phosphatase (N=1236) 195 (5) 182 (6) 0.001
    Highest plasma GGT – IU/L (N = 1225) 85 (7) 64 (5) 0.003
    Highest plasma ALT – IU/L (N = 1270) 85 (9) 118 (20) 0.33
    Highest plasma AST – IU/L (N = 1268) 202 (28) 271 (48) 0.82
Infl ammation - mean (SEM)
    Highest plasma CRP – mg/L (N = 1307) 87 (4) 93 (4) 0.09
Mean plasma glucose – mg/dL (N= 1391) 117 (1.5) 100 (1.2) < 0.001
PN=Parenteral Nutrition, PICU=Pediatric Intensive Care Unit, SEM= Standard Error of the Mean, GGT= 
Gamma-Glutamyltransferase, ALT= Alanine Aminotransferase, AST= Aspartate Aminotransferase, CRP= 
C-reactive protein
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INTRODUCTION
Understanding the stress response to critical illness is essential for nutritional recommendations 
in critically ill children. Nutrient restriction early during critical illness might be beneficial 
for short and long-term outcomes, while inclining caloric and protein requirements allow 
for a more aggressive feeding approach during the stable and recovery phase. In order to 
provide the optimal amount of nutrition and prevent the detrimental effects associated with 
malnutrition, both under- and overfeeding should be identified, but current definitions fail 
to do this accurately. Although the enteral route is preferred because of its association with 
improved outcome, (supplemental) parenteral nutrition (PN) is often administered to improve 
intake adequacy despite potential disadvantages.
This thesis provided insight in the practice and evidence of the timing and goals of PN and thus 
the development and the subsequent outcome of underfeeding or overfeeding in critically ill 
children.
CURRENT NUTRITIONAL PRACTICES
Paediatric guidelines
Globally, guidelines for nutritional support have been released by expert committees of 
non-profit nutritional organisations such as the American Society for Parenteral and Enteral 
Nutrition (A.S.P.E.N.), the European Society for Clinical Nutrition and Metabolism (ESPEN), and 
the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) 
(Chapter 2). Due to a lack of high-level evidence, the consensus-based guidelines offer basic 
recommendations that are largely driven by expert opinion and extrapolations from studies in 
adults or noncritically ill children1,2.
Current guidelines versus clinical practices worldwide
These inconclusive guidelines make clinical implementation in PICUs across the world difficult. 
This leads to a wide variation of nutritional practices in PICUs, which were quantified by use of 
an online worldwide survey (Chapter 2). The first survey described local nutritional strategies 
in 156 PICUs worldwide. Subsequently, a point prevalence study was performed to collect 
nutritional data from critically ill children on a single day in these same PICUs. By comparing 
results from the initial survey with the point prevalence data, the deviation between intended 
and applied nutritional practices was highlighted. Aspects that differed most between PICUs 
can therefore be presumed to be in greatest need of high-quality evidence to guide future 
clinical practice. These aspects were identified in both parts of the survey. In chapters 1 and 5 
the lack of clinical outcome studies on the use of PN in the PICU has been underlined. Indeed, 
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according to the survey, a striking lack of consensus was identified on parenteral glucose intake 
and on the timing and threshold for use of (supplemental) PN (Chapter 2). The limitations of 
indirect calorimetry (IC) (Chapters 1 and 3), were reflected by a limited availability of IC in only 
14% of PICUs. The general inadequacy of predictive equations to determine resting energy 
expenditure (REE) in absence of IC (Chapter 4) combined with conflicting evidence on the 
effect of patient- and disease-related factors on REE (Chapter 1), resulted in adoption of at 
least 10 different equations for energy expenditure, adjusted for a wide variety of correction 
factors (Chapter 2). 
Early initiation of enteral nutrition is preferred
The most consistent finding between PICUs was the preference for enteral nutrition (EN) as 
route of nutrient delivery and its early initiation within 24 hours after admission (Chapter 2). This 
is in line with the general acceptance of the benefits of early EN, as shown in previous studies 
in critically ill adults and children3-8 and recommendations by current guidelines for critically 
ill adults9-11. However, the beneficial physiologic effects from early provision of EN, established 
in many laboratory and animal models, do not automatically reflect improvement of clinical 
outcome. In chapter 1 it was shown that studies that claimed an improved clinical outcome 
with early EN in critically ill children were all observational in design. Their conclusions should 
be interpreted cautiously because patients who are more tolerant for EN, are usually more 
likely to be less severely ill. Only for critically ill children with burns, superiority of early EN has 
been proven by a randomised study design12, but recommendations for other PICU patients 
cannot be derived directly from this data. Despite the circumstantial evidence on the benefits 
of early provision of EN, there is a general consensus that EN should be initiated within 24-48 
hours after PICU admission, if possible (Chapter 2)1.
In contrast, the optimal amount of early EN remains a topic of debate. Several studies found 
an association between higher enteral intake in critically ill children and improved outcome8. 
This perception was reflected in the survey by the intention to meet caloric targets by the 
enteral route within 3 days in the majority of PICUs (Chapter 2). However, higher enteral intake 
is predominantly defined as a higher percentage of caloric targets achieved by the enteral 
route. As shown in chapter 2 and 4, caloric targets vary widely between PICUs, so an equal 
amount of EN provided in these PICUs might be reflected by different percentages of caloric 
target achieved. Careful interpretation of these data is therefore warranted. 
What to do with current guidelines
With grade C as the maximum level of evidence, recommendations in current guidelines 
for nutrition support in critically ill children are based on insufficient data (Chapter 1 and 5). 
Many of the studies on which the guidelines are based are limited by sample size, patient 
heterogeneity, variability in disease severity and lack of baseline nutritional status (Chapter 5). 
The guidelines also do not cover every aspect of nutritional support; the A.S.P.E.N. guideline 
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does not provide recommendations on macronutrient intake, whereas the ESPEN/ESPGHAN 
only has a guideline on adult EN, not on EN in children. Moreover, the PN guidelines of the 
ESPEN/ESPGHAN are targeted at children in general, and information on critically ill children is 
limited to specific and generally small sections. Finally, the phase of critical illness (Chapter 1 
and 4) is not taken into account in any of the recommendations for critically ill children, while 
a large proportion of nutritional studies are limited to the (semi)acute phase.
Even after a highly needed update of current guidelines, recommendations guided by high-
level evidence remain scarce. However, as alternatives are lacking, they reflect the best 
available evidence. Furthermore, since availability of a nutritional protocol, even if based on 
low-grade evidence8, is associated with improved outcome, clinical implementation of these 
recommendations is useful. The judgment of the clinician based on individual circumstances 
of the patient must always take precedence over these guidelines10.
ENERGY EXPENDITURE
Measurement of REE
Current guidelines advise to match REE by caloric intake to limit caloric deficit1. In a subgroup 
of patients with suspected metabolic alterations or malnutrition, accurate measurement of 
energy expenditure using IC is desirable1. This practice is challenging however, due to the 
limited availability of IC (Chapter 2) and the inaccuracy of predictive equations (Chapter 4) 
to calculate REE. Ventilator-derived VCO
2 
measurements are a promising alternative method 
to determine REE in mechanically ventilated children weighing 15 kg or more because of 
its increased precision compared to the current predictive equations (Chapter 3). However, 
these results should mainly be regarded as a proof of concept, mainly due to the small study 
population. Further validation of this method to improve accuracy of the measurements 
and to detect sources of error in a larger cohort of critically ill children is needed before 
implementation in clinical practice is possible. This could be done by collecting and comparing 
REE values derived from IC and the ventilator whenever IC is performed (Chapter 3), and 
ultimately by investigating whether adjustment of nutrition based on ventilator-derived VCO
2 
measurements improves clinical outcome of critically ill children. 
Since this method appears to be valid only in children weighing ≥15 kg, around 60% of PICU 
patients at risk will still need to rely on inadequate predictive equations to determine REE in 
absence of IC. The inadequacy of the ventilator-derived method in children <15 kg, presumably 
caused by sampling specifications, is not likely to be resolved in the near future. However, this 
method should again be investigated in smaller children, when the technical performance 
of the CO
2 
sensor is improved (by an increased accuracy and sampling frequency), and an 
improved version of the airway adapter causes less increase of dead space and turbulence. 
Moreover, even in children weighing ≥15 kg, this method cannot be validated using regular IC. 
Chapter 8
158
R1
R0
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
In children with tube leak and children on HFO and ECMO, measurement of expiratory VCO
2
 is 
inherently meaningless. In children with a supplied oxygen level of more than 60%, validation 
is restricted by the limitations of IC, so other validation techniques (e.g. double-labelled water) 
can be used to study this method in these children.
Although limited to a selected group of patients, clinical implementation of the ventilator-
derived method will provide a more reliable determination of REE. Continuous provision of 
values will help to visualise the course of REE values during PICU stay and thereby allow early 
detection of changes in REE, as can be expected in septic neonates, children with fever and 
neonates after surgery (Chapter 1). In order to do so, VCO
2
 values from the ventilator need to 
be automatically registered by the patient data management system and recalculated into REE 
based on the previously validated metabolic equation13. Measurements with more than 10% 
fluctuation in VCO
2 
will need to be discarded automatically. Based on the remaining steady-
state VCO
2
 measurements, mean REE values can be provided to the attending clinicians to 
guide nutritional therapy. Although repeated measurements of REE improved outcome in 
geriatric patients following surgery14 and showed a trend towards improved hospital mortality 
in mechanically ventilated adults15, a single determination of REE is sufficient to guide nutrition 
in the majority of critically ill children. Repeated measurements may be useful only in children 
with suspected metabolic alterations or malnutrition16.
Use of REE to guide nutritional support
In contrast with the paediatric guidelines, results from recent large RCTs in the adult ICU 
question the need for matching REE by the enteral route during the acute phase of critical 
illness. No differences in mortality or other clinical outcome measures were found between 
permissive underfeeding and planned delivery of a full amount of nonprotein calories in 
critically ill adults17,18. Moreover, no faster recovery was observed in critically ill adults receiving 
more than 30% of the caloric goal by the enteral route compared to adults receiving less than 
30% during the first week of the adult version of the PEPaNIC trial (EPaNIC trial)19. Finally, 
endogenous energy production during the acute phase of critical illness limits the use of 
exogenous provided energy. The optimal amount of required energy to supplement this 
endogenous production cannot be measured by IC.
Therefore, emphasis on measurement of REE to guide nutritional therapy is likely to shift to 
subsequent phases of critical illness, aimed at restoration of lean body mass while synthesis 
of excess fat mass should be avoided. This is already practiced in the NICU, where longitudinal 
IC measurements are mainly used to guarantee appropriate growth for this population20,21. 
However, these phases are characterised by weaning or even absence of ventilatory support 
(Chapter 1), limiting the use of IC or ventilator-derived values. Moreover, independently of 
the phase, application of IC in preterm infants is extremely challenging and therefore hardly 
practiced outside research settings. In absence of REE measurements, early initiation of 
nutrition is aspired in all preterm infants (Chapter 5), irrespective of severity of illness22.
General discussion
159
8
R1
R0
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
The use of REE to identify overfeeding is also presumed to be limited to the stable and recovery 
phase. Overfeeding in the most general sense is defined by a worsening of outcome due to an 
excess of nutrients. Despite the current lack of outcome-based definitions, detrimental effects 
from overfeeding have been identified (Chapter 1 and 4). Different concepts of overfeeding, 
such as excessive amounts of caloric intake or separate macronutrients (glucose, amino acids 
or lipids) can occur isolated or simultaneously, and are associated with specific disadvantages. 
Early caloric overfeeding is associated with increased mortality in critically ill adults23, and 
with liver dysfunction and hepatobiliary complications in children24,25. Current definitions of 
caloric overfeeding based on IC measurements are inaccurate and show a varying specificity. 
Depending on the definition used, up to 61% of children on the PICU were identified as being 
overfed26. The risk of caloric overfeeding and its complications are presumed to be influenced 
by age and nutritional status of the child (Chapter 4), the phase of critical illness (Chapter 1 and 
4), and by the route of nutrition. In order to prevent the adverse effects of overfeeding during 
these phases, a new definition of overfeeding needs to be identified (Chapter 4) and should 
preferably be calibrated on clinical outcome measures.
Since overfeeding and underfeeding both depend on the same requirements, it can be 
presumed that underfeeding is influenced by similar patient- and disease related factors. 
Therefore, IC-derived definitions to identify underfeeding27 are likely to be just as inaccurate as 
those for overfeeding (Chapter 4). Whereas full nutrition in the acute phase will easily result in 
overfeeding, the risk of underfeeding is highest during the stable and recovery phase due to 
increasing requirements (Chapter 1). If requirements are not met during these last two phases, 
recovery and (catch-up) growth are hampered, thereby affecting outcome.
SUPPLEMENTAL PARENTERAL NUTRITION 
The beneficial effect of withholding PN up to day 8 after PICU admission
The use of EN exclusively puts the patient at risk for the development of substantial 
macronutrient deficits during PICU stay. Despite the aim of most PICUs to meet caloric targets 
within 3 days by the enteral route, the point prevalence measurement showed that 40% of 
PICUs failed to achieve this (Chapter 2). Although solid evidence for use of PN in the PICU is 
lacking (Chapter 5), the survey showed that in 40% of PICUs PN is already started when EN 
fails to meet 80% of caloric targets (Chapter 2). These specific PICUs represent approximately 
36.000 admissions per year. As 16% of PICUs was estimated to participate in the survey, this 
means that each year at least 200.000 critically ill children receive a medical treatment with 
only very limited clinical evidence. This is in line with the estimation that 30-50% of critically 
ill children in Europe and the United States receive this therapy, representing 118.000-196.000 
children, based on the number of PICU beds and average length of stay in the United States28. 
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In contrast with this current practice and the findings of previous observational studies8,29, the 
PEPaNIC trial (Chapter 6 and 7) showed that withholding PN during the first week of PICU stay 
is clinically superior to the early initiation of (supplemental) PN, with fewer new infections, 
shorter duration of intensive care dependency and a shorter hospital stay. This trial was 
conducted in 1440 critically ill children at nutritional risk (Chapter 6). Non-critically ill children 
were excluded, because the lower severity of stress enabled them to be monitored without 
any form of organ support and/or to be discharged from the PICU within 24 hours. This group 
mainly consisted of patients after heart catheterisation, endoscopy, surgical corrections of atrial 
and septum ventricular defects, inguinal hernia and craniotomy. Also children with asthma 
exacerbations or congenital heart disease without cardiac failure were excluded. Children at 
low nutritional risk (STRONGkids score <2) were excluded, since the need for artificial nutrition 
in this population is low. By doing so, the application of the study results are reserved for at-risk 
patients, with pre-existent malnourishment, increased energy requirements and/or gastro-
intestinal losses who are likely to benefit most from withholding PN. 
However, underlying mechanisms for the observed benefits with late PN remain speculative. 
Several aspects may have played a role:
- Amplification of the acute catabolic stress response
- Preservation of autophagy (fasting response)
- Maintenance of muscle integrity and function
- Prevention of PN-related complications 
Amplification of the acute catabolic stress response
An increase in the acute inflammatory response was found with late initiation of PN, as 
indicated by the plasma CRP (Chapter 7), confirming the findings of the EPaNIC trial30. It might 
be speculated that this increase is caused by the expected increased use of insulin in the early 
PN group, rather than by nutrient restriction in the late PN group31. An increase in CRP has been 
associated with enhanced catabolism by reducing protein synthesis and increasing protein 
breakdown32. 
Also, a rise in total bilirubin was detected (Chapter 7), possibly reflecting amplification of the 
metabolic component of the stress response with omitting PN up to day 8. Caloric restriction 
early during critical illness might increase the redirection of conjugated bilirubin from the 
hepatocyte back into the bloodstream, instead of transporting it against the concentration 
gradient into the bile, resulting in preservation of energy33. 
Inactivation of thyroid hormone, possibly also reflecting an adaptive beneficial response32,33, 
is enhanced in response to nutrient restriction during the acute phase34 and associated with 
a better outcome34,35 (Chapter 1). Possible alterations of the neuro-endocrine axes with late 
PN, and its association with acute and long-term clinical outcomes, will be investigated in 
a mechanistic study of PEPaNIC data. This will be combined with the current data and an 
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evaluation of functional, physical and neurocognitive outcome 2 and 4 years after admission 
to the PICU (Chapter 6).
Although amplification of these presumed adaptive processes appear to be beneficial during 
the acute phase, they may become maladaptive with prolonged critical illness36,37. As reflected 
by an early discharge (before the fourth day of PICU stay) of almost 50% of PEPaNIC patients 
(Chapter 7), this acute phase is likely to last only for a short period of time in the majority of 
critically ill children. 
Preservation of autophagy (fasting response)
Preservation of autophagy by parenteral nutrient restriction in the acute phase may have 
contributed to the observed beneficial effects, given its importance for innate immunity 
and for quality control in cells with a long half-life38-40. The exact role of autophagy in the 
PEPaNIC study will be investigated with analyses of leukocyte samples (Chapter 6). Nutrients 
provided by the enteral route also affect the severity of starvation, and therefore possibly 
suppress autophagy as well. Long before activation of autophagy was suggested as a possible 
underlying mechanism for benefits of withholding artificial nutrition early in critical illness, 
studies showed that forced EN in septic mice decreased survival time, whereas starvation 
decreased mortality and promoted pathogen clearance41,42. Strikingly, the greatest survival 
was observed in mice who lost the most weight, whereas in many nutritional studies weight 
gain is considered a primary beneficial outcome in critically ill children.
Maintenance of muscle integrity and function
In the EPaNIC trial, preservation of autophagy in skeletal muscle explained the reduced 
ICU-acquired weakness and enhanced recovery observed with late PN40. Due to ethical 
considerations, no tissue biopsies were performed in the critically ill children participating 
in PEPaNIC. Alternatively, early detection of muscle mass wasting is challenging, due to 
unreliability of ultrasonography43, and does not automatically reflect loss of muscle function44. 
Muscle function can be quantified by measurements of muscle strength, most easily 
performed by use of a dynamometer to measure hand grip strength. This method is however 
not generally applicable to the PICU population, since baseline values are often lacking due to 
clinical instability or sedation. These factors also limit use of hand dynamometry later during 
PICU stay in children with prolonged critical illness that are most at risk for loss of muscle 
function. Investigation of the effect of late PN and critical illness on muscle function will 
therefore remain reserved to the long-term follow-up and will be quantified by measurements 
of hand grip strength, a 6-minute walk test, the timed up and go test and preferably also by use 
of a physical activity monitor. Results from the PEPaNIC patients at planned follow-up visits will 
be compared with reference values and healthy volunteers, and can be correlated to patient- 
and disease related factors during PICU stay, such as length of stay, duration of ventilation and 
nutritional data.
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Prevention of PN-related complications 
By withholding PN, complications associated with central venous access45 and composition of 
PN solutions46 might be prevented. Despite these additional complications of PN administration, 
only 3.5% of PICUs would withhold PN for at least 7 days (Chapter 2). Also, after the first week 
of PICU stay, a large proportion (38%) of the PEPaNIC children depended on PN with its added 
risk. The complications associated with central venous access devices are not likely to have 
contributed to the beneficial effects of late PN, since the percentage of central venous lines is 
expected to be similar between the two treatment groups. Moreover, the reduced proportion 
of patients with a new infection in the late PN group was not only attributable to fewer patients 
acquiring a blood stream infection, but also to fewer airway infections. Clinical implementation 
of the late PN strategy will most likely decrease the number of venous access devices and 
associated complications in the future, although venous access remains essential for different 
reasons than provision of PN in the large proportion of children with multi-organ failure and/
or underlying chronic diseases.
Use of PN has also been identified as a risk factor for caloric overfeeding47,48. Furthermore, 
patients with the lowest cumulative caloric intake (lowest dose intervals) showed a similar 
or better outcome than any of the higher doses in post-hoc analyses of adult RCTs19,49. By 
reducing the total caloric intake with late initiation of PN (Chapter 7), the prevalence of caloric 
overfeeding and its complications are likely to decrease. However, it is difficult to investigate 
the prevalence of overfeeding and its contribution to the unfavourable outcome in the early 
PN group. Endogenous glucose production is presumed to match 50-75% of REE the first days 
after admission50, resulting in an uncertainty of actual energy requirements when endogenous 
sources are used for energy. Current definitions of overfeeding are considered inadequate 
because they fail to take this and several other essential patient and disease related factors into 
account, and even identify patients with an intake below the threshold to equilibrate nitrogen 
balance as overfed (Chapter 4). 
On the other hand, one might state that recommendations by current guidelines reflect 
overfeeding in the acute phase of critical illness, because providing early PN in agreement 
with these guidelines is clinically inferior to withholding PN during this phase. 
In summary, despite the lack of adequate definitions, macronutrient intake should be 
reduced during the acute phase, since introduction of (supplemental) PN will easily result in 
overfeeding51 (Chapter 1). 
The role of macronutrient dose
Strategies of early and late initiation of PN differed in parenteral macronutrient intake, with no 
provision of amino acids and lipids and reduced intake of glucose in the late PN group (Chapter 
6). High parenteral intake of glucose and amino acids are known to cause multiple, mostly 
metabolic, side effects in children23,52-59.
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Protein
Recent large prospective studies have particularly stressed the importance of a high total (but 
predominantly enteral) protein intake in critically ill children and adults due to its association 
with decreased mortality and reduced length of stay, independently of caloric intake23,60,61. 
However, co-occurrence of high protein intake and improved outcome does not imply 
causation. Also, as with the association between higher caloric intake and improved outcome, 
protein intake goals vary widely between PICUs (Chapter 2). Administration of protein enriched 
enteral formulas in critically ill children consistently increases total protein synthesis/balance 
and levels of amino acids62-66. However, relations between these surrogate endpoints and 
clinically relevant outcomes are often non-existent or weak. Sometimes surrogate endpoints 
even suggest a benefit whereas the clinical outcomes indicate harm (Chapter 5 and 7). 
Cumulative amino acid dose early during ICU stay was associated with delayed recovery in 
a post-hoc analysis of the EPaNIC trial19. Some amino acids, such as leucine, exert a primary 
anabolic effect in skeletal muscle and inhibit the initiating step of autophagy67 by activation 
of mTOR (mammalian target of rapamycin)68, thereby reducing tolerance to oxidative stress, 
increasing risk for organ failure (especially liver and kidney) and cell death, eventually resulting 
in worse clinical outcome69. 
Lipids
Due to a lack of evidence, the optimal amount of lipid administration in critically ill children 
remains unclear, reflected by a wide range in parenteral lipid targets (from below 1.5 to 
above 3.5 g/kg/day) (Chapter 2). Provision of saturated fatty acids is known to provoke more 
endoplasmatic reticulum (ER) stress and inflammation in liver and adipose tissue of rats than 
provision of unsaturated fatty acids70, resulting in catabolism and ultimately in apoptosis71. 
Intravenous lipid emulsions provided in critically ill children are traditionally rich in n-6 fatty 
acids impacting neural development, growth, immune function and outcome after surgery72. 
The alternative lipid emulsions, enriched with n-3 fatty acids, are safe and effective in reducing 
the infection rate and length of stay of adult ICU patients73 and might promote the resolution 
of the inflammatory process in children post-surgically74. However, evidence for the use of 
these emulsions in critically ill children is solely based on surrogate endpoints (Chapter 5) and 
therefore differs between PICUs (Chapter 2). 
Also in the PEPaNIC study, different types of lipid emulsions were used (predominantly 
SMOFlipid® in Leuven and Intralipid® in Rotterdam). A more detailed analysis is needed to 
investigate the relation between type of lipid emulsion and clinical outcomes, such as PICU 
dependency and incidence of new infections.
With the current lacking and conflicting evidence, the macronutrient dose dependency 
analysis of PEPaNIC is eagerly awaited. The optimal timing for the initiation of PN should be 
marked by the moment in which its benefits on clinical outcomes by providing essential 
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nutrients exceed the adverse effects of its provision. This moment is likely to depend on the 
age and clinical status of the child (Chapter 4) and also on the phase of critical illness (Chapter 
1 and 4). With the PEPaNIC trial, the most optimal timing so far for initiation of PN in critically ill 
children is determined at 8 days after PICU admission. Since the majority of patients will have 
left the PICU by that time, they will not receive any PN during their stay on the PICU.
Effect of early parenteral nutrient restriction in children at nutritional risk
The clinical superiority of late PN was present irrespective of the admission diagnosis, the 
severity of illness and the STRONGkids category. Certain populations within the PICU, such 
as neonates and malnourished children, are presumed to have less metabolic reserve75. 
Other children are at greater nutritional risk76 due to higher requirements, decreased intake 
or increased losses77-79. Especially for these groups of ‘at-risk’ patients, fear for profound 
cumulative macronutrient deficits exists. Indeed, malnourishment was frequently mentioned 
as condition for early initiation of PN in the survey (Chapter 2, data not shown). The PEPaNIC 
trial did not stratify for different nutritional risk categories a priori. Planned subgroup analyses 
of this trial will investigate differences in effect size of withholding PN between certain patient 
groups, and may generate new hypotheses.
STRONGkids score
The beneficial effect size observed in children in the highest STRONGkids risk category was 
larger than in children in the medium STRONGkids risk category (Chapter 7), even after 
correction for diagnosis, age and severity of illness. The STRONGkids screening tool was initially 
developed and validated to identify hospitalised children at nutritional risk76. We successfully 
used this tool to also identify critically ill children at nutritional risk. Clinically, the highest 
STRONGkids scores were mainly reserved for critically ill children with malignancies, severe 
cardiac disease (cardiomyopathy, hypoplastic heart syndrome) or after surgical correction of 
gastro-intestinal tract anomalies. 
In order to implement the strategy of withholding PN during the first week of PICU stay in 
children at nutritional risk and to identify children that will possibly benefit most from this 
strategy, determination of the STRONGkids or another nutritional risk score in every child upon 
admission to the PICU is recommended. 
The distinct effect in children at higher nutritional risk, questions the reservation of early 
PN for children at-risk, as often applied in North American PICUs. The effect of late PN on 
clinical outcomes in children that are malnourished (SD-score for BMI <-2) and on children 
with a contra-indication for EN will be investigated in planned sub-group analyses. Possible 
underlying explanations for the enhanced effect in these children at higher nutritional risk will 
also be studied by comparing the amount of PN provided and macro- and micronutrient status 
upon admission. 
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Hypoglycaemia with parenteral nutrient restriction
Despite the clinical benefits, late PN increased the incidence of hypoglycaemia from 4.8% to 
9.1% (Chapter 7). However, experiencing hypoglycaemia with late PN did not reduce its impact 
on any of the primary or secondary outcomes (Supplementary appendix, chapter 7). Previous 
studies have shown that brief episodes of hypoglycaemia, either during paediatric critical 
illness or in premature/mature newborns, did not negatively affect long-term neurocognitive 
outcomes80,81
. 
A follow-up study of all PEPaNIC patients is currently conducted to evaluate 
functional, physical and neurocognitive outcome 2 and 4 years after admission to the PICU 
(Chapter 6). Data will be compared between the two treatment groups, but also between 
PEPaNIC patients and matched healthy controls. Results from this study will provide more 
insight in the long-term effects of critical illness in general and nutritional support in the PICU 
in particular.
FUTURE PERSPECTIVES
Future research
The results described in this thesis have provided some important answers, but also raised 
questions. The PEPaNIC trial has provided the long awaited evidence for use of (supplemental) 
PN in critically ill children of all age groups and diagnoses during the first week of PICU stay. The 
rigid study protocol, although practical for large clinical trials, is unlikely to have represented 
an optimal nutritional strategy for every individual patient, but has provided a strategy that is 
generally applicable with a risk of being unfocused.
Pre-planned subgroup analyses from the PEPaNIC trial might support specific evidence-based 
guidelines in respect to disease and settings, in order to individualise nutritional support on 
the PICU. The following subgroups will be investigated: cardiac patients, patients with sepsis, 
malnourished patients and children with contra-indication for EN on admission. Also, the 
enhanced beneficial effect of late PN in neonates (Chapter 7) will be further analysed. 
Pre-planned mechanistic studies on endocrine, inflammatory and genetic markers and a 
dose- and macronutrient dependency analysis might unravel underlying mechanisms of the 
beneficial effect of early parenteral nutrient restriction.
In order to translate nutritional recommendations to clinical practice, it is essential to make a 
distinction between the phases of critical illness (Chapter 1). For the PEPaNIC trial, the acute 
phase was defined as the first 7 days after PICU admission. However, in the majority of the 
children the acute phase was shorter because they had left the PICU within the first 7 days 
(Chapter 7) or because enteral caloric intake was already sufficient to meet caloric goals on day 
8 (60% of children present at day 8). 
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To further individualise and thereby optimise nutritional support, (bio)markers involved in the 
neuro-endocrine, immunologic/inflammatory and metabolic part of the stress response, could 
be used to identify the onset of the different phases within each child. Due to the insufficient 
sensitivity, specificity or availability of most (bio)markers, integration of several markers 
combined with clinical characteristics might be most promising to optimise individualised 
nutritional therapy in the PICU. 
To investigate the effect of such a patient-tailored approach on short-, and preferably also 
long-term clinical outcomes, clinical trials are needed to compare a strategy of marker-targeted 
feeding with the current generally applied nutritional practices.
This information will add valuable evidence to current guidelines, that as of now do not 
distinguish between phase of critical illness, severity of illness and diagnoses. Recommendations 
derived from the high-level evidence provided by the PEPaNIC trial are also generally 
applicable, but provide specific recommendations on provision of PN in respect to phase of 
illness. Because recommendations on other aspects of nutritional support, such as enteral 
caloric and macronutrient goals, should take these phases into account as well51,82 (Chapter 1), 
an update of current guidelines is urgently needed. Until other studies have provided evidence 
to individualise nutritional support to disease and settings, these updated guidelines should 
be used as a foundation for nutritional therapy, whilst considering the physiology of the 
individual patient.
In the PEPaNIC trial, the strategy of withholding PN was limited to the period following PICU 
admission. One might question if deterioration of clinical status beyond this period might 
evoke a similar acute stress response and therefore if the child might benefit from parenteral 
nutrient restriction as well. When more insight can be provided into the relation between the 
stress response and the beneficial effects of late PN based on the PEPaNIC trial, application of 
this strategy later during PICU stay might need to be investigated. 
Finally, since we have shown that permissive parenteral underfeeding is beneficial early 
in critical illness, avoidance of overfeeding has become even more significant. In order to 
improve its detection, a new definition of overfeeding is urgently needed and should take into 
account the age and nutritional status of the child, the phase of critical illness, and possibly 
also the route of nutrition. However, to develop such a phase-dependent definition, adequate 
identification of these phases is essential. In a subset of PEPaNIC patients, results from REE 
measurements by IC will be analysed to gain more insight in the concept of overfeeding on 
the PICU. 
Other nutritional aspects in critically ill children that were beyond the scope of this thesis, but 
in profound need of high-level evidence, are the optimal amount of EN early in critical illness 
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and the optimal macronutrient and micronutrient composition of both enteral and parenteral 
formulas. 
Suggestions for clinical implementation
Protocol adherence in a research setting mainly depends on the effectiveness of the research 
team. Successful clinical implementation of study results on the other hand, depends on the 
personal adherence of the involved clinicians and other health care workers. This process could 
be improved by modification of a protocol to local context while considering current practice, 
resources and costs. Nonetheless, extensive education of all involved clinicians remains 
essential. Continuous evaluation on the execution of the new strategy is needed to detect the 
challenges and pitfalls of this practice when carried out in a in a clinical setting. 
In order to implement the PEPaNIC strategy in the PICU of the Sophia Children’s Hospital–
Erasmus MC in Rotterdam, several concessions to the study protocol have been made to comply 
with the availability and compatibility of local PN components and the current infrastructure 
of the local pharmacy.
Based on the results presented in this thesis and the available literature, the following 
nutritional strategies in critically ill children are recommended:
1. Critically ill children at nutritional risk should be identified in order to decide which 
type of nutritional support should be given
2. Use of a nutritional risk score such as the STRONGkids is recommended
3. In critically ill children at nutritional risk, parenteral amino acids and lipids should be 
withheld and parenteral glucose intake should be reduced during the first week of 
PICU stay (Fig 1. and Table 1)
4. Electrolytes, minerals, trace elements and vitamins should be provided as 
recommended by the guidelines2 in an age-dependent manner from day 2 onwards. 
Parenteral supplementation should be stopped as soon as enteral nutrition provides 
≥80% of caloric goal (Fig. 1)
5. Enteral macronutrient intake in the first week of PICU stay depends on the route of 
nutrition, weight of the child and phase of critical illness (Table 1) 
6. Enteral nutrition should ideally be initiated within 24-48 hours after admission 
7. Increase of macronutrient intake after 1 week in the PICU depends on the phase of 
critical illness and can be classified as follows: 
a. acute phase: requirement of (escalating) vital organ support
b. stable phase: stabilisation or weaning of vital organ support
c. recovery phase: clinical mobilisation of the child, that is no longer in need of 
vital organ support
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8. Children receiving <80% of caloric goals by the enteral route after one week of PICU 
stay can be provided with supplemental PN (Fig. 1)
9. Macronutrient intake after the acute phase should ideally be guided by REE, preferably 
by IC- or ventilator-derived measurements, or, in absence of such a device, by use 
of predictive equations without use of correction factors. The upper limit of caloric 
intake varies with the route of nutrition and phase of critical illness (Table 1)
In conclusion, while enteral nutrition should ideally be initiated early during PICU stay, 
during the acute phase of critical illness less parenteral nutrition is more!
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On admission (day 1):  
1. Infusion gluc 3%/NaCl 0.36% with calcium gluconate 
0.011 mmol/L according to maintenance fluid 
requirements neonates 
2. After 6 hr initiate EN, if possible 
 
 
Admission to PICU 
≥1 exclusion criteria? 
 
1. STRONGkids score <2, and/or expected stay <24 hr, and/or oral intake 
2. Transfer from another NICU or PICU after stay >7 days 
3. Preterm infant 
4. Short bowel syndrome or other condition requiring PN 
5. (Suspicion of) Inborn metabolic diseases 
6. Ketoacidotic or hyperosmolar coma 
 
Readmission <48 hr:  
restart day count from 1st day of previous admission    
Diagnosis/patient 
specific protocols 
Newborn? 
From day 8 onwards: 
Switch to regular PN, if EN covers <80% of caloric goal 
Blood glucose < 2.6 mmol/L: 
1. Bolus glucose 10% 2 ml/kg 
2. Double glucose intake 
3. Blood glucose 2x > 4.5 mmol/L Æ back to 
gluc 3%/NaCl 0.36% 
Yes 
No 
No Yes 
Day 2-7: 
1.Infusion gluc 3%/NaCl 0.36% with elektrolytes* 
2.Infusion vitamins/trace elements* until EN covers ≥80% 
of caloric goal 
 
 
On admission (day 1):  
1. Infusion gluc 3%/NaCl 0.36% according to maintenance 
fluid requirements older children 
2. After 6 hr initiate EN, if possible 
NB: consider NaCl 0.9% in case of traumatic brain injury, 
sepsis, bronchiolitis, excessive diarrhoea or CNS infection 
Figure 1. Flowchart for nutritional support in critically ill children after admission to the PICU 
*Composition age-dependent, based on ESPEN/ESPGHAN guidelines2
Critically ill children at nutritional risk (STRONGkids score≥2)76, with an expected PICU stay of at least 24 
hours without oral intake, and not fulfilling any of the exclusion criteria84, will be provided with an infusion 
of glucose 3% /NaCl 0.36% upon admission. For newborns, this infusion will be supplemented with extra 
calcium to meet the higher requirements in this population.
If possible, enteral nutrition (EN) is initiated after 6 hours, prefe rably by post-pyloric tube, using 
commercially available formulas. If placement of a post-pyloric tube fails, gastric feedings should be 
attempted. The aim of EN administration is to reach caloric and protein goals by day 3: use of caloric and 
protein enriched formulas may be necessary to achieve this. Details of the local EN protocol have been 
described previously85.
From the morning following admission (day 2) up to day 8, pharmacy-made parenteral nutrition (PN) 
solutions for different weight categories, containing glucose 3%/NaCl 0.36% and electrolytes, are provided 
at rates based on maintenance fluid requirements proposed by Holliday-Segar86, or lower in case of fluid 
restriction or concomitant enteral nutrient administration, according to the judgement of the attending 
physician. No parenteral lipids or amino acids are to be administered during the first week of PICU stay.
Vitamins and trace elements are provided by a continuous parenteral infusion (neonates-children 30 kg) 
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or as a bolus once a day (children >30 kg), until EN provides ≥80% of preset caloric goals, PICU discharge, 
or up to day 8 of PICU stay, whichever comes first.
On the morning of day 8 after admission, if still present in the PICU, children receiving <80% of caloric 
goals by the enteral route, will be switched to regular PN solutions containing lipids and amino acids with 
a composition based on the ESPEN/ESPGHAN guidelines2. After discharge from the PICU, the nutritional 
management is at the discretion of the physicians on the regular wards.
Table 1. Suggested energy and macronutrient intake during the different phases of critical illness
Acute phase Stable phase Recovery phase
                                         Enteral nutrition (Preferred route)
Energy Start as soon as possible to match REE 
and gradually increase if tolerated
2xREE and higher if 
necessary to enable 
growth
Protein (g/kg/day) 1-2 2-3 3-4
                                          Parenteral nutrition
Energy <REE 1.3-1.5xREE 2xREE
Carbohydrates (mg/kg/min)
Newborn
28d-10 kg
11-30 kg
31-45 kg
>45 kg
2.5-5
2-4
1.5-2.5
1-1.5
0.5-1
5-10
4-6
2-4
1.5-3
1-2
5-10
6-10
3-6
3-4
2-3
Protein (g/kg/day) 0 1-2 2-3
Lipids (g/kg/day) 0 1-1.5 1.5-3
REE= Resting Energy Expenditure
From: Nutritional support and the role of the stress response in critically ill children, K. Joosten, D. Kerklaan, 
S. Verbruggen. Curr Opin Clin Nutr Metab Care 201683. Copyright©. Reprinted with permission.
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The main findings of this thesis are summarised in Table 1.
Chapter 1
Nutritional support affects recovery and outcome in critically ill children, but its application 
is supported by a scarcity of high-level evidence. For that reason, the optimal timing, amount 
and route of nutrition in the Paediatric Intensive Care Unit (PICU) remain debatable. This results 
in a wide variation in clinical practice, which impacts outcome of critically ill children.
In the introduction of this thesis an overview is provided of the different aspects of nutritional 
support in critically ill children in relation to the different phases of the stress response. The 
characteristics of the different phases of critical illness are described, followed by an elaboration 
on the optimal nutrition strategy for each phase. 
Finally, an overview is given on the use of energy expenditure to guide nutritional therapy 
throughout the course of critical illness. Chapter 1 ends with the aims and outline of this thesis.
Chapter 2
International consensus-based guidelines on nutritional support in critically ill children 
generally rely on expert opinions and studies in adults or non-critically ill children, and 
provide rather non-specific recommendations. To identify local strategies and guidelines, 
we distributed a two-part online survey to PICUs across the world. In addition we compared 
the local guidelines with nutritional data collected in all patients present on a single day in a 
subgroup of the responding PICUs. We observed that, due to the limited guidelines, current 
nutritional practices vary widely between PICUs worldwide. Most variation was observed in 
macronutrient targets, the estimation of energy requirements and the threshold for the use 
of (supplemental) parenteral nutrition (PN). Subsequently, we found that applied nutritional 
practice deviated from local protocols or strategies on multiple occasions. The only wide-spread 
consensus appeared to be on the preference for the enteral route and its early initiation. These 
results highlight the need for sound clinical studies to develop evidence-based guidelines on 
nutritional support for critical ill children, since inconclusive and low-level evidence appears to 
represent a barrier to clinical implementation.
Chapter 3
Measurement of resting energy expenditure (REE) through indirect calorimetry (IC) is the 
preferred method to determine energy requirements in critically ill children. Since availability 
of IC is limited worldwide, most PICUs rely on predictive equations to determine REE. However, 
these equations cannot accurately predict REE in critical illness, because they are derived 
from measurements in healthy children. Fortunately, VCO
2
 values to calculate REE can also be 
automatically subtracted from a ventilator.
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In chapter 3 we have shown that VCO
2
 measurements by the Servo-I® ventilator are more 
precise in determination of REE than the frequently used predictive equations in mechanically 
ventilated children weighing more than 15 kg. This provides a promising alternative to the 
limited available IC. However, for the large proportion of PICU patients weighing less than 15 
kg this method is not sufficiently accurate due to the technical specifications of the sampling 
method.
Chapter 4
Energy overfeeding is associated with worse outcome and is frequently observed in critically ill 
children. In a cohort of mechanically ventilated children, we found that the number of children 
identified as overfed ranged widely depending on the definition used. Even children with an 
energy intake below the presumed threshold to equilibrate nitrogen balance were identified 
as overfed, indicating inaccuracy of current definitions.
The maximum caloric intake is likely to depend on the age and nutritional status of the child 
and the phase of critical illness. However, current definitions of overfeeding fail to take these 
factors into account, and are therefore not generally applicable to the PICU population. To 
prevent the detrimental effects of overfeeding, an age- and phase dependent definition of 
overfeeding is warranted, preferably based on hard clinical outcomes.
Chapter 5
Provision of enteral nutrition (EN) in critically ill children often results in a pronounced caloric 
deficit, which is associated with poor outcomes and impaired growth. Use of (supplemental) 
PN helps reaching preset goals, but with the added risk of metabolic disturbances and an 
increased nosocomial infection rate.
Chapter 5 reviews the available evidence from RCTs supporting the use of PN in critically ill 
children. Only six small RCTs were identified, showing a beneficial effect of increased or altered 
PN. However, these studies focused only on surrogate endpoints, such as nitrogen balance 
or inflammatory markers, underlining the lack of high-level evidence on clinical outcomes in 
critically ill children regarding the effect of timing, amount and composition of PN.
Chapter 6 and 7
Evidence from high-quality RCTs in critically adults no longer supports early initiation of 
(supplemental) PN. To determine if a pronounced macronutrient deficit could also be tolerated 
in critically ill children, we performed an international multicentre RCT in 1440 critically ill 
children at nutritional risk.
We found that withholding PN for one week in the PICU was clinically superior to early provision 
of PN, with fewer new infections, shorter duration of intensive care dependency and shorter 
hospital stay. This beneficial effect was detected irrespective of the treatment centre, severity 
of illness, STRONGkids category, age and diagnosis on admission. The effect was even larger in 
children with the highest nutritional risk and in critically ill neonates. 
Summary
181
9
R1
R0
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Therefore this approach should be implemented in current nutritional practice on PICUs 
worldwide. 
Chapter 8
This chapter provides a general discussion in which the main findings of this thesis are 
evaluated and substantiated by speculations on underlying mechanisms. Based on the 
findings and available literature, current gaps in knowledge of nutritional support in critically 
ill children are highlighted and are followed by future perspectives on clinical practice and 
nutritional research.
Table 1. Main findings of this thesis
Findings
Chapter 1
Introduction
Understanding the stress response of critical illness and its phases is essential 
to provide recommendations on amount, timing and route of nutrition in 
critically ill children
Chapter 2
Worldwide survey of 
nutritional practices in 
PICUs
Current nutritional practices vary widely between PICUs worldwide, especially 
on macronutrient targets, estimation of energy requirements and threshold for 
the use of (supplemental) PN. Applied nutritional practice deviated from local 
protocols or strategies on multiple occasions.
There appears to be wide-spread consensus on the preference for the enteral 
route and its early initiation 
Chapter 3
Ventilator-derived 
VCO
2
 measurements to 
determine REE 
Use of VCO
2
 measurements by the Servo-I® ventilator is a feasible and more 
precise method to determine REE in mechanically ventilated children >15 kg 
than predictive equations. It may be a promising method to compensate for 
the limited availability of indirect calorimetry in the future
Chapter 4
Use of indirect 
calorimetry to detect 
overfeeding
The number of children identifi ed as overfed ranges widely depending on the 
defi nition used. Current defi nitions of overfeeding fail to take into account 
several factors associated with critical illness and are therefore not generally 
applicable to the PICU population
Chapter 5
Evidence for the use of 
PN in the PICU
There is currently no evidence to support any of the current PN practices for 
critically ill children. Available RCTs focus on surrogate outcome measures 
instead of hard clinical outcomes. The evidence from high quality RCTs in 
critically ill adults no longer supports the early use of PN
Chapter 6 and 7
PEPaNIC trial
Withholding PN for one week in the PICU is clinically superior to early 
provision of PN, with fewer new infections, shorter duration of intensive care 
dependency and a shorter hospital stay
PICU= Paediatric Intensive Care Unit, REE= Resting Energy Expenditure, PN= Parenteral Nutrition, RCT= 
Randomised Controlled Trial
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Inleiding (Hoofdstuk 1)
Kritisch zieke kinderen, die opgenomen zijn op de intensive care afdeling, kunnen meestal niet 
zelf eten. Als onderdeel van de behandeling wordt daarom al vroeg gestart met het toedienen 
van kunstmatige voeding. Dit gebeurt, afhankelijk van de diagnose en ernst van ziekte, middels 
een voedingssonde in het maag-darmstelsel (enterale voeding) of via een infuus (parenterale 
voeding). Uit beschouwend onderzoek is bekend dat deze voedingsstrategieën het beloop en 
herstel van de ziekte kunnen beïnvloeden, maar tot nu toe is er weinig kwalitatief hoogstaand 
wetenschappelijk bewijs geleverd op dit gebied. Er is dan ook nog veel discussie over de 
optimale timing, hoeveelheid en toegangsweg van kunstmatige voeding bij kritisch zieke 
kinderen. Dit leidt ook tot veel variatie bij het geven van voeding op de kinder-intensive-care 
afdeling (PICU). 
Het doel van dit proefschrift is om meer inzicht te verschaffen in huidige voedingsstrategieën 
in kritisch zieke kinderen. 
De inleiding van dit proefschrift bevat een overzicht van de verschillende aspecten die een rol 
spelen bij het toedienen van kunstmatige voeding aan kritisch zieke kinderen. Deze aspecten 
worden weergegeven in relatie tot de fase van de zogeheten stress respons van kritieke ziekte. 
Deze evolutionaire respons op schade door ernstige ziekte, trauma of een operatie bestaat uit 
complexe veranderingen in de hormoonhuishouding en stofwisseling met als doel de kritieke 
ziekte te overleven. 
Er kunnen 3 verschillende fasen worden onderscheiden in kinderen: de acute, de stabiele en 
de herstelfase. Zowel de duur als de intensiteit van elke fase is afhankelijk van de leeftijd van 
het kind en de ernst van de ziekte. De optimale voedingsstrategie verschilt per fase: in de acute 
fase lijkt het beperken van voeding, en dan met name parenterale voeding, beter te zijn (op 
basis van studies in volwassenen), terwijl het tijdens de stabiele en herstelfase beter lijkt te 
zijn om de inname van voedingsstoffen te verhogen om te voldoen aan de toename van de 
energiebehoefte. 
Omdat de energiebehoefte per kind kan wisselen, wordt de hoeveelheid voeding meestal 
gebaseerd op het individuele rust energieverbruik (REE) per kind. REE kan worden berekend 
met formules, maar de waarde is het meest betrouwbaar wanneer die gemeten wordt. Deze 
meting bestaat uit het bepalen van het zuurstofverbruik en de koolstofdioxideproductie 
met behulp van de uitademingslucht, wat indirecte calorimetrie wordt genoemd. Indirecte 
calorimetrie is echter kostbaar, tijdsintensief en alleen toepasbaar in een selecte groep 
kinderen en wordt in een minderheid van de PICUs gebruikt. Daarom hebben we in hoofdstuk 
2 met behulp van een online vragenlijst onder andere onderzocht op welke manier PICUs REE 
bepalen. In hoofdstuk 3 hebben we een alternatieve methode getest om het REE te meten, 
zodat indirecte calorimetrie niet langer noodzakelijk is.
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De nadruk van dit proefschrift ligt op calorische overvoeding en parenterale voeding. Wanneer 
er sprake is van overvoeding is niet altijd duidelijk gedefinieerd; de problemen en uitdagingen 
die hiermee verbonden zijn worden besproken in hoofdstuk 4. De voorkeur voor parenterale 
voeding om gestelde doelen gemakkelijker te bereiken wordt onderzocht in hoofdstuk 5, ook 
hier blijkt de associatie of verwachting sterker dan het klinisch bewijs. Er is dus hoogstaand 
wetenschappelijk onderzoek nodig naar de timing, hoeveelheid en samenstelling van voeding 
bij kritische zieke kinderen.
Om meer inzicht te krijgen in hoe we de voeding bij deze groep kinderen het beste kunnen 
reguleren en toedienen hebben we een grootschalig onderzoek opgezet in samenwerking 
met Leuven en Edmonton. De resultaten van deze studie, die we hebben uitgevoerd bij 
1440 kinderen verspreid over drie ziekenhuizen, worden besproken in hoofdstuk 6 en 7. In 
hoofdstuk 8 worden onze resultaten in perspectief geplaatst en wordt de huidige stand van 
zaken beschouwd.
Hoofdstuk 2
Verschillende internationale voedingsorganisaties hebben richtlijnen uitgebracht over het 
voorschrijven van voeding aan kritisch zieke kinderen. Door het tekort aan solide studies 
over het effect van voeding op kritisch zieke kinderen, zijn deze richtlijnen voornamelijk 
gebaseerd op de mening van experts op dit gebied, en afgeleid van studies die gedaan zijn 
bij volwassenen in plaats van kinderen. De adviezen in deze richtlijnen zijn daarom niet altijd 
even concreet. 
Om te onderzoeken welke voedingsstrategieën er op verschillende PICUs gehanteerd worden, 
hebben we een online vragenlijst verstuurd naar PICUs over de hele wereld. De vragenlijst 
bestond uit twee delen. In het eerste deel werd gevraagd naar de lokale protocollen op het 
gebied van voeding bij kinderen. In het tweede deel werd gevraagd om de voedingsgegevens 
te noteren van alle kinderen die op één en dezelfde dag aanwezig waren in de PICU. De 
vragenlijst werd ingevuld voor 156 PICUs in 52 verschillende landen en 6 continenten. 
Uit de resultaten van deze vragenlijst bleek er veel variatie te zijn in de gehanteerde 
voedingsstrategieën bij de verschillende PICUs. De strategieën varieerden vooral wat betreft 
het bepalen van de macronutriënt- (koolhydraat, eiwit en vet) en energiebehoefte, en de 
drempel voor het gebruik van parenterale voeding. Een van de weinige overeenkomsten 
tussen de PICUs was de intentie om vroeg te starten met enterale voeding. Bij het vergelijken 
van het eerste met het tweede deel van de vragenlijst bleek tevens dat de werkelijke uitvoering 
van de voedingsstrategieën vaak verschilt van de lokale protocollen (zoals genoemd in het 
eerste deel). Deze resultaten geven aan dat er solide klinische studies nodig zijn naar voeding 
bij kritisch zieke kinderen, omdat het tekort aan bewijs een duidelijke barrière vormt voor het 
implementeren van de protocollen op de PICU.
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Hoofdstuk 3
Om de energiebehoefte van kritisch zieke kinderen te bepalen heeft het meten van het rust 
energieverbruik (REE) middels indirecte calorimetrie de voorkeur. Helaas is deze methode 
slechts beperkt beschikbaar en wordt de energiebehoefte in veel PICUs berekend met behulp 
van formules. De meest gebruikte formules zijn echter afgeleid van metingen bij gezonde 
kinderen, en zijn minder betrouwbaar in gebruik bij kritisch zieke kinderen. Een alternatieve 
mogelijkheid om de energiebehoefte te bepalen is om REE te berekenen op basis van de 
koolstofdioxideproductie per minuut (VCO
2
), een waarde die direct kan worden afgelezen van 
de beademingsmachine. 
Wij hebben deze methode getest bij 41 kinderen die aan de beademing lagen. De methode 
was veilig en praktisch goed uit te voeren. Bij kinderen met een gewicht vanaf 15 kg kwamen 
de uitslagen van deze methode goed overeen met die van indirecte calorimetrie. De methode 
bleek ook betrouwbaarder in het bepalen van de energiebehoefte dan het gebruik van de 
standaardformules. Helaas was de methode bij kinderen met een gewicht onder de 15 kg 
onvoldoende betrouwbaar, waarschijnlijk doordat de meting niet precies genoeg was voor de 
kleinere luchtwegen en hogere ademsnelheid in deze groep. 
Het gebruik van de beademingsmachine is een veelbelovende methode om REE te bepalen 
bij kritisch zieke kinderen vanaf 15 kg die zijn opgenomen op PICUs die niet beschikken over 
indirecte calorimetrie en nu nog afhankelijk zijn van het gebruik van formules.
Hoofdstuk 4
Kritisch zieke kinderen worden regelmatig calorisch overvoed, doordat ze meer energie binnen 
krijgen dan ze verbruiken. Calorische overvoeding op de intensive care wordt geassocieerd met 
leverfalen, langere beademingsduur, en een grotere kans op overlijden en op infecties, maar 
een eenduidige definitie van overvoeding ontbreekt. Wij hebben de verschillende definities 
van calorische overvoeding, gebaseerd op metingen met indirecte calorimetrie, vergeleken 
bij 78 kinderen met mechanische beademing. Het aantal kinderen dat geïdentificeerd werd 
als overvoed varieerde, afhankelijk van de gebruikte definitie, van 23% tot 50%. Sommige 
kinderen kregen minder calorieën dan de minimale hoeveelheid die nodig lijkt te zijn om 
eiwitafbraak te kunnen compenseren, maar werden wel geïdentificeerd als overvoed. Huidige 
definities van calorische overvoeding zijn dus ontoereikend. 
De energiebehoefte is logischerwijs afhankelijk van de leeftijd en de voedingsstatus van het 
kind. Ook de fase van kritieke ziekte heeft invloed op de energiebehoefte. Met deze factoren 
wordt geen rekening gehouden in de huidige definities van calorische overvoeding, waardoor 
deze definities niet consequent toegepast kunnen worden in de gehele populatie van kritisch 
zieke kinderen. Om de nadelige effecten van calorische overvoeding te voorkomen is een 
nieuwe definitie nodig die leeftijds-, voedingsstatus- en fase-afhankelijk is.
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Hoofdstuk 5
Het toedienen van enterale voeding aan kritisch zieke kinderen wordt vaak uitgesteld of 
onderbroken, waardoor er ten opzichte van de gestelde voedingsdoelen een tekort aan 
energie en/of macronutriënten ontstaat. Het toevoegen van parenterale voeding zorgt ervoor 
dat de gestelde doelen gemakkelijker behaald kunnen worden, maar kan ook tot verschillende 
bijwerkingen leiden. 
Hoofdstuk 5 geeft een overzicht van het wetenschappelijk bewijs voor het gebruik van 
parenterale voeding bij kritisch zieke kinderen. Van de 584 artikelen over dit onderwerp, 
werden slechts 6 kleine studies geïdentificeerd die dit onderwerp hadden onderzocht in 
kritisch zieke kinderen met behulp van gerandomiseerde studies. Deze studies lieten een 
positief effect zien van het ophogen of aanpassen van parenterale voeding, maar enkel op 
surrogaat uitkomstparameters (eiwitbalans, ontsteking). Een positief effect op surrogaat 
uitkomstparameters reflecteert echter niet altijd een positief effect op klinische uitkomstmaten, 
zoals duur van de beademing of verblijf op de PICU, die veel belangrijker zijn om te bepalen 
of een behandeling nut heeft. Hoogstaande wetenschappelijke studies naar het effect van 
timing, hoeveelheid en samenstelling van parenterale voeding bij kritisch zieke kinderen op 
klinische uitkomstmaten zijn dus nog hard nodig. 
Hoofdstuk 6 en 7
Het idee dat vroeg starten van (aanvullende) parenterale voeding bij kritisch zieke volwassenen 
om de gestelde macronutriënt- en energie doelen te behalen de voorkeur heeft, wordt op 
basis van de resultaten van recente grote klinische studies niet langer ondersteund. 
Samen met het UZ Leuven (België) en het Stollery Kinderziekenhuis in Edmonton (Canada) 
hebben wij een gerandomiseerde studie uitgevoerd onder 1440 kritisch zieke kinderen, om 
te onderzoeken of het later starten van parenterale voeding ook in deze populatie voordelig 
kan zijn. Kritisch zieke kinderen met risico op ondervoeding (bepaald aan de hand van een 
risicoscore) werden gerandomiseerd voor het vroeg (binnen 24 uur) of laat (op dag 8 van PICU 
opname) starten van parenterale voeding op het moment dat er onvoldoende enterale voeding 
kon worden gegeven. In beide groepen werd dezelfde hoeveelheid vocht, micronutriënten en 
enterale voeding toegediend.
Kinderen die de eerste week op de PICU geen parenterale voeding kregen toegediend, 
bleken inderdaad minder vatbaar voor nieuwe infecties, verbleven korter op de PICU en in het 
ziekenhuis, en waren een kortere periode afhankelijk van de beademing, dan kinderen waar 
parenterale voeding binnen 24 uur was gestart. 
Dit positieve effect van het onthouden van parenterale voeding was onafhankelijk van het 
ziekenhuis waar de studie werd uitgevoerd, de ernst van ziekte, de leeftijd, de diagnose en het 
risico op ondervoeding. Bij kritisch zieke neonaten (kinderen < 1 maand oud) en bij kinderen 
met het hoogste risico op ondervoeding was het positieve effect nog groter. Deze resultaten 
tonen aan dat het doorvoeren van de late voedingsstrategie in alle PICUs wenselijk is bij deze 
groepen kritisch zieke kinderen.
Samenvatting
187
9
R1
R0
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Discussie (Hoofdstuk 8)
In hoofdstuk 8 zijn de belangrijkste bevindingen van dit proefschrift gecombineerd, 
geanalyseerd en verder onderbouwd. Met behulp van de nieuwe bevindingen en de beschikbare 
literatuur, wordt de huidige stand van zaken op het gebied van voedingsstrategieën bij kritisch 
zieke kinderen uitvoerig beschouwd. Er worden verschillende mechanismen besproken die 
het positieve effect van het onthouden van parenterale voeding kunnen verklaren. 
Omdat het onwaarschijnlijk is dat de optimale timing voor het starten van (aanvullende) 
parenterale voeding voor alle kinderen gelijk is, is meer onderzoek nodig om de timing te 
kunnen individualiseren. Door groepen met verschillende patiëntkenmerken te vergelijken, 
zowel binnen de huidige studie, als in toekomstige studies, en door meer inzicht te 
verkrijgen in de onderliggende mechanismen, kunnen voedingsstrategieën in de toekomst 
geïndividualiseerd worden om de best mogelijke uitkomst te bewerkstelligen, zowel op korte als 
op langere termijn. Naast deze toekomstperspectieven op het gebied van voedingsonderzoek 
worden er in dit hoofdstuk adviezen geven voor implementatie van de bevindingen van dit 
proefschrift in de dagelijkse praktijk.
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LIST OF ABBREVIATIONS
ALT Alanine Aminotransferase
AST Aspartate Aminotransferase
A.S.P.E.N. American Society for Parenteral and Enteral Nutrition
BMI Body Mass Index
BMR Basal Metabolic Rate
CI Confidence Interval
CRP C-Reactive Protein
DSMB Data Safety Monitoring Board
DNR Do Not Resuscitate
eCRF electronic Case Record Form 
EN Enteral Nutrition 
ESPEN European Society for Clinical Nutrition and Metabolism
ESPGHAN European Society for Paediatric Gastroenterology Hepatology and Nutrition
ESPNIC European Society of Paediatric and Neonatal Intensive Care 
GGT Gamma-Glutamyltransferase
GRV Gastric Residual Volume
HR Hazard Ratio
IC Indirect Calorimetry
ICU Intensive Care Unit
IQR Interquartile Ranges
IV Intravenous
LOS Length Of Stay
LCT Long Chain Triglycerides
MCT Medium Chain Triglycerides
MREE Measured Resting Energy Expenditure
NST Nutrition Support Team
OR Odds Ratio
PELOD PEdiatric Logistic Organ Dysfunction 
PEPaNIC Pediatric Early versus Late Parenteral Nutrition In Critical Illness 
PICU Pediatric Intensive Care Unit 
PN Parenteral Nutrition 
PREE Predicted Resting Energy Expenditure
PRISM Pediatric Risk of Mortality 
RACHS Risk-Adjustment in Congenital Heart Surgery 
RCT Randomized Controlled Trial 
RDA Recommended Dietary Allowances
REE Resting Energy Expenditure
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RQ Respiratory Quotient
RRT Renal Replacement Therapy 
SAE  Serious Adverse Event 
SD Standard Deviation
SEM Standard Error of the Mean
SPN Supplemental Parenteral Nutrition
TEE  Total Energy Expenditure
TPN Total Parenteral Nutrition
 VCO
2 
CO
2
 production per minute
WFPICCS  World Federation of Pediatric Intensive and Critical Care Societies
WHO  World Health Organization
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General academic skills
BROK (Basiscursus Regelgeving Klinisch Onderzoek) Erasmus University 
Rotterdam
2012 1.0
CPO mini course 2013-2014 0.6
Biomedical English writing and communication 2014 3.0
Integrity in scientifi c research 2015 2.0
Research skills 
MolMed - Basic Introduction Course on SPSS 2013 1.0
Nihes - Biostatistical Methods 1: basic principles 2014 5.7
Nihes - Regression Analysis for Clinicians 2015 1.4
Seminars and workshops
Theme Sophia Research Days 2013-2016 1.2
2nd Erasmus Critical Care Day 2013 0.3
24th annual meeting of ESPNIC: postgraduate course Nutrition 2013 0.3
Fresenius Kabi Advanced Nutrition Conference on Pediatrics (FRANC Ped), Bad 
Homburg, Germany
2014 0.6
Young Investigator Days (Tulips) 2014-2015 0.6
(Inter)national conferences and presentations
24th annual meeting of the ESPNIC, Rotterdam, The Netherlands: poster 
presentation
2013 1.0
7th World Congress on Pediatric Intensive and Critical Care, Istanbul, Turkey: 
invited speaker & oral presentation
2014 3.0
7th and 9th ‘Nationale Voedingscongres’, Arnhem, The Netherlands: invited 
speaker
2014-2016 4.0
36th ESPEN Congress, Geneva, Switzerland: oral presentation & poster 
presentation
2014 2.0
26th annual meeting of the ESPNIC, Vilnius, Lithuania: oral presentation 2015 2.0
ESPGHAN Young Investigators Platform: oral presentation 2015 2.0
PhD portfolio
199
P
R1
R0
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Year Workload 
(ECTS)
Symposium Research group Metabolism, Endocrinology and Nutrition: invited 
speaker
36th International Symposium on Intensive Care and Emergency Medicine, 
Brussels, Belgium
Theme Sophia Research Day, Rotterdam, The Netherlands: oral presentation
Symposium ‘Sectie Intensive Care Kinderen’, The Netherlands: oral presentation
2015
2016
2016
2016
1.3
0.2
2.0
2.0
Teaching activities
Tutoring 1st year medical students 2013 1.5
Tutoring ‘Getting acquainted with the medical profession’ 2014 0.5
Supervising 3 students in their research project 2014-2015 1.6
Other
Board member Sophia Researchers Association (SOV) 2013-2015 3.0
Organisation Theme Sophia Research days 2013-2015 4.0
Research meeting Metabolism, Endocrinology and Nutrition 2013-2016 1.5
SCCM practical application of nutrition/immunonutrition 2013 0.3
ESPEN Life Long Learning in Clinical Nutrition and Metabolism 2013-2016 0.5
ECTS = European Credit Transfer and Accumulation System (1 ECTS represents 28 hours)
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DANKWOORD
Het bereiken van de top van de Kilimanjaro was dan wel mijn letterlijke hoogtepunt van de 
afgelopen vier jaar, de inspanning die daarvoor nodig was valt volledig in het niet bij al het 
werk dat is geleverd voor dit proefschrift. Dat werk heb ik niet alleen gedaan, en had ik ook niet 
alleen kunnen doen. Daarom wil ik graag alle mensen bedanken die hebben meegewerkt om 
PEPaNIC en dit proefschrift tot een succes te maken.
Mijn grootste dank gaat uit naar alle kinderen en hun ouders die hebben deelgenomen aan dit 
onderzoek. Ik heb groot respect voor hun bereidwilligheid tot deelname en hun betrokkenheid 
bij wetenschappelijk onderzoek, zelfs onder de meest zware persoonlijke omstandigheden. 
Zonder hun medewerking en inzet zou het nooit mogelijk zijn geweest om deze studie 
succesvol uit te voeren.
Het uitvoeren van de studie was ook onmogelijk geweest zonder de medewerking van alle 
artsen, verpleegkundigen, zorgassistenten, secretaresses en overige medewerkers van de IC 
Kinderen, en zonder hulp van de apothekers, apothekersassistenten en het PDMS team.
Ik ben jullie allemaal enorm dankbaar voor alle nachtelijke telefoontjes, spoedinfusen, 
duizenden buisjes urine, nieuwe ordersets en alle andere input! 
Daarnaast wil ik een aantal personen in het bijzonder bedanken.
Prof.dr. Tibboel, beste prof, u hebt mij de kans geboden om met dit geweldige project een 
substantiële bijdrage te leveren aan de zorg voor kritisch zieke kinderen. Onder uw begeleiding 
hebben we tevens de Sophia Research Day kunnen uitbouwen tot een succesvol begrip. Dank 
voor uw kritische blik en andere invalshoek bij de beoordeling van mijn manuscripten.
Dr. Joosten, beste Koen, toen ik vier jaar geleden begon aan dit avontuur was mijn kennis 
van voeding bij kinderen beperkt tot het voorschrijven van de juiste flesvoeding. Jij hebt me 
al snel laten inzien dat de voedingswereld zoveel meer is. Ik ben heel trots dat we nu samen 
het belang van voeding op de ICK hebben kunnen benadrukken. Hopelijk kunnen we dat 
voor indirecte calorimetrie ook nog bereiken! Ik heb grote waardering voor jouw kennis en 
overzicht, waardoor studies en resultaten niet langer op zichzelf staan maar een grotere 
betekenis krijgen. Je was een geweldige coach, dank voor deze basisplek in de Champions 
League.
Dr. Verbruggen, beste Sascha, de praktische zaken van het onderzoek en het promoveren 
waren niet altijd aan je besteed, maar dat heb je meer dan ruimschoots gecompenseerd met 
enthousiasme, gedrevenheid en een enorme berg aan nieuwe ideeën, wat erg aanstekelijk 
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werkte. Onze discussies prikkelden me elke keer om het nog net een stapje beter te doen. 
En wie zegt dat empathie niet aan te leren is… Ik had me geen betere aanvoerder kunnen 
wensen, het is een eer jouw eerste promovenda te zijn!
Prof.dr. Van den Berghe, beste Greet, mijn uitstapjes naar Leuven waren door onze 
samenwerking altijd uiterst inspirerend en leerzaam (enerverend durf ik niet meer te 
gebruiken). Indrukwekkend en ongeëvenaard hoe we samen binnen een week een New 
England paper hebben neergezet, en u eigenlijk ondertussen al meerdere studies verder bent. 
Bedankt voor deze inspiratie en de goede begeleiding.
Dr. Mehta, dear Nilesh, thank you for your willingness to oppose in my thesis defence. I have 
appreciated your high-quality comments on several chapters, which inspired me and helped 
to improve this thesis.
Verder wil ik prof.dr. Escher hartelijk bedanken voor de uitgebreide beoordeling van mijn 
proefschrift en prof.dr. van Goudoever en prof.dr. Wijnen voor het plaatsnemen in de grote 
commissie. 
Het onderzoeksteam van Leuven ben ik erg dankbaar voor de geweldige samenwerking. Lieve 
Sandra, Sylvia, Pieter, Dieter, Ilse, Jan, Jenny, door jullie heb ik me vanaf het eerste moment 
thuis gevoeld in Leuven. Bedankt voor jullie enorme hulp bij alle staal-problemen, database-
stress, maar vooral ook voor alle gezelligheid, het was plezant!
Lieve Tom, het is misschien geen officiële duo-promotie, maar ik had me geen betere 
promotiepartner kunnen wensen. Onze samenwerking scheelde niet alleen in de grote 
hoeveelheid werk en stress, maar heeft het promoveren vooral een stuk leuker gemaakt!
Alle coauteurs wil ik bedanken voor de prettige samenwerking. Jessie, speciaal bedankt voor 
je kritische blik en uitgebreide statistische hulp. De studenten die ik de afgelopen jaren heb 
begeleid: Neelke, Bregje, Emma, dank voor jullie inzet voor de database, topdokters worden 
jullie!
Ook het onderzoeksteam in Rotterdam ben ik zeer dankbaar. Lieve Mirjam en Marjolein, mijn 
reddende engelen! Door jullie ging ik elke maandag en woensdag met extra veel plezier naar 
werk. Mir, ik ga onze zeer frequente gezellige eet- en snoeppauzes missen. Dank voor het 
minutieus perfectioneren van de database. Marjolein, onze trip naar Istanbul was onvergetelijk. 
Bedankt voor je onmisbare bijdrage aan de Deltatracs en het VCO
2
 project. Marianne en Joke, 
hartelijk bedankt voor al jullie hulp met de praktische kanten van het promoveren. De weekend-
en-vakantie-PEPaNICers, Navin, Miriam en Esther, zonder jullie hulp was ik nog steeds bezig 
geweest met includeren. Navin, jij stond altijd klaar om de studie over te nemen. Dank voor alle 
Dankwoord
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mooie feestjes! Mir, fijn om in Rotterdam nog een beetje Mestreech te hebben. Ik kijk ernaar 
uit om straks weer collega’s te zijn. Esther, jouw eeuwige enthousiasme en optimisme kwamen 
precies op het goede moment. Ik had me geen betere PEPaNIC follow-upper kunnen wensen.
Ik wil graag alle Sophia onderzoekers bedanken voor de gezelligheid, borrels, bonte skidagen, 
kookworkshops, barbecues en nieuwjaarsdiners en dan in het bijzonder mijn mede-SOV 
bestuursgenootjes Aukje, Lidewij en Marjolein. Wie zegt dat vergaderen saai is.. ik vond het 
één groot feest! Lieve Auk, dank voor je luisterend oor en je geweldige hypnose technieken, je 
wist me altijd nog vrolijker te maken dan ik al was. Lieve Lid, het was super om naast samen te 
SOVen ook samen te skiën en te zeilen. Helaas nu niet meer samen in Utrecht, maar hopelijk 
straks daar wel samen in opleiding. Lieve Marjolein, vanaf mijn eerste moment in het Sophia 
was jij erbij, dank voor je onaflatende steun. En verder natuurlijk nog bijzonder dank aan 
Manouk, bij jou kon ik altijd terecht met alle leuke, hele leuke, maar ook met de minder leuke 
kanten van het promoveren.
Dan ben ik nog een speciale groep onderzoekers zeer dankbaar voor de dagelijkse 
ondersteuning en afleiding, mijn (ex)roomies in Sk-1324, Sp-4020 en Sp-2430. Lieve Annelieke, 
Bianca, Lisette, Manuel, Willem, Tanja, Nienke en Erik, dank voor alle taartjes, foute muziek, 
knutsel-sessies en natuurlijk de liters thee. Lieve Alex, dank dat je er altijd voor ons was, ook 
al had je het zelf nog zo druk. Lieve Marlous, als kameroudste was jij natuurlijk mijn grote 
voorbeeld. Dank voor alle melige donderdagen. Lieve Rais, soms weet je gewoon dat het goed 
is, maar is speciale vermelding toch ook wel heel leuk. 
Mijn liefste vriendjes en vriendinnetjes binnen en buiten het Sophie, bedankt dat jullie er 
altijd voor me zijn, en extra veel dank voor alle niet-promotie-gerelateerde activiteiten de 
afgelopen vier jaar. Zonder alle theetjes, taartjes, heerlijke diners (maar vooral veel pizza’s), 
bierproeverijen, dagjes Efteling, weekendjes weg, slechte films anywhere, verjaardagsfeestjes, 
(historische) dansjes en zeilavonturen had ik de laatste jaren lang niet zo leuk gevonden. 
Lieve paranimfen, Maaike en Kitty, wat ben ik blij dat jullie mij op deze belangrijke dag bijstaan. 
Lieve Maaike, al sinds het begin van onze vriendschap, nu ruim 20 jaar geleden, sta je altijd 
voor me klaar. Jouw pragmatische benadering en eerlijke ongezouten mening helpen iedere 
keer om van mijn zelf-gefabriceerde olifanten weer kleine muggen te maken. Dank voor al je 
hulp bij het organiseren van deze geweldige dag en natuurlijk voor je taalkundige bijdrage 
aan mijn boekje. Best friends forever!
Lieve Kit, een week na jouw promotie staan we weer zij aan zij. Ik vind het zo fijn dat we ons 
promotietraject samen hebben doorlopen en elk hoogte- en dieptepunt hebben kunnen 
delen. Samen treinen maakte alle NS-vertragingen een stuk draaglijker en vooral een stuk 
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leuker. Dank voor je steun en hulp, zowel tijdens ziekenhuisuren als daarbuiten, en alle mooie 
promotiemomenten van de afgelopen jaren. Op naar nog veel meer mooie momenten samen 
in Utrecht!
Lieve Robin, grote kleine broer. Dank voor je geweldige illustraties die mijn proefschrift 
tot een echt boek hebben gemaakt. Trots op jou! Lieve Mijkie, superfijn om ook in Utrecht 
familie dichtbij te hebben, en zeker niet alleen vanwege de rode kater, vele dansjes en 
jeugdsentimentele tv-series.
Liefste pappie en mammie, jullie hebben elke stap van dit promotietraject, groot of klein, met 
me meegeleefd. Ik kan jullie niet genoeg bedanken voor jullie onvoorwaardelijke liefde en 
steun. 
Mijn allerliefste, jouw relaxte persoonlijkheid en enorme relativeringsvermogen hebben me 
geholpen om ondanks alle promotiestress rustig te blijven ademen en vooral ook om overal 
de leuke kant van in te zien. Met jou kan ik elke bergtop aan. Ik kijk uit naar nog veel meer 
hoogtepunten samen! 
Dorian
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